ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
For discussion of 2018 items and year-over-year comparisons between 2019 and 2018 that are not included in this 2020 Form 10-K, refer to "Item 7. – Management Discussion and Analysis of Financial Condition and Results of Operations" found in our Form 10-K for the year ended December 31, 2019, that was filed with the Securities and Exchange Commission on February 20, 2020.
Executive Overview
General
Humana Inc., headquartered in Louisville, Kentucky, is a leading health and well-being company committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and well‐being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large. To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools, such as in‐home care, behavioral health, pharmacy services, data analytics and wellness solutions, combine to produce a simplified experience that makes health care easier to navigate and more effective.
Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs, excluding Merger termination fee and related costs, net, and depreciation and amortization, as a percentage of total revenue less investment income, represents a statistic used to measure administrative spending efficiency.
COVID-19
During 2020 we took actions to protect, inform, and care for our members, providers, employees, and other stakeholders associated with the outbreak of the novel coronavirus, or COVID-19. Specifically, we highlight the following actions to support our members:
• waiving all cost sharing for COVID-19 treatment and testing, including inpatient hospital admissions as well as in-network primary care, outpatient behavioral health, and telehealth visits, to reduce financial barriers to members seeking care and to re-engage with their physician, while continuing to encourage the use of telehealth;
• delivering meals to our senior members in need;
• making it easier for members to be tested for COVID-19 by offering at-home testing, as well as offering in-home preventive screening and diabetes testing kits to encourage members to seek preventive care that may have been delayed during the pandemic.
• proactively delivering safety kits, including face masks, to members and employee homes to facilitate access to care and support visits to providers safely;
• extending grace periods for premium payments for our fully-insured commercial group members, to ensure continuity of coverage during times of financial stress; and
• establishing a clinical outreach team to proactively engage with our most vulnerable members.
In addition, we took steps to support our provider partners and boost system viability by:
• increasing provider funding, simplifying and expanding claims processing and releasing advanced funding to providers, to get reimbursement payments to providers as quickly as possible and ease financial concerns so that members are able to continue to access the care and information they need; and
• expanding modifications to certain utilization management processes, to ease administrative stress and make sure providers are able to most efficiently care for their patients.
We also supported our workforce keeping them safe and addressing other needs during this time, highlighting the following:
• transitioning nearly 94% of the workforce to work-at-home and equipping them with the necessary technology and resources for a successful remote work environment.
• providing funding for emergency relief for elder and child caregiving and financial hardship from family job loss, food insecurity and household essentials.
• adjusting pay and leave policies to provide additional paid time off to manage personal challenges as a result of COVID-19 including school closings and child care.
Finally, we continued to support the communities we serve by donating $200 million to the Humana Foundation to address social determinants of health in an effort to promote more health days and encourage greater health equity.
The emergence and spread of COVID-19 has impacted our business. Beginning in the second half of March 2020, the implementation of stay-at-home and physical distancing orders and other restrictions on movement and economic activity resulted in the temporary deferral of non-essential care and significant reduction in hospital admissions and overall healthcare system utilization during April 2020. Non-COVID utilization then began to increase during May and June 2020, and continued to rebound throughout the third quarter and early in the fourth quarter of 2020, reaching approximately 95% of historic baseline levels as of the end of October 2020. Then, in the latter half of November and accelerating throughout the month of December, we experienced a significant increase in COVID-19 admissions in nearly all of the markets in which we operate across our Medicare Advantage, Medicaid, and group commercial insurance business lines, resulting in higher COVID-19 treatment and testing costs. During this period, we also experienced a corresponding decline in non-COVID utilization in all service categories to well below the near baseline levels of non-COVID utilization witnessed as late as the end of October 2020 (with non-COVID utilization in our Medicare Advantage business running approximately 15% below normal levels at the close of the fourth quarter of 2020). The impact of this decline in non-COVID utilization more than offset the higher COVID-19 treatment and testing costs during this period. Our 2020 results were also impacted by our ongoing pandemic relief efforts and strategic investments in our integrated care delivery model.
We currently anticipate that the higher levels of COVID-19 admissions experienced late in 2020, and the corresponding decrease in non-COVID utilization, will continue for at least the first few months of 2021. Over the course of 2021, we then expect COVID utilization to decline as more of our members are vaccinated, and that non-COVID utilization will trend back to more normal levels. The significant disruption in utilization during 2020, and in particular the unanticipated decline in non-COVID utilization in November and December, also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles. We currently expect this may impact our 2021 revenues under the risk adjustment payment model for Medicare Advantage plans, but that these trends will also normalize in 2022 as non-COVID utilization trends back to more normal levels throughout 2021. However, the course and magnitude of these trends and their associated impact remains highly uncertain and subject to a significant number of variables and uncertainties including, among others, the severity and duration of the pandemic, continued actions taken to mitigate the spread of COVID-19 (including new COVID-19 variants) and in turn, relax those restrictions, the timing and degree in resumption of demand for deferred health care services, the pace of administration of COVID-19 vaccines and the effectiveness of those vaccines, and level and cost of treatment and testing, all of which are difficult to predict. As such, our response to this global health crisis and the subsequent recovery will continue to evolve over the coming months.
Business Segments
We manage our business with three reportable segments: Retail, Group and Specialty, and Healthcare Services. Beginning January 1, 2018, we exited the individual commercial fully-insured medical health insurance business, as well as certain other business in 2018, and therefore no longer report separately the Individual Commercial segment and the Other Businesses category in the current year. Previously, the Other Businesses category included businesses that were not individually reportable because they did not meet the quantitative thresholds required by generally accepted accounting principles, primarily our closed-block of commercial long-term care insurance policies which were sold in 2018. The reportable segments are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources. See Note 18 to the consolidated financial statements included in Item 8. - Financial Statements and Supplementary Data for segment financial information.
The Retail segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts. In addition, the Retail segment also includes our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. The Group and Specialty segment consists of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO products. In addition, our Group and Specialty segment includes our military services business, primarily our TRICARE T2017 East Region contract. The Healthcare Services segment includes services offered to our health plan members as well as to third parties, including pharmacy solutions, provider services, and clinical care service, such as home health and other services and capabilities to promote wellness and advance population health, including our non-consolidating minority investment in Kindred at Home and the strategic partnership with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers.
The results of each segment are measured by income before income taxes and equity in net earnings from equity method investments, or segment earnings. Transactions between reportable segments primarily consist of sales of services rendered by our Healthcare Services segment, primarily pharmacy, provider, and clinical care services, to our Retail and Group and Specialty segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations.
Seasonality
COVID-19 disrupted the pattern of our quarterly earnings and operating cash flows in 2020 largely due to the temporary deferral of non-essential care which resulted in significant reductions in hospital admissions and lower overall healthcare system utilization during higher levels of COVID-19 hospital admissions. Similar impacts and seasonal disruptions from either higher or lower utilization are expected to persist as we respond to and recover from the COVID-19 global health crisis.
One of the product offerings of our Retail segment is Medicare stand-alone prescription drug plans, or PDPs, under the Medicare Part D program. Our quarterly Retail segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our membership. The Medicare Part D benefit design results in coverage that varies as a member’s cumulative out-of-pocket costs pass through successive stages of a member’s plan period, which begins annually on January 1 for renewals. These plan designs generally result in us sharing a greater portion of the responsibility for total prescription drug costs in the early stages and less
in the latter stages. As a result, the PDP benefit ratio generally decreases as the year progresses. In addition, the number of low income senior members as well as year-over-year changes in the mix of membership in our stand-alone PDP products affects the quarterly benefit ratio pattern.
In addition, the Retail segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the second half of the year associated with the Medicare marketing season.
Our Group and Specialty segment also experiences seasonality in the benefit ratio pattern. However, the effect is opposite of Medicare stand-alone PDP in the Retail segment, with the Group and Specialty segment’s benefit ratio increasing as fully-insured members progress through their annual deductible and maximum out-of-pocket expenses.
Recent Transactions
In the first quarter of 2020, we purchased privately held Enclara Healthcare, or Enclara, one of the nation’s largest hospice pharmacy and benefit management providers for cash consideration of approximately $709 million, net of cash received.
Also, in the first quarter of 2020, we entered into a strategic partnership with WCAS to accelerate the expansion of our primary care model. The WCAS partnership opened 20 payor-agnostic, senior-focused primary care centers during 2020, and is expected to open an additional 30 over the next 2 years.
These transactions are more fully discussed in Note 3 to the consolidated financial statements.
Highlights
•Our 2020 results reflect the continued implementation of our strategy to offer our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement. These include performance bonuses, shared savings and shared risk relationships. At December 31, 2020, approximately 2,650,100 members, or 67%, of our individual Medicare Advantage members were in value-based relationships under our integrated care delivery model, as compared to 2,407,000 members, or 67%, at December 31, 2019. Medicare Advantage and dual demonstration program membership enrolled in a Humana chronic care management program was 910,600 at December 31, 2020, an increase of 4.8% from 868,800 at December 31, 2019. These members may not be unique to each program since members have the ability to enroll in multiple programs. The increase is driven by our improved process for identifying and enrolling members in the appropriate program at the right time, coupled with growth in Special Needs Plans, or SNP, membership.
•On January 15, 2021, Centers for Medicare & Medicaid Services, or CMS, published its Announcement of Calendar Year 2022 Medicare Advantage Capitation Rates and Part C and Part D Payment Policies, or the Final Rate Notice. We expect the Final Rate Notice to result in a 3.7% rate increase for non end stage renal disease, or ESRD, Medicare Advantage business, excluding the impact of Employer Group Waiver Plan, or EGWP, funding changes. Our 3.7% rate increase compares to CMS’s estimate for the sector of 4.08% on a comparable basis, with the variance primarily driven by county rebasing and our geographic footprint. CMS also establishes separate rates of payment for ESRD beneficiaries enrolled in Medicare Advantage plans. We expect the Final Rate Notice to result in a 5.0% rate increase in 2021 for ESRD beneficiaries. Our estimate of 5.0% is equivalent to CMS’s estimate.
The 2022 benchmark increase of 3.7% includes roughly 0.8% for the projected cost of COVID-19 vaccines.
•Net income was $3.4 billion for 2020 compared to $2.7 billion in 2019 and earnings per diluted common share increased $5.21 from $20.10 earnings per diluted common share in 2019 to $25.31 earnings per diluted common share in 2020. These comparisons were significantly impacted by the change in the fair value of publicly-traded equity securities, the net receipt of commercial risk corridor receivables previously written off, and the put/call valuation adjustments associated with certain equity method investments. The change in the fair value of our publicly-traded equity securities relates primarily to our common stock holdings, including both the gain resulting from the initial conversion of our prior ownership interest in certain privately held companies, primarily in Oak Street Health, Inc., or OSH, into common stock upon such companies' initial public offering, or IPO, during the third quarter of 2020, and the subsequent changes in the market value of such securities from their IPO through the end of 2020. In 2020 we received $578 million, net of related fees and expenses pursuant to the U.S. Supreme Court ruling that the government is obligated to pay the losses under the risk corridor program. The receipt of the risk corridor payments was associated with losses incurred under the Health Care Reform business in 2014 to 2016. The receipt of these risk corridor payments accounted for less than half of our accumulated losses before income taxes from this business during that time period. The impact of these adjustments to our consolidated income before income taxes and equity in net earnings and diluted earnings per common share was as follows for 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
Consolidated income before income taxes and equity in net earnings:
|
|
|
|
Change in the fair value of publicly-traded equity securities
|
$
|
745
|
|
|
$
|
—
|
|
Receipt of commercial risk corridor receivables previously written-off
|
578
|
|
—
|
|
Put/call valuation adjustments
|
(103)
|
|
|
506
|
|
$
|
1,220
|
|
|
$
|
506
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
Diluted earnings per common share:
|
|
|
|
Change in the fair value of publicly-traded equity securities
|
$
|
4.32
|
|
|
$
|
—
|
|
Receipt of commercial risk corridor receivables previously written-off
|
3.35
|
|
|
—
|
|
Put/call valuation adjustments
|
(0.60)
|
|
|
2.89
|
|
|
$
|
7.07
|
|
|
$
|
2.89
|
|
•Excluding these adjustments, our results of operations reflect the impact of the ongoing COVID-19 pandemic. Comparisons were impacted by cost reductions due to lower non-COVID utilization patterns from stay-at-home and physical distancing orders and other restrictions on movement offset by cost increases due to COVID-19 treatment and testing costs and our ongoing pandemic relief efforts and strategic investments in our integrated care delivery model. These changes were also favorably impacted by a lower number of shares used to compute dilutive earnings per common share, primarily reflecting share repurchases completed during 2019, partially offset by a higher tax rate resulting from the return of the non-deductible health insurance industry fee in 2020.
Health Care Reform
The Health Care Reform Law enacted significant reforms to various aspects of the U.S. health insurance industry. Certain significant provisions of the Health Care Reform Law include, among others, mandated coverage requirements, mandated benefits and guarantee issuance associated with commercial medical insurance, rebates to policyholders based on minimum benefit ratios, adjustments to Medicare Advantage premiums, the establishment of federally facilitated or state-based exchanges coupled with programs designed to spread risk among insurers, and the introduction of plan designs based on set actuarial values. In addition, the Health Care Reform Law established insurance industry assessments, including an annual health insurance industry fee. The annual health insurance industry fee, which is not deductible for income tax purposes and significantly increases our effective tax rate, was suspended in 2019, resumed for calendar year 2020 and, under current law, has been permanently repealed beginning in calendar year 2021.
It is reasonably possible that the Health Care Reform Law and related regulations, as well as other current or future legislative, judicial or regulatory changes such as the Families First Coronavirus Response Act (the "Families First Act"), the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") and other legislative or regulatory action taken in response to COVID-19 including restrictions on our ability to manage our provider network or otherwise operate our business, or restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, increases in member benefits or changes to member eligibility criteria without corresponding increases in premium payments to us, or increases in regulation of our prescription drug benefit businesses, in the aggregate may have a material adverse effect on our results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs, further lowering our Medicare payment rates and increasing our expenses associated with assessments); our financial position (including our ability to maintain the value of our goodwill); and our cash flows.
We intend for the discussion of our financial condition and results of operations that follows to assist in the understanding of our financial statements and related changes in certain key items in those financial statements from year to year, including the primary factors that accounted for those changes. Transactions between reportable segments primarily consist of sales of services rendered by our Healthcare Services segment, primarily pharmacy, provider, and clinical care services, to our Retail and Group and Specialty segment customers and are described in Note 18 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data in this 2020 Form 10-K.
Comparison of Results of Operations for 2020 and 2019
Certain financial data on a consolidated basis and for our segments was as follows for the years ended December 31, 2020 and 2019:
Consolidated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change
|
|
|
2020
|
|
2019
|
|
Dollars
|
|
Percentage
|
|
|
(dollars in millions, except per
common share results)
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
Premiums:
|
|
|
|
|
|
|
|
|
Retail
|
|
$
|
67,124
|
|
|
$
|
56,254
|
|
|
$
|
10,870
|
|
|
19.3
|
%
|
Group and Specialty
|
|
6,460
|
|
|
6,694
|
|
|
(234)
|
|
|
(3.5)
|
%
|
Corporate
|
|
602
|
|
|
—
|
|
|
602
|
|
|
100.0
|
%
|
Total premiums
|
|
74,186
|
|
|
62,948
|
|
|
11,238
|
|
|
17.9
|
%
|
Services:
|
|
|
|
|
|
|
|
|
Retail
|
|
19
|
|
|
17
|
|
|
2
|
|
|
11.8
|
%
|
Group and Specialty
|
|
780
|
|
|
790
|
|
|
(10)
|
|
|
(1.3)
|
%
|
Healthcare Services
|
|
1,016
|
|
|
632
|
|
|
384
|
|
|
60.8
|
%
|
|
|
|
|
|
|
|
|
|
Total services
|
|
1,815
|
|
|
1,439
|
|
|
376
|
|
|
26.1
|
%
|
Investment income
|
|
1,154
|
|
|
501
|
|
|
653
|
|
|
130.3
|
%
|
Total revenues
|
|
77,155
|
|
|
64,888
|
|
|
12,267
|
|
|
18.9
|
%
|
Operating expenses:
|
|
|
|
|
|
|
|
|
Benefits
|
|
61,628
|
|
|
53,857
|
|
|
7,771
|
|
|
14.4
|
%
|
Operating costs
|
|
10,052
|
|
|
7,381
|
|
|
2,671
|
|
|
36.2
|
%
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
489
|
|
|
458
|
|
|
31
|
|
|
6.8
|
%
|
Total operating expenses
|
|
72,169
|
|
|
61,696
|
|
|
10,473
|
|
|
17.0
|
%
|
Income from operations
|
|
4,986
|
|
|
3,192
|
|
|
1,794
|
|
|
56.2
|
%
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
283
|
|
|
242
|
|
|
41
|
|
|
16.9
|
%
|
Other expense (income), net
|
|
103
|
|
|
(506)
|
|
|
609
|
|
|
(120.4)
|
%
|
Income before income taxes and equity in net earnings
|
|
4,600
|
|
|
3,456
|
|
|
1,144
|
|
|
33.1
|
%
|
Provision for income taxes
|
|
1,307
|
|
|
763
|
|
|
544
|
|
|
71.3
|
%
|
Equity in net earnings
|
|
74
|
|
|
14
|
|
|
60
|
|
|
428.6
|
%
|
Net income
|
|
$
|
3,367
|
|
|
$
|
2,707
|
|
|
$
|
660
|
|
|
24.4
|
%
|
Diluted earnings per common share
|
|
$
|
25.31
|
|
|
$
|
20.10
|
|
|
$
|
5.21
|
|
|
25.9
|
%
|
Benefit ratio (a)
|
|
83.1
|
%
|
|
85.6
|
%
|
|
|
|
(2.5)
|
%
|
Operating cost ratio (b)
|
|
13.2
|
%
|
|
11.5
|
%
|
|
|
|
1.7
|
%
|
Effective tax rate
|
|
28.0
|
%
|
|
22.0
|
%
|
|
|
|
6.0
|
%
|
(a)Represents total benefits expense as a percentage of premiums revenue.
(b)Represents total operating costs, excluding depreciation and amortization, as a percentage of total revenues less investment income.
Premiums Revenue
Consolidated premiums increased $11.2 billion, or 17.9%, from $62.9 billion for 2019 to $74.2 billion for 2020 primarily due to higher premium revenues from Medicare Advantage and state-based contracts membership growth, higher per member Medicare Advantage premiums, and the receipt of commercial risk corridor receivables previously written off, partially offset by the impact of declining stand-alone PDP and fully-insured group commercial medical membership as more fully described in the detailed segment results discussion that follows.
Services Revenue
Consolidated services revenue increased $376 million, or 26.1%, from $1.4 billion for 2019 to $1.8 billion for 2020, primarily due to an increase in services revenue in the Healthcare Services segment associated with higher external pharmacy revenues resulting from the Enclara acquisition in the first quarter of 2020.
Investment Income
Investment income was $1.2 billion for 2020, increasing $653 million, or 130.3%, from 2019, primarily due to the $745 million change in fair value of publicly-traded equity securities during 2020.
Benefits Expense
Consolidated benefits expense was $61.6 billion for 2020, an increase of $7.8 billion, or 14.4%, from 2019. The consolidated benefit ratio for 2020 was 83.1%, a decrease of 250 basis points from 2019 primarily reflecting significantly depressed non-COVID utilization in the first half of 2020 as well as the last two months of the fourth quarter, the reinstatement of the non-deductible health insurance industry fee in 2020 that was contemplated in the pricing and benefit design of our products, along with the receipt of the commercial risk corridor receivables previously written off. These decreases were partially offset by the meaningful COVID-19 treatment and testing costs along with our ongoing pandemic relief efforts and strategic investments in our integrated care delivery model, as well as lower prior-period medical claims reserve development.
We experienced favorable medical claims reserve development related to prior fiscal years of $313 million in 2020 and $336 million in 2019. The favorable prior-period medical claims reserve development decreased the consolidated benefit ratio by approximately 40 basis points in 2020 and 50 basis points in 2019.
Operating Costs
Our segments incur both direct and shared indirect operating costs. We allocate the indirect costs shared by the segments primarily as a function of revenues. As a result, the profitability of each segment is interdependent.
Consolidated operating costs increased $2.7 billion, or 36.2%, from 2019 to $10.1 billion in 2020 reflecting an increase in operating costs in the Retail and the Group and Specialty segments as discussed in the detailed segment results discussion that follows.
The consolidated operating cost ratio for 2020 was 13.2%, increasing 170 basis points from 11.5% in 2019 primarily due to the reinstatement of the non-deductible health insurance industry fee in 2020, COVID-19 related administrative costs, including those associated with purchasing personal protective equipment for our clinicians and the build-out of infrastructure necessary to support employees working remotely. Higher marketing spend associated with the Medicare Annual Election Period, or AEP, strategic investments in our integrated care delivery model and continued support for our constituents, including a $200 million contribution to the Humana Foundation to support the communities served by us, particularly those with social and health disparities, also contributed to the increase. These increases were partially offset by scale efficiencies associated with growth in our Medicare Advantage membership, significant operating cost efficiencies in 2020 driven by previously disclosed productivity initiatives, and the net impact of the receipt of the commercial risk corridor receivables previously written off. The nondeductible health insurance industry fee impacted the operating cost ratio by 160 basis points in 2020.
Depreciation and Amortization
Depreciation and amortization in 2020 totaled $489 million compared to $458 million in 2019, an increase of 6.8%, primarily due to capital expenditures.
Interest Expense
Interest expense was $283 million for 2020 compared to $242 million for 2019, an increase of $41 million, or 16.9%. This increase primarily was due to the higher average borrowings outstanding.
Income Taxes
Our effective tax rate during 2020 was 28.0% compared to the effective tax rate of 22.0% in 2019. This change primarily was due to the reinstatement of the non-deductible health insurance industry fee in 2020. See Note 12 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data for a complete reconciliation of the federal statutory rate to the effective tax rate.
Retail Segment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change
|
|
|
2020
|
|
2019
|
|
Members
|
|
Percentage
|
Membership:
|
|
|
|
|
|
|
|
|
Medical membership:
|
|
|
|
|
|
|
|
|
Individual Medicare Advantage
|
|
3,962,700
|
|
|
3,587,200
|
|
|
375,500
|
|
|
10.5
|
%
|
Group Medicare Advantage
|
|
613,200
|
|
|
525,300
|
|
|
87,900
|
|
|
16.7
|
%
|
Medicare stand-alone PDP
|
|
3,866,700
|
|
|
4,365,200
|
|
|
(498,500)
|
|
|
(11.4)
|
%
|
Total Retail Medicare
|
|
8,442,600
|
|
|
8,477,700
|
|
|
(35,100)
|
|
|
(0.4)
|
%
|
State-based Medicaid
|
|
772,400
|
|
|
469,000
|
|
|
303,400
|
|
|
64.7
|
%
|
Medicare Supplement
|
|
335,600
|
|
|
298,400
|
|
|
37,200
|
|
|
12.5
|
%
|
Total Retail medical members
|
|
9,550,600
|
|
|
9,245,100
|
|
|
305,500
|
|
|
3.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change
|
|
|
|
2020
|
|
2019
|
|
Dollars
|
|
Percentage
|
|
|
|
(in millions)
|
|
Premiums and Services Revenue:
|
|
|
|
|
|
|
|
|
|
Premiums:
|
|
|
|
|
|
|
|
|
|
Individual Medicare Advantage
|
|
$
|
51,697
|
|
|
$
|
43,128
|
|
|
$
|
8,569
|
|
|
19.9
|
%
|
|
Group Medicare Advantage
|
|
7,774
|
|
|
6,475
|
|
|
1,299
|
|
|
20.1
|
%
|
|
Medicare stand-alone PDP
|
|
2,742
|
|
|
3,165
|
|
|
(423)
|
|
|
(13.4)
|
%
|
|
Total Retail Medicare
|
|
62,213
|
|
|
52,768
|
|
|
9,445
|
|
|
17.9
|
%
|
|
State-based Medicaid
|
|
4,223
|
|
|
2,898
|
|
|
1,325
|
|
|
45.7
|
%
|
|
Medicare Supplement
|
|
688
|
|
|
588
|
|
|
100
|
|
|
17.0
|
%
|
|
Total premiums
|
|
67,124
|
|
|
56,254
|
|
|
10,870
|
|
|
19.3
|
%
|
|
Services
|
|
19
|
|
|
17
|
|
|
2
|
|
|
11.8
|
%
|
|
Total premiums and services revenue
|
|
$
|
67,143
|
|
|
$
|
56,271
|
|
|
$
|
10,872
|
|
|
19.3
|
%
|
|
Segment earnings
|
|
$
|
3,017
|
|
|
$
|
2,235
|
|
|
$
|
782
|
|
|
35.0
|
%
|
|
Benefit ratio
|
|
84.2
|
%
|
|
86.4
|
%
|
|
|
|
(2.2)
|
%
|
|
Operating cost ratio
|
|
11.0
|
%
|
|
9.4
|
%
|
|
|
|
1.6
|
%
|
|
Segment Earnings
•Retail segment earnings were $3.0 billion in 2020, an increase of $782 million, or 35.0%, compared to $2.2 billion in 2019 primarily resulting from the net favorable impact of a lower benefit ratio, partially offset by a higher operating cost ratio as more fully described below.
Enrollment
•Individual Medicare Advantage membership increased 375,500 members, or 10.5%, from 3,587,200 members as of December 31, 2019 to 3,962,700 members as of December 31, 2020, primarily due to membership additions associated with the 2020 Annual Election Period, or AEP, continued enrollment due to special elections, age-ins, and and Dual Eligible Special Need Plans, or D-SNP, members as well as the 2020 Open Election Period, or OEP, for Medicare beneficiaries. The 2020 OEP sales period, which ran from January 1 to March 31, 2020, added approximately 30,000 members. individual Medicare Advantage membership includes 406,100 D-SNP members as of December 31, 2020, a net increase of 117,900, or 40.9%, from 288,200 December 31, 2019. For the full year 2021, we anticipate a net membership increase in our individual Medicare Advantage offerings of 425,000 members to 475,000 members.
•Group Medicare Advantage membership increased 87,900 members, or 16.7%, from 525,300 members as of December 31, 2019 to 613,200 members as of December 31, 2020, primarily due to the addition of a large account in January 2020, along with net membership additions associated with the 2020 selling season. For the full year 2021, we anticipate a net membership decline in our Group Medicare Advantage offerings of approximately 50,000 members.
•Medicare stand-alone PDP membership decreased 498,500 members, or 11.4%, from 4,365,200 members as of December 31, 2019 to 3,866,700 members as of December 31, 2020, primarily resulting from terminations driven by premium and benefit adjustments experienced by members that were previously enrolled in our 2019 Humana Walmart Rx plan and the 2019 Humana Enhanced plan, which were consolidated into the Premier Rx plan in 2020. The PDP losses were partially offset by growth in the new low-price Humana Walmart Value Rx plan, driven by both new sales and plan to plan changes. For the full year 2021, we anticipate a net membership decline in our Medicare stand-alone PDP offerings of approximately 300,000 members.
•State-based Medicaid membership increased 303,400 members, or 64.7%, from 469,000 members as of December 31, 2019 to 772,400 members as of December 31, 2020, primarily reflecting the impact of discontinuing the reinsurance agreement with CareSource and the assumption of full financial risk for the existing Kentucky Medicaid contract as of January 1, 2020, as well as additional enrollment resulting from the current economic downturn due to the COVID-19 pandemic.
Premiums revenue
•Retail segment premiums increased $10.9 billion, or 19.3%, from 2019 to 2020 primarily due to higher premiums as a result of Medicare Advantage and state-based contracts membership growth and higher per member Medicare Advantage premiums. These favorable items were partially offset by the decline in membership in our stand-alone PDP offerings.
Benefits expense
•The Retail segment benefit ratio of 84.2% for 2020 decreased 220 basis points from 86.4% in 2019 primarily reflecting significantly depressed non-COVID utilization in the first half of 2020 as well as in the last two months of 2020 and the reinstatement of the non-deductible health insurance industry fee in 2020 which was contemplated in the pricing and benefit design of our products. These were partially offset by meaningful COVID-19 treatment costs and testing, our ongoing pandemic relief efforts and strategic investments in our integrated care delivery model, the impact from a shift in Medicare membership mix, and lower favorable prior-period medical claims reserve development.
•The Retail segment’s benefits expense for 2020 included the beneficial effect of $266 million in favorable prior-year medical claims reserve development versus $386 million in 2019. This favorable prior-year medical claims reserve development decreased the Retail segment benefit ratio by approximately 40 basis points in 2020 versus approximately 70 basis points in 2019.
Operating costs
•The Retail segment operating cost ratio of 11.0% for 2020 increased 160 basis points from 9.4% in 2019 primarily due to the reinstatement of the non-deductible health insurance industry fee in 2020, COVID-19 related administrative costs as previously discussed, continued support for our constituents and strategic investments in our integrated care delivery model, and increased spending associated with Medicare AEP. These were partially offset by scale efficiencies associated with growth in our Medicare Advantage membership and significant operating cost efficiencies driven by previously disclosed productivity initiatives.
•The non-deductible health insurance industry fee increased the operating cost ratio by approximately 160 basis points in 2020.
Group and Specialty Segment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change
|
|
|
2020
|
|
2019
|
|
Members
|
|
Percentage
|
Membership:
|
|
|
|
|
|
|
|
|
Medical membership:
|
|
|
|
|
|
|
|
|
Fully-insured commercial group
|
|
777,400
|
|
|
908,600
|
|
|
(131,200)
|
|
|
(14.4)
|
%
|
ASO
|
|
504,900
|
|
|
529,200
|
|
|
(24,300)
|
|
|
(4.6)
|
%
|
Military services
|
|
5,998,700
|
|
|
5,984,300
|
|
|
14,400
|
|
|
0.2
|
%
|
Total group medical members
|
|
7,281,000
|
|
|
7,422,100
|
|
|
(141,100)
|
|
|
(1.9)
|
%
|
Specialty membership (a)
|
|
5,310,300
|
|
|
5,425,900
|
|
|
(115,600)
|
|
|
(2.1)
|
%
|
(a)Specialty products include dental, vision, and life insurance benefits. Members included in these products may not be unique to each product since members have the ability to enroll in multiple products.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change
|
|
|
2020
|
|
2019
|
|
Dollars
|
|
Percentage
|
|
|
(in millions)
|
|
|
Premiums and Services Revenue:
|
|
|
|
|
|
|
|
|
Premiums:
|
|
|
|
|
|
|
|
|
Fully-insured commercial group
|
|
$
|
4,761
|
|
|
$
|
5,123
|
|
|
$
|
(362)
|
|
|
(7.1)
|
%
|
Specialty
|
|
1,699
|
|
|
1,571
|
|
|
128
|
|
|
8.1
|
%
|
|
|
|
|
|
|
|
|
|
Total premiums
|
|
6,460
|
|
|
6,694
|
|
|
(234)
|
|
|
(3.5)
|
%
|
Services
|
|
780
|
|
|
790
|
|
|
(10)
|
|
|
(1.3)
|
%
|
Total premiums and services revenue
|
|
$
|
7,240
|
|
|
$
|
7,484
|
|
|
$
|
(244)
|
|
|
(3.3)
|
%
|
Segment (loss) earnings
|
|
$
|
(143)
|
|
|
$
|
28
|
|
|
$
|
(171)
|
|
|
(610.7)
|
%
|
Benefit ratio
|
|
85.6
|
%
|
|
86.0
|
%
|
|
|
|
(0.4)
|
%
|
Operating cost ratio
|
|
25.0
|
%
|
|
22.0
|
%
|
|
|
|
3.0
|
%
|
Segment Earnings
•Group and Specialty segment loss was $143 million in 2020, a decrease of $171 million, or 610.7%, from $28 million of segment earnings in 2019 primarily due to the net negative impact of a higher operating cost ratio, partially offset by a slightly lower benefit ratio as more fully described below.
Enrollment
•Fully-insured commercial group medical membership decreased 131,200 members, or 14.4% from 908,600 members as of December 31, 2019 primarily reflecting lower membership in small group accounts due in part to more small group accounts selecting level-funded ASO products, as well as the loss of certain large group accounts due to disciplined pricing in the competitive environment. Additionally, the declines in membership were impacted by the current economic downturn driven by the COVID-19 pandemic resulting in higher unemployment rates and loss of coverage for fully-insured commercial group members. The portion of group fully-insured commercial medical membership in small group accounts was approximately 54% at December 31, 2020 and 59% at December 31, 2019.
•Group ASO commercial medical membership decreased 24,300 members, or 4.6%, from 529,200 members as of December 31, 2019 to 504,900 members as of December 31, 2020 primarily reflecting the loss of certain large group accounts due to continued discipline in pricing of services for self-funded accounts amid a highly competitive environment and the impact of the current economic downturn driven by the COVID-19 pandemic as previously discussed, partially offset by more small group accounts selecting level-funded ASO products. Small group membership comprised 45% of group ASO medical membership at December 31, 2020 versus 40% at December 31, 2019.
•Military services membership increased 14,400 members, or 0.2%, from 5,984,300 members as of December 31, 2019 to 5,998,700 members as of December 31, 2020. Membership includes military service members, retirees, and their families to whom we are providing healthcare services under the current TRICARE East Region contract.
•Specialty membership decreased 115,600 members, or 2.1%, from 5,425,900 as of December 31, 2019 to 5,310,300 members as of December 31, 2020 primarily due to the loss of certain group accounts offering stand-alone dental and vision products, as well as the impact of the current economic downturn driven by the COVID-19 pandemic as previously discussed.
Premiums revenue
•Group and Specialty segment premiums decreased $234 million, or 3.5%, from $6.7 billion in 2019 to $6.5 billion in 2020, primarily due to the decline in our fully-insured group commercial membership, partially offset by higher stop-loss premiums related to our level-funded ASO accounts resulting from membership growth in this product and higher per member premiums across the fully-insured commercial business.
Services revenue
•Group and Specialty segment services revenue decreased $10 million, or 1.3%, from 2019 to 2020 primarily due to lower ASO membership described previously.
Benefits expense
•The Group and Specialty segment benefit ratio decreased 40 basis points from 86.0% in 2019 to 85.6% in 2020 primarily due to significantly depressed non-COVID utilization in the first half of 2020 and again in the last two months of 2020, the reinstatement of the non-deductible health insurance industry fee in 2020 which was contemplated in the pricing and benefit design of our products, and higher favorable prior-period medical claims reserve development. These items were partially offset by meaningful COVID-19 treatment costs and testing and our ongoing pandemic relief efforts and strategic investments as previously described.
•The Group and Specialty segment’s benefits expense included the favorable effect of $47 million in prior-period medical claims reserve development in 2020 versus the unfavorable effect of $50 million in favorable prior-period medical claims reserve development in 2019. This favorable prior-period medical claims reserve development decreased the Group and Specialty segment benefit ratio by approximately 70 basis points in 2020 while the unfavorable prior-period medical claims reserve development increased the Group and Specialty segment benefit ratio by approximately 70 basis points in 2019.
Operating costs
•The Group and Specialty segment operating cost ratio of 25.0% for 2020 increased 300 basis points from 22.0% for 2019, primarily due to COVID-19 related administrative costs as previously discussed, continued support for our constituents and strategic investments in the segment to position the business for long-term success, and the reinstatement of the non-deductible health insurance industry fee in 2020. These increases were partially offset by significant operating cost efficiencies driven by previously disclosed productivity initiatives.
•The non-deductible health insurance industry fee increased the operating cost ratio by approximately 130 basis points in 2020.
Healthcare Services Segment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change
|
|
|
2020
|
|
2019
|
|
Dollars
|
|
Percentage
|
|
|
(in millions)
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
Services:
|
|
|
|
|
|
|
|
|
Clinical care services
|
|
$
|
107
|
|
|
$
|
140
|
|
|
$
|
(33)
|
|
|
(23.6)
|
%
|
Pharmacy solutions
|
|
581
|
|
|
186
|
|
|
395
|
|
|
212.4
|
%
|
Provider services
|
|
328
|
|
|
306
|
|
|
22
|
|
|
7.2
|
%
|
Total services revenues
|
|
1,016
|
|
|
632
|
|
|
384
|
|
|
60.8
|
%
|
Intersegment revenues:
|
|
|
|
|
|
|
|
|
Pharmacy solutions
|
|
24,587
|
|
|
22,189
|
|
|
2,398
|
|
|
10.8
|
%
|
Provider services
|
|
2,266
|
|
|
2,344
|
|
|
(78)
|
|
|
(3.3)
|
%
|
Clinical care services
|
|
566
|
|
|
616
|
|
|
(50)
|
|
|
(8.1)
|
%
|
Total intersegment revenues
|
|
27,419
|
|
|
25,149
|
|
|
2,270
|
|
|
9.0
|
%
|
Total services and intersegment revenues
|
|
$
|
28,435
|
|
|
25,781
|
|
|
$
|
2,654
|
|
|
10.3
|
%
|
Segment earnings
|
|
$
|
944
|
|
|
$
|
789
|
|
|
$
|
155
|
|
|
19.6
|
%
|
Operating cost ratio
|
|
96.3
|
%
|
|
96.4
|
%
|
|
|
|
(0.1)
|
%
|
Segment Earnings
•Healthcare Services segment earnings were $944 million in 2020, an increase of $155 million, or 19.6%, from 2019 reflecting the same factors that resulted in a lower operating cost ratio as more fully described below, as well as higher earnings from equity method investments in 2020.
Script Volume
•Humana Pharmacy Solutions® script volumes for the Retail and Group and Specialty segment membership increased to approximately 478 million in 2020, up 4.8% versus scripts of approximately 456 million in 2019. The increase primarily was driven by higher Medicare Advantage and state-based contracts membership, partially offset by the decline in stand-alone PDP membership.
Services revenue
•Services revenue increased $384 million, or 60.8%, from 2019 to $1.0 billion for 2020 primarily due to the additional pharmacy revenues associated with the acquisition of Enclara in 2020.
Intersegment revenues
•Intersegment revenues increased $2.3 billion, or 9.0%, from 2019 to $27.4 billion for 2020 primarily due to strong Medicare Advantage membership growth and a slight shift by members to 90-day mail supply, partially offset by the loss of intersegment revenues associated with the decline in stand-alone PDP membership.
Operating costs
•The Healthcare Services segment operating cost ratio of 96.3% for 2020 decreased 10 basis points from 96.4% in 2019 due to operational improvements and reduced utilization resulting from COVID-19 in our provider services business, as well as significant operating cost efficiencies in 2020 driven by previously disclosed productivity initiatives. These decreases were partially offset by COVID-19 administrative related costs, including expenses associated with additional safety measures taken for our pharmacy, provider, and clinical teams who have continued to provide services to members during the COVID-19 pandemic. The increase further reflects higher costs incurred in the pharmacy business to ensure timely delivery of prescriptions amid the COVID-19 pandemic and additional investments in the segment's provider business related to marketing and AEP initiatives.
Liquidity
Historically, our primary sources of cash have included receipts of premiums, services revenue, and investment and other income, as well as proceeds from the sale or maturity of our investment securities, and borrowings. Our primary uses of cash historically have included disbursements for claims payments, operating costs, interest on borrowings, taxes, purchases of investment securities, acquisitions, capital expenditures, repayments on borrowings, dividends, and share repurchases. Because premiums generally are collected in advance of claim payments by a period of up to several months, our business normally should produce positive cash flows during periods of increasing premiums and enrollment. Conversely, cash flows would be negatively impacted during periods of decreasing premiums and enrollment. From period to period, our cash flows may also be affected by the timing of working capital items including premiums receivable, benefits payable, and other receivables and payables. Our cash flows are impacted by the timing of payments to and receipts from CMS associated with Medicare Part D subsidies for which we do not assume risk. The use of cash flows may be limited by regulatory requirements of state departments of insurance (or comparable state regulators) which require, among other items, that our regulated subsidiaries maintain minimum levels of capital and seek approval before paying dividends from the subsidiaries to the parent. Our use of cash flows derived from our non-insurance subsidiaries, such as in our Healthcare Services segment, is generally not restricted by state departments of insurance (or comparable state regulators).
For additional information on our liquidity risk, please refer to Item 1A. – Risk Factors in this 2020 Form 10-K.
Cash and cash equivalents increased to $4.7 billion at December 31, 2020 from $4.1 billion at December 31, 2019. The change in cash and cash equivalents for the years ended December 31, 2020, 2019 and 2018 is summarized as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
2018
|
|
(in millions)
|
Net cash provided by operating activities
|
$
|
5,639
|
|
|
$
|
5,284
|
|
|
$
|
2,173
|
|
Net cash used in investing activities
|
(3,065)
|
|
|
(1,278)
|
|
|
(3,087)
|
|
Net cash used in financing activities
|
(1,955)
|
|
|
(2,295)
|
|
|
(785)
|
|
Increase (decrease) in cash and cash equivalents
|
$
|
619
|
|
|
$
|
1,711
|
|
|
$
|
(1,699)
|
|
Cash Flow from Operating Activities
The increase in operating cash flows in 2020 was primarily due to the impact of higher earnings and the timing of working capital items, in particular; the impact of Medicare Advantage membership growth on IBNR, described below, as claim payments related to new members lag the related premium collected.
The most significant drivers of changes in our working capital are typically the timing of payments of benefits expense and receipts for premiums. We illustrate these changes with the following summaries of benefits payable and receivables.
The detail of benefits payable was as follows at December 31, 2020, 2019 and 2018:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change
|
|
|
|
|
|
2020
|
|
2019
|
|
2018
|
|
2020
|
|
|
|
|
|
(in millions)
|
|
|
|
|
IBNR (1)
|
$
|
5,290
|
|
|
$
|
4,150
|
|
|
$
|
3,361
|
|
|
$
|
1,140
|
|
|
|
|
|
Reported claims in process (2)
|
816
|
|
|
628
|
|
|
617
|
|
|
188
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other benefits payable (3)
|
2,037
|
|
|
1,226
|
|
|
884
|
|
|
811
|
|
|
|
|
|
Total benefits payable
|
$
|
8,143
|
|
|
$
|
6,004
|
|
|
$
|
4,862
|
|
|
2,139
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)IBNR represents an estimate of benefits payable for claims incurred but not reported (IBNR) at the balance sheet date and includes unprocessed claim inventories. The level of IBNR is primarily impacted by membership levels, medical claim trends and the receipt cycle time, which represents the length of time between when a claim is initially incurred and when the claim form is received and processed (i.e. a shorter time span results in a lower IBNR).
(2)Reported claims in process represents the estimated valuation of processed claims that are in the post claim adjudication process, which consists of administrative functions such as audit and check batching and handling, as well as amounts owed to our pharmacy benefit administrator which fluctuate due to bi-weekly payments and the month-end cutoff.
(3)Other benefits payable include amounts owed to providers under capitated and risk sharing arrangements.
The increase in benefits payable in 2020 was primarily due to an increase in IBNR, mainly as a result of Medicare Advantage membership growth. In addition, 2020 was impacted by an increase in the amounts owed to providers under capitated and risk sharing arrangements, primarily related to Medicare Advantage membership growth in risk sharing arrangements and higher provider surplus amounts driven by lower utilization due to COVID-19.
The detail of total net receivables was as follows at December 31, 2020, 2019 and 2018:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change
|
|
2020
|
|
2019
|
|
2018
|
|
2020
|
|
(in millions)
|
Medicare
|
$
|
928
|
|
|
$
|
835
|
|
|
$
|
836
|
|
|
$
|
93
|
|
Commercial and other
|
122
|
|
|
162
|
|
|
135
|
|
|
(40)
|
|
Military services
|
160
|
|
|
128
|
|
|
123
|
|
|
32
|
|
Allowance for doubtful accounts
|
(72)
|
|
|
(69)
|
|
|
(79)
|
|
|
(3)
|
|
Total net receivables
|
$
|
1,138
|
|
|
$
|
1,056
|
|
|
$
|
1,015
|
|
|
82
|
|
Reconciliation to cash flow statement:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in receivables disposed from sale of
business
|
|
|
|
|
|
|
3
|
|
Change in receivables per cash flow statement
resulting in cash used by operations
|
|
|
|
|
|
|
$
|
85
|
|
Medicare receivables are impacted by changes in revenue associated with individual and group Medicare membership changes as well as the timing of accruals and related collections associated with the CMS risk-adjustment model.
Military services receivables at December 31, 2020, 2019, and 2018 primarily consist of administrative services only fees owed from the federal government for administrative services provided under our TRICARE contracts.
Many provisions of the Health Care Reform Law became effective in 2014, including the non-deductible health insurance industry fee. The annual health insurance industry fee, which is not deductible for income tax purposes and significantly increases our effective tax rate, was suspended in 2019, resumed for calendar year 2020 and, under current law, has been permanently repealed beginning in calendar year 2021. We paid the federal government annual health insurance industry fees of $1.18 billion in 2020.
Cash Flow from Investing Activities
In the first quarter of 2020, we acquired privately held Enclara for cash consideration of approximately $709 million, net of cash received as discussed in Note 3 to the consolidated financial statements included in Item 8 - Financial Statements and Supplementary Data.
Our ongoing capital expenditures primarily relate to our information technology initiatives, support of services in our provider services operations including medical and administrative facility improvements necessary for activities such as the provision of care to members, claims processing, billing and collections, wellness solutions, care coordination, regulatory compliance and customer service. Total capital expenditures, excluding acquisitions, were $964 million in 2020, $736 million in 2019, and $612 million in 2018. The increase in capital expenditures year over year was primarily due to information technology expenditures supporting our integrated care delivery model.
In 2018, we completed the sale of our wholly-owned subsidiary KMG America Corporation, or KMG, to Continental General Insurance Company, or CGIC. Upon closing, we funded the transaction with approximately $190 million of parent company cash contributed into KMG, subject to customary adjustments, in addition to the transfer of approximately $160 million of statutory capital with the sale. Total cash and cash equivalents, including parent company funding, disposed at the time of sale, was $805 million. See Note 3 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
During 2018 we paid cash consideration of approximately $1.1 billion to acquire a 40% minority interest in Kindred at Home, $169 million to acquire the remaining interest in MCCI Holdings, LLC, or MCCI, and $185 million to acquire all of Family Physicians Group, or FPG, as discussed in Notes 3 and 4 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
We reinvested a portion of our operating cash flows in investment securities, primarily investment-grade fixed income debt securities, totaling $1.4 billion, $542 million, and $221 million, during 2020, 2019 and 2018, respectively.
Cash Flow from Financing Activities
Our financing cash flows are significantly impacted by the timing of claims payments and the related receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk. Monthly prospective payments from CMS for reinsurance and low-income cost subsidies are based on assumptions submitted with our annual bid. Settlement of the reinsurance and low-income cost subsidies is based on a reconciliation made approximately 9 months after the close of each calendar year. Claim payments were higher than receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk by $938 million, $560 million and $653 million in the 2020, 2019 and 2018 periods, respectively. Our net receivable from CMS for subsidies and brand name prescription drug discounts was $1.2 billion at December 31, 2020 compared to a net receivable of $229 million at December 31, 2019.
Under our administrative services only TRICARE contract, health care costs payments for which we do not assume risk exceeded reimbursements from the federal government by $1 million and $63 million in the 2020 and 2019 periods, respectively, and reimbursements from the federal government exceeded health care costs payments for which we do not assume risk by $38 million in the 2018 period.
Claim payments associated with cost sharing provisions of the Health Care Reform Law for which we do not assume risk were $25 million in the 2018 period.
In December 2020, we repaid $400 million aggregate principal amount of our 2.5% senior notes due on their maturity date of December 15, 2020.
In March 2020, we issued $600 million of 4.500% senior notes due April 1, 2025 and $500 million of 4.875% senior notes due April 1, 2030. Our net proceeds, reduced for the underwriters' discount and commission and offering expenses paid were $1,088 million.
In March 2020, we drew $1 billion on our existing term loan commitment and repaid the $1 billion outstanding amount in November 2020.
In August 2019, we issued $500 million of 3.125% senior notes due August 15, 2029 and $500 million of 3.950% senior notes due August 15, 2049. Our net proceeds, reduced for the underwriters' discount and commission and offering expenses paid were $987 million. We used the net proceeds from this offering, together with available cash, to repay the $650 million outstanding amount due under our term note in August 2019, and the $400 million aggregate principal amount of our 2.625% senior notes due on its maturity date of October 1, 2019.
In November 2018, we entered into a $1.0 billion term note agreement with a bank at a variable rate of interest due within one year. We repaid $350 million of the outstanding amount in 2018. For a detailed discussion of our debt please refer to Note 13 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
We repurchased common shares for $1.82 billion, $1.07 billion and $1.09 billion in 2020, 2019 and 2018 under share repurchase plans authorized by the Board of Directors and in connection with employee stock plans.
We paid dividends to stockholders of $323 million in 2020, $291 million in 2019, and $265 million in 2018.
We entered into a commercial paper program in October 2014. Net proceeds from issuance of commercial paper were $295 million in 2020 and the maximum principal amount outstanding at any one time during 2020 was $600 million. Net repayments from the issuance of commercial paper were $360 million in 2019 and the maximum principal amount outstanding at any one time during 2019 was $801 million. Net proceeds from issuance of commercial paper were $485 million in 2018 and the maximum principal amount outstanding at any one time during 2018 was $923 million.
The remainder of the cash used in or provided by financing activities in 2020, 2019, and 2018 primarily resulted from proceeds from stock option exercises and the change in book overdraft.
Future Sources and Uses of Liquidity
Dividends
For a detailed discussion of dividends to stockholders, please refer to Note 16 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
Stock Repurchases
For a detailed discussion of stock repurchases, please refer to Note 16 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
Debt
In December 2020, we repaid $400 million aggregate principal amount of our 2.5% senior notes due on their maturity date of December 15, 2020.
In March 2020, we issued $600 million of 4.500% senior notes due April 1, 2025 and $500 million of 4.875% senior notes due April 1, 2030. Our net proceeds, reduced for the underwriters' discount and commission and offering expenses paid, were approximately $1,088 million as of December 31, 2020. We used the net proceeds for general corporate purposes.
In February 2020, we entered into a new $1 billion term loan commitment with a bank that matures 1 year after the first draw, subject to a 1 year extension. In March 2020, we made a draw on the entire term loan commitment of $1 billion. The facility fee, interest rate and financial covenants are consistent with those of our revolving credit agreement. The note was prepayable without penalty. We repaid the $1 billion outstanding balance in November 2020.
For a detailed discussion of our debt, including our senior notes, credit agreement and commercial paper program, please refer to Note 13 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
Acquisitions and Divestiture
During 2020, we completed the acquisition of privately held Enclara, one of the nation’s largest hospice pharmacy and benefit management providers for cash consideration of approximately $709 million, net of cash received. For a detailed discussion of our acquisitions and divestitures, please refer to Notes 3 and 4 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
Liquidity Requirements
We believe our cash balances, investment securities, operating cash flows, and funds available under our credit agreement and our commercial paper program or from other public or private financing sources, taken together, provide adequate resources to fund ongoing operating and regulatory requirements, acquisitions, future expansion opportunities, and capital expenditures for at least the next twelve months, as well as to refinance or repay debt, and repurchase shares.
Adverse changes in our credit rating may increase the rate of interest we pay and may impact the amount of credit available to us in the future. Our investment-grade credit rating at December 31, 2020 was BBB+ according to Standard & Poor’s Rating Services, or S&P, and Baa3 according to Moody’s Investors Services, Inc., or Moody’s. A downgrade by S&P to BB+ or by Moody’s to Ba1 triggers an interest rate increase of 25 basis points with respect to $250 million of our senior notes. Successive one notch downgrades increase the interest rate an additional 25 basis
points, or annual interest expense by $1 million, up to a maximum 100 basis points, or annual interest expense by $3 million.
In addition, we operate as a holding company in a highly regulated industry. Humana Inc., our parent company, is dependent upon dividends and administrative expense reimbursements from our subsidiaries, most of which are subject to regulatory restrictions. We continue to maintain significant levels of aggregate excess statutory capital and surplus in our state-regulated operating subsidiaries. Cash, cash equivalents, and short-term investments at the parent company decreased to $772 million at December 31, 2020 from $1.4 billion at December 31, 2019. This decrease primarily reflects common stock repurchases, insurance subsidiaries' capital contributions, repayment of debt and capital expenditures partially offset by insurance subsidiaries dividends, non-insurance subsidiaries' profits and net proceeds from debt issuance. Our use of operating cash derived from our non-insurance subsidiaries, such as our Healthcare Services segment, is generally not restricted by Departments of Insurance (or comparable state regulatory agencies). Our regulated insurance subsidiaries paid dividends to our parent company of $1.3 billion in 2020, $1.8 billion in 2019, and $2.3 billion in 2018. Subsidiary capital requirements from significant premium growth has impacted the amount of regulated subsidiary dividends over the last two years. Refer to our parent company financial statements and accompanying notes in Schedule I - Parent Company Financial Information. The amount of ordinary dividends that may be paid to our parent company in 2021 is approximately $1.4 billion, in the aggregate. Actual dividends paid may vary due to consideration of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix.
Regulatory Requirements
For a detailed discussion of our regulatory requirements, including aggregate statutory capital and surplus as well as dividends paid from the subsidiaries to our parent, please refer to Note 16 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
Off-Balance Sheet Arrangements
As of December 31, 2020, we were not involved in any special purpose entity, or SPE, transactions. For a detailed discussion of off-balance sheet arrangements, please refer to Note 17 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
Guarantees and Indemnifications
For a detailed discussion of our guarantees and indemnifications, please refer to Note 17 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
Government Contracts
For a detailed discussion of our government contracts, including our Medicare, Military, and Medicaid contracts, please refer to Note 17 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
Critical Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements and accompanying notes, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements and accompanying notes requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We continuously evaluate our estimates and those critical accounting policies primarily related to benefits expense and revenue recognition as well as accounting for impairments related to our investment securities, goodwill, and long-lived assets. These estimates are based on knowledge of current events and anticipated future events and, accordingly, actual results ultimately may differ from those estimates. We believe the following critical accounting policies involve the most significant judgments and estimates used in the preparation of our consolidated financial statements.
Benefits Expense Recognition
Benefits expense is recognized in the period in which services are provided and includes an estimate of the cost of services which have been incurred but not yet reported, or IBNR. IBNR represents a substantial portion of our benefits payable as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2020
|
|
Percentage
of Total
|
|
December 31, 2019
|
|
Percentage
of Total
|
|
(dollars in millions)
|
IBNR
|
$
|
5,290
|
|
|
65.0
|
%
|
|
$
|
4,150
|
|
|
69.1
|
%
|
Reported claims in process
|
816
|
|
|
10.0
|
%
|
|
628
|
|
|
10.5
|
%
|
|
|
|
|
|
|
|
|
Other benefits payable
|
2,037
|
|
|
25.0
|
%
|
|
1,226
|
|
|
20.4
|
%
|
Total benefits payable
|
$
|
8,143
|
|
|
100.0
|
%
|
|
$
|
6,004
|
|
|
100.0
|
%
|
Our reserving practice is to consistently recognize the actuarial best point estimate within a level of confidence required by actuarial standards. For further discussion of our reserving methodology, including our use of completion and claims per member per month trend factors to estimate IBNR, refer to Note 2 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
The completion and claims per member per month trend factors are the most significant factors impacting the IBNR estimate. The portion of IBNR estimated using completion factors for claims incurred prior to the most recent two months is generally less variable than the portion of IBNR estimated using trend factors. The following table illustrates the sensitivity of these factors assuming moderately adverse experience and the estimated potential impact on our operating results caused by reasonably likely changes in these factors based on December 31, 2020 data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Completion Factor (a):
|
|
Claims Trend Factor (b):
|
Factor
Change (c)
|
|
Decrease in
Benefits Payable
|
|
Factor
Change (c)
|
|
Decrease in
Benefits Payable
|
(dollars in millions)
|
0.70%
|
|
$(348)
|
|
3.00%
|
|
$(332)
|
0.60%
|
|
$(298)
|
|
2.75%
|
|
$(304)
|
0.50%
|
|
$(249)
|
|
2.50%
|
|
$(276)
|
0.40%
|
|
$(199)
|
|
2.25%
|
|
$(249)
|
0.30%
|
|
$(149)
|
|
2.00%
|
|
$(221)
|
0.20%
|
|
$(99)
|
|
1.75%
|
|
$(194)
|
0.10%
|
|
$(50)
|
|
1.50%
|
|
$(166)
|
(a)Reflects estimated potential changes in benefits payable at December 31, 2020 caused by changes in completion factors for incurred months prior to the most recent two months.
(b)Reflects estimated potential changes in benefits payable at December 31, 2020 caused by changes in annualized claims trend used for the estimation of per member per month incurred claims for the most recent two months.
(c)The factor change indicated represents the percentage point change.
The following table provides a historical perspective regarding the accrual and payment of our benefits payable. Components of the total incurred claims for each year include amounts accrued for current year estimated benefits expense as well as adjustments to prior year estimated accruals. Refer to Note 11 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data for Retail and Group and Specialty segment tables including information about incurred and paid claims development as of December 31, 2020, net of reinsurance, as well as cumulative claim frequency and the total of IBNR included within the net incurred claims amounts.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
2018
|
|
|
(in millions)
|
Balances at January 1
|
|
$
|
6,004
|
|
|
$
|
4,862
|
|
|
$
|
4,668
|
|
|
|
|
|
|
|
|
Less: Reinsurance recoverables
|
|
(68)
|
|
|
(95)
|
|
|
(70)
|
|
Balances at January 1, net
|
|
5,936
|
|
|
4,767
|
|
|
4,598
|
|
|
|
|
|
|
|
|
Incurred related to:
|
|
|
|
|
|
|
Current year
|
|
61,941
|
|
|
54,193
|
|
|
46,385
|
|
Prior years
|
|
(313)
|
|
|
(336)
|
|
|
(503)
|
|
Total incurred
|
|
61,628
|
|
|
53,857
|
|
|
45,882
|
|
Paid related to:
|
|
|
|
|
|
|
Current year
|
|
(54,003)
|
|
|
(48,421)
|
|
|
(41,736)
|
|
Prior years
|
|
(5,418)
|
|
|
(4,267)
|
|
|
(3,977)
|
|
Total paid
|
|
(59,421)
|
|
|
(52,688)
|
|
|
(45,713)
|
|
|
|
|
|
|
|
|
Reinsurance recoverable
|
|
—
|
|
|
68
|
|
|
95
|
|
Balances at December 31
|
|
$
|
8,143
|
|
|
$
|
6,004
|
|
|
$
|
4,862
|
|
The following table summarizes the changes in estimate for incurred claims related to prior years attributable to our key assumptions. As previously described, our key assumptions consist of trend and completion factors estimated using an assumption of moderately adverse conditions. The amounts below represent the difference between our original estimates and the actual benefits expense ultimately incurred as determined from subsequent claim payments.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Favorable Development by Changes in Key Assumptions
|
|
2020
|
|
2019
|
|
2018
|
|
Amount
|
|
Factor
Change (a)
|
|
Amount
|
|
Factor
Change (a)
|
|
Amount
|
|
Factor
Change (a)
|
|
(dollars in millions)
|
Trend factors
|
$
|
(167)
|
|
|
(1.9)
|
%
|
|
$
|
(233)
|
|
|
(3.1)
|
%
|
|
$
|
(229)
|
|
|
(3.3)
|
%
|
Completion factors
|
(146)
|
|
|
(0.3)
|
%
|
|
(103)
|
|
|
(0.3)
|
%
|
|
(274)
|
|
|
(0.8)
|
%
|
Total
|
$
|
(313)
|
|
|
|
|
$
|
(336)
|
|
|
|
|
$
|
(503)
|
|
|
|
(a)The factor change indicated represents the percentage point change.
As previously discussed, our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. We experienced favorable medical claims reserve development related to prior fiscal years of $313 million in 2020, $336 million in 2019, and $503 million in 2018. The table below details our favorable medical claims reserve development related to prior fiscal years by segment for 2020, 2019, and 2018.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Favorable) Unfavorable Medical Claims Reserve
Development
|
|
Change
|
|
2020
|
|
2019
|
|
2018
|
|
2020
|
|
2019
|
|
(in millions)
|
Retail Segment
|
$
|
(266)
|
|
|
$
|
(386)
|
|
|
$
|
(398)
|
|
|
$
|
120
|
|
|
$
|
12
|
|
Group and Specialty Segment
|
(47)
|
|
|
50
|
|
|
(46)
|
|
|
(97)
|
|
|
96
|
|
Individual Commercial Segment
|
—
|
|
|
—
|
|
|
(57)
|
|
|
—
|
|
|
57
|
|
Other Businesses
|
—
|
|
|
—
|
|
|
(2)
|
|
|
—
|
|
|
2
|
|
Total
|
$
|
(313)
|
|
|
$
|
(336)
|
|
|
$
|
(503)
|
|
|
$
|
23
|
|
|
$
|
167
|
|
The favorable medical claims reserve development for 2020, 2019, and 2018 primarily reflects the consistent application of trend and completion factors estimated using an assumption of moderately adverse conditions. Our favorable development for each of the years presented above is discussed further in Note 11 to the consolidated financial statements included in Item 8. – Financial Statements and Supplementary Data.
We continually adjust our historical trend and completion factor experience with our knowledge of recent events that may impact current trends and completion factors when establishing our reserves. Because our reserving practice is to consistently recognize the actuarial best point estimate using an assumption of moderately adverse conditions as required by actuarial standards, there is a reasonable possibility that variances between actual trend and completion factors and those assumed in our December 31, 2020 estimates would fall towards the middle of the ranges previously presented in our sensitivity table.
Revenue Recognition
We generally establish one-year commercial membership contracts with employer groups, subject to cancellation by the employer group on 30-day written notice. Our Medicare contracts with CMS renew annually. Our military services contracts with the federal government and certain contracts with various state Medicaid programs generally are multi-year contracts subject to annual renewal provisions.
We receive monthly premiums from the federal government and various states according to government specified payment rates and various contractual terms. We bill and collect premiums from employer groups and members in our Medicare and other individual products monthly. Changes in premium revenues resulting from the periodic changes in risk-adjustment scores derived from medical diagnoses for our membership are estimated by projecting the ultimate annual premium and recognized ratably during the year with adjustments each period to reflect changes in the ultimate premium.
Premiums revenue is estimated by multiplying the membership covered under the various contracts by the contractual rates. Premiums revenue is recognized as income in the period members are entitled to receive services, and is net of estimated uncollectible amounts, retroactive membership adjustments, and adjustments to recognize rebates under the minimum benefit ratios required under the Health Care Reform Law. We estimate policyholder rebates by projecting calendar year minimum benefit ratios for the small group and large group markets, as defined by the Health Care Reform Law using a methodology prescribed by HHS, separately by state and legal entity. Medicare Advantage products are also subject to minimum benefit ratio requirements under the Health Care Reform Law. Estimated calendar year rebates recognized ratably during the year are revised each period to reflect current experience. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. We routinely monitor the collectability of specific accounts, the aging of receivables, historical retroactivity trends, estimated rebates, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. Premiums received prior to the service period are recorded as unearned revenues.
Medicare Risk-Adjustment Provisions
CMS utilizes a risk-adjustment model which apportions premiums paid to Medicare Advantage, or MA, plans according to health severity. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997 (BBA) and the Benefits Improvement and Protection Act of 2000 (BIPA), generally pays more for enrollees with predictably higher costs. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses this diagnosis data to calculate the risk-adjusted premium payment to MA plans. Rates paid to MA plans are established under an actuarial bid model, including a process that bases our payments on a comparison of our beneficiaries’ risk scores, derived from medical diagnoses, to those enrolled in the government’s Medicare FFS program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our payment received from CMS under the actuarial risk-adjustment model. We also rely on providers to appropriately document all medical data, including the diagnosis data submitted with claims. CMS is phasing-in the process of calculating risk scores using diagnoses data from the Risk Adjustment Processing System, or RAPS, to diagnoses
data from the Encounter Data System, or EDS. The RAPS process requires MA plans to apply a filter logic based on CMS guidelines and only submit diagnoses that satisfy those guidelines. For submissions through EDS, CMS requires MA plans to submit all the encounter data and CMS will apply the risk adjustment filtering logic to determine the risk scores. For 2020, 50% of the risk score was calculated from claims data submitted through EDS. CMS increased that percentage to 75% for 2021 and will complete the phased-in transition from RAPS to EDS by using only EDS data to calculate risk scores in 2022. The phase-in from RAPS to EDS could result in different risk scores from each dataset as a result of plan processing issues, CMS processing issues, or filtering logic differences between RAPS and EDS, and could have a material adverse effect on our results of operations, financial position, or cash flows. We estimate risk-adjustment revenues based on medical diagnoses for our membership. The risk-adjustment model, including CMS changes to the submission process, is more fully described in Item 1. – Business under the section titled “Individual Medicare,” and in Item 1A. - Risk Factors.
Investment Securities
Investment securities totaled $13.8 billion, or 39% of total assets at December 31, 2020, and $11.4 billion, or 39% of total assets at December 31, 2019. The investment portfolio was primarily comprised of debt securities, detailed below, at December 31, 2020 and entirely at December 31, 2019. The fair value of investment securities were as follows at December 31, 2020 and 2019:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12/31/2020
|
|
Percentage
of Total
|
|
12/31/2019
|
|
Percentage
of Total
|
|
|
|
|
|
|
|
|
|
|
|
(dollars in millions)
|
U.S. Treasury and other U.S. government
corporations and agencies:
|
|
|
|
|
|
|
|
|
U.S. Treasury and agency obligations
|
|
$
|
616
|
|
|
4.5
|
%
|
|
$
|
354
|
|
|
3.1
|
%
|
Mortgage-backed securities
|
|
3,254
|
|
|
23.6
|
%
|
|
3,710
|
|
|
32.6
|
%
|
Tax-exempt municipal securities
|
|
1,447
|
|
|
10.5
|
%
|
|
1,463
|
|
|
12.9
|
%
|
Mortgage-backed securities:
|
|
|
|
|
|
|
|
|
Residential
|
|
17
|
|
|
0.1
|
%
|
|
—
|
|
|
—
|
%
|
Commercial
|
|
1,318
|
|
|
9.6
|
%
|
|
804
|
|
|
7.1
|
%
|
Asset-backed securities
|
|
1,372
|
|
|
10.0
|
%
|
|
1,093
|
|
|
9.6
|
%
|
Corporate debt securities
|
|
4,927
|
|
|
35.8
|
%
|
|
3,947
|
|
|
34.7
|
%
|
Total debt securities
|
|
12,951
|
|
|
94.1
|
%
|
|
11,371
|
|
|
99.9
|
%
|
Common stock
|
|
815
|
|
|
5.9
|
%
|
|
7
|
|
|
0.1
|
%
|
Total investment securities
|
|
$
|
13,766
|
|
|
100.0
|
%
|
|
$
|
11,378
|
|
|
100.0
|
%
|
Approximately 96% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by S&P at December 31, 2020. Most of the debt securities that were below investment-grade were rated BB, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.
Gross unrealized losses and fair values aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position were as follows at December 31, 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less than 12 months
|
|
12 months or more
|
|
Total
|
|
Fair
Value
|
|
Gross
Unrealized
Losses
|
|
Fair
Value
|
|
Gross
Unrealized
Losses
|
|
Fair
Value
|
|
Gross
Unrealized
Losses
|
|
|
(in millions)
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Treasury and other U.S. government
corporations and agencies:
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Treasury and agency obligations
|
$
|
225
|
|
|
$
|
(1)
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
225
|
|
|
$
|
(1)
|
|
Mortgage-backed securities
|
199
|
|
|
(1)
|
|
|
—
|
|
|
—
|
|
|
199
|
|
|
(1)
|
|
Tax-exempt municipal securities
|
16
|
|
|
—
|
|
|
19
|
|
|
—
|
|
|
35
|
|
|
—
|
|
Mortgage-backed securities:
|
|
|
|
|
|
|
|
|
|
|
|
Residential
|
17
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
17
|
|
|
—
|
|
Commercial
|
193
|
|
|
(1)
|
|
|
43
|
|
|
—
|
|
|
236
|
|
|
(1)
|
|
Asset-backed securities
|
65
|
|
|
—
|
|
|
498
|
|
|
(2)
|
|
|
563
|
|
|
(2)
|
|
Corporate debt securities
|
342
|
|
|
(1)
|
|
|
16
|
|
|
—
|
|
|
358
|
|
|
(1)
|
|
Total debt securities
|
$
|
1,057
|
|
|
$
|
(4)
|
|
|
$
|
576
|
|
|
$
|
(2)
|
|
|
$
|
1,633
|
|
|
$
|
(6)
|
|
Prior to January 1, 2020, we applied the other-than-temporary impairment model for securities in an unrealized loss position which did not result in any material impairments for 2019 or 2018. Beginning on January 1, 2020, we adopted the new current expected credit losses, or CECL, model which retained many similarities from the previous other-than-temporary impairment model except eliminating from consideration in the impairment analysis the length of time over which the fair value had been less than cost. Also, under the CECL model, expected losses on available for sale debt securities are recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities. For debt securities whose fair value is less than their amortized cost which we do not intend to sell or are not required to sell, we evaluate the expected cash flows to be received as compared to amortized cost and determine if an expected credit loss has occurred. In the event of an expected credit loss, only the amount of the impairment associated with the expected credit loss is recognized in income with the remainder, if any, of the loss recognized in other comprehensive income. To the extent we have the intent to sell the debt security or it is more likely than not we will be required to sell the debt security before recovery of our amortized cost basis, we recognize an impairment loss in income in an amount equal to the full difference between the amortized cost basis and the fair value.
Potential expected credit loss impairment is considered using a variety of factors, including the extent to which the fair value has been less than cost; adverse conditions specifically related to the industry, geographic area or financial condition of the issuer or underlying collateral of a debt security; changes in the quality of the debt security's credit enhancement; payment structure of the debt security; changes in credit rating of the debt security by the rating agencies; failure of the issuer to make scheduled principal or interest payments on the debt security and changes in prepayment speeds. For debt securities, we take into account expectations of relevant market and economic data. For example, with respect to mortgage and asset-backed securities, such data includes underlying loan level data and structural features such as seniority and other forms of credit enhancements. We estimate the amount of the expected credit loss component of a debt security as the difference between the amortized cost and the present value of the expected cash flows of the security. The present value is determined using the best estimate of future cash flows discounted at the implicit interest rate at the date of purchase. The expected credit loss cannot exceed the full difference between the amortized cost basis and the fair value.
The risks inherent in assessing the impairment of an investment include the risk that market factors may differ from our expectations, facts and circumstances factored into our assessment may change with the passage of time, or we may decide to subsequently sell the investment. The determination of whether a decline in the value of an
investment is related to a credit event requires us to exercise significant diligence and judgment. The discovery of new information and the passage of time can significantly change these judgments. The status of the general economic environment and significant changes in the national securities markets influence the determination of fair value and the assessment of investment impairment. There is a continuing risk that declines in fair value may occur and additional material realized losses from sales or expected credit loss impairments may be recorded in future periods.
All issuers of debt securities we own that were trading at an unrealized loss at December 31, 2020 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time the debt securities were purchased. At December 31, 2020, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position at December 31, 2020. There were no material other-than-temporary impairments in 2019 or 2018.
Goodwill and Long-lived Assets
At December 31, 2020, goodwill and other long-lived assets represented 20% of total assets and 52% of total stockholders’ equity, compared to 21% and 50%, respectively, at December 31, 2019.
We are required to test at least annually for impairment at a level of reporting referred to as the reporting unit, and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. A reporting unit either is our operating segments or one level below the operating segments, referred to as a component, which comprise our reportable segments. A component is considered a reporting unit if the component constitutes a business for which discrete financial information is available that is regularly reviewed by management. We are required to aggregate the components of an operating segment into one reporting unit if they have similar economic characteristics. Goodwill is assigned to the reporting unit that is expected to benefit from a specific acquisition.
We use the one-step process to review goodwill for impairment to determine both the existence and amount of goodwill impairment, if any. Our strategy, long-range business plan, and annual planning process support our goodwill impairment tests. These tests are performed, at a minimum, annually in the fourth quarter, and are based on an evaluation of future discounted cash flows. We rely on this discounted cash flow analysis to determine fair value. However outcomes from the discounted cash flow analysis are compared to other market approach valuation methodologies for reasonableness. We use discount rates that correspond to a market-based weighted-average cost of capital and terminal growth rates that correspond to long-term growth prospects, consistent with the long-term inflation rate. Key assumptions in our cash flow projections, including changes in membership, premium yields, medical and operating cost trends, and certain government contract extensions, are consistent with those utilized in our long-range business plan and annual planning process. If these assumptions differ from actual, including the impact of the Health Care Reform Law or changes in government reimbursement rates, the estimates underlying our goodwill impairment tests could be adversely affected. The fair value of our reporting units with significant goodwill exceeded carrying amounts by a substantial margin. However, unfavorable changes in key assumptions or combinations of assumptions including a significant increase in the discount rate, decrease in the long-term growth rate or substantial reduction in our underlying cash flow assumptions, including revenue growth rates, medical and operating cost trends, and projected operating income could have a significant negative impact on the estimated fair value of our clinical and provider reporting units, which accounted for $524 million and $761 million, respectively. Impairment tests completed for 2020, 2019, and 2018 did not result in an impairment loss.
Long-lived assets consist of property and equipment and other finite-lived intangible assets. These assets are depreciated or amortized over their estimated useful life, and are subject to impairment reviews. We periodically review long-lived assets whenever adverse events or changes in circumstances indicate the carrying value of the asset may not be recoverable. In assessing recoverability, we must make assumptions regarding estimated future cash flows and other factors to determine if an impairment loss may exist, and, if so, estimate fair value. We also must estimate and make assumptions regarding the useful life we assign to our long-lived assets. If these estimates
or their related assumptions change in the future, we may be required to record impairment losses or change the useful life, including accelerating depreciation or amortization for these assets. There were no material impairment losses in the last three years.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Humana Inc.
CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
2020
|
|
2019
|
|
(in millions, except
share amounts)
|
ASSETS
|
|
|
|
Current assets:
|
|
|
|
Cash and cash equivalents
|
$
|
4,673
|
|
|
$
|
4,054
|
|
Investment securities
|
12,554
|
|
|
10,972
|
|
Receivables, less allowance for doubtful accounts
of $72 in 2020 and $69 in 2019
|
1,138
|
|
|
1,056
|
|
Other current assets
|
5,276
|
|
|
3,806
|
|
|
|
|
|
Total current assets
|
23,641
|
|
|
19,888
|
|
Property and equipment, net
|
2,371
|
|
|
1,955
|
|
Long-term investment securities
|
1,212
|
|
|
406
|
|
Goodwill
|
4,447
|
|
|
3,928
|
|
Equity method investments
|
1,170
|
|
|
1,063
|
|
Other long-term assets
|
2,128
|
|
|
1,834
|
|
Total assets
|
$
|
34,969
|
|
|
$
|
29,074
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
Current liabilities:
|
|
|
|
Benefits payable
|
$
|
8,143
|
|
|
$
|
6,004
|
|
Trade accounts payable and accrued expenses
|
4,013
|
|
|
3,754
|
|
Book overdraft
|
320
|
|
|
225
|
|
Unearned revenues
|
318
|
|
|
247
|
|
Short-term debt
|
600
|
|
|
699
|
|
|
|
|
|
Total current liabilities
|
13,394
|
|
|
10,929
|
|
Long-term debt
|
6,060
|
|
|
4,967
|
|
Other long-term liabilities
|
1,787
|
|
|
1,141
|
|
Total liabilities
|
21,241
|
|
|
17,037
|
|
Commitments and contingencies (Note 17)
|
|
|
|
Stockholders’ equity:
|
|
|
|
Preferred stock, $1 par; 10,000,000 shares authorized; none issued
|
—
|
|
|
—
|
|
Common stock, $0.16 2/3 par; 300,000,000 shares authorized;
198,648,742 shares issued at December 31, 2020 and 198,629,992
shares issued at December 31, 2019
|
33
|
|
|
33
|
|
Capital in excess of par value
|
2,705
|
|
|
2,820
|
|
Retained earnings
|
20,517
|
|
|
17,483
|
|
Accumulated other comprehensive income (loss)
|
391
|
|
|
156
|
|
Treasury stock, at cost, 69,787,614 shares at December 31, 2020
and 66,524,771 shares at December 31, 2019
|
(9,918)
|
|
|
(8,455)
|
|
Total stockholders’ equity
|
13,728
|
|
|
12,037
|
|
Total liabilities and stockholders’ equity
|
$
|
34,969
|
|
|
$
|
29,074
|
|
The accompanying notes are an integral part of the consolidated financial statements.
Humana Inc.
CONSOLIDATED STATEMENTS OF INCOME
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31,
|
|
2020
|
|
2019
|
|
2018
|
|
(in millions, except per share results)
|
Revenues:
|
|
|
|
|
|
Premiums
|
$
|
74,186
|
|
|
$
|
62,948
|
|
|
$
|
54,941
|
|
Services
|
1,815
|
|
|
1,439
|
|
|
1,457
|
|
Investment income
|
1,154
|
|
|
501
|
|
|
514
|
|
Total revenues
|
77,155
|
|
|
64,888
|
|
|
56,912
|
|
Operating expenses:
|
|
|
|
|
|
Benefits
|
61,628
|
|
|
53,857
|
|
|
45,882
|
|
Operating costs
|
10,052
|
|
|
7,381
|
|
|
7,525
|
|
|
|
|
|
|
|
Depreciation and amortization
|
489
|
|
|
458
|
|
|
405
|
|
Total operating expenses
|
72,169
|
|
|
61,696
|
|
|
53,812
|
|
Income from operations
|
4,986
|
|
|
3,192
|
|
|
3,100
|
|
Loss on sale of business
|
—
|
|
|
—
|
|
|
786
|
|
Interest expense
|
283
|
|
|
242
|
|
|
218
|
|
Other expense (income), net
|
103
|
|
|
(506)
|
|
|
33
|
|
Income before income taxes and equity in net earnings
|
4,600
|
|
|
3,456
|
|
|
2,063
|
|
Provision for income taxes
|
1,307
|
|
|
763
|
|
|
391
|
|
Equity in net earnings
|
74
|
|
|
14
|
|
|
11
|
|
Net income
|
$
|
3,367
|
|
|
$
|
2,707
|
|
|
$
|
1,683
|
|
Basic earnings per common share
|
$
|
25.47
|
|
|
$
|
20.20
|
|
|
$
|
12.24
|
|
Diluted earnings per common share
|
$
|
25.31
|
|
|
$
|
20.10
|
|
|
$
|
12.16
|
|
The accompanying notes are an integral part of the consolidated financial statements.
Humana Inc.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31,
|
|
2020
|
|
2019
|
|
2018
|
|
(in millions)
|
Net income
|
$
|
3,367
|
|
|
$
|
2,707
|
|
|
$
|
1,683
|
|
Other comprehensive income (loss):
|
|
|
|
|
|
Change in gross unrealized investment gains/losses
|
393
|
|
|
450
|
|
|
(189)
|
|
Effect of income taxes
|
(89)
|
|
|
(105)
|
|
|
51
|
|
Total change in unrealized investment
gains/losses, net of tax
|
304
|
|
|
345
|
|
|
(138)
|
|
Reclassification adjustment for net realized
gains included in investment income
|
(90)
|
|
|
(34)
|
|
|
(53)
|
|
Effect of income taxes
|
20
|
|
|
8
|
|
|
17
|
|
Total reclassification adjustment, net of tax
|
(70)
|
|
|
(26)
|
|
|
(36)
|
|
Other comprehensive income (loss), net of tax
|
234
|
|
|
319
|
|
|
(174)
|
|
Comprehensive income (loss) attributable to equity method
investments
|
1
|
|
|
(4)
|
|
|
(4)
|
|
Comprehensive income
|
$
|
3,602
|
|
|
$
|
3,022
|
|
|
$
|
1,505
|
|
The accompanying notes are an integral part of the consolidated financial statements.
Humana Inc.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock
|
|
Capital In
Excess of
Par Value
|
|
Retained
Earnings
|
|
Accumulated
Other
Comprehensive
Income (Loss)
|
|
Treasury
Stock
|
|
Total
Stockholders’
Equity
|
|
Issued
Shares
|
|
Amount
|
|
|
(dollars in millions, share amounts in thousands)
|
Balances, January 1, 2018
|
198,572
|
|
|
$
|
33
|
|
|
$
|
2,445
|
|
|
$
|
13,670
|
|
|
$
|
19
|
|
|
$
|
(6,325)
|
|
|
$
|
9,842
|
|
Net income
|
|
|
|
|
|
|
1,683
|
|
|
|
|
|
|
1,683
|
|
Other comprehensive income
|
|
|
|
|
|
|
(4)
|
|
|
(178)
|
|
|
|
|
(182)
|
|
Common stock repurchases
|
—
|
|
|
|
|
50
|
|
|
|
|
|
|
(1,140)
|
|
|
(1,090)
|
|
Dividends and dividend
equivalents
|
|
|
|
|
—
|
|
|
(277)
|
|
|
|
|
|
|
(277)
|
|
Stock-based compensation
|
|
|
|
|
137
|
|
|
|
|
|
|
|
|
137
|
|
Restricted stock unit vesting
|
—
|
|
|
—
|
|
|
(145)
|
|
|
|
|
|
|
145
|
|
|
—
|
|
Stock option exercises
|
23
|
|
|
—
|
|
|
48
|
|
|
|
|
|
|
—
|
|
|
48
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances, December 31, 2018
|
198,595
|
|
|
33
|
|
|
2,535
|
|
|
15,072
|
|
|
(159)
|
|
|
(7,320)
|
|
|
10,161
|
|
Net income
|
|
|
|
|
|
|
2,707
|
|
|
|
|
|
|
2,707
|
|
Other comprehensive loss
|
|
|
|
|
|
|
—
|
|
|
315
|
|
|
|
|
315
|
|
Common stock repurchases
|
—
|
|
|
|
|
150
|
|
|
|
|
|
|
(1,220)
|
|
|
(1,070)
|
|
Dividends and dividend
equivalents
|
|
|
|
|
—
|
|
|
(296)
|
|
|
|
|
|
|
(296)
|
|
Stock-based compensation
|
|
|
|
|
163
|
|
|
|
|
|
|
|
|
163
|
|
Restricted stock unit vesting
|
32
|
|
|
—
|
|
|
(48)
|
|
|
|
|
|
|
48
|
|
|
—
|
|
Stock option exercises
|
3
|
|
|
—
|
|
|
20
|
|
|
|
|
|
|
37
|
|
|
57
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances, December 31, 2019
|
198,630
|
|
|
33
|
|
|
2,820
|
|
|
17,483
|
|
|
156
|
|
|
(8,455)
|
|
|
12,037
|
|
Net income
|
|
|
|
|
|
|
3,367
|
|
|
|
|
|
|
3,367
|
|
Impact of adopting accounting standard
|
|
|
|
|
|
|
(2)
|
|
|
|
|
|
|
(2)
|
|
Other comprehensive income
|
|
|
|
|
|
|
—
|
|
|
235
|
|
|
|
|
235
|
|
Common stock repurchases
|
—
|
|
|
|
|
(263)
|
|
|
|
|
|
|
(1,557)
|
|
|
(1,820)
|
|
Dividends and dividend
equivalents
|
|
|
|
|
—
|
|
|
(331)
|
|
|
|
|
|
|
(331)
|
|
Stock-based compensation
|
|
|
|
|
181
|
|
|
|
|
|
|
|
|
181
|
|
Restricted stock unit vesting
|
19
|
|
|
—
|
|
|
(59)
|
|
|
|
|
|
|
59
|
|
|
—
|
|
Stock option exercises
|
—
|
|
|
—
|
|
|
26
|
|
|
|
|
|
|
35
|
|
|
61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances, December 31, 2020
|
198,649
|
|
|
$
|
33
|
|
|
$
|
2,705
|
|
|
$
|
20,517
|
|
|
$
|
391
|
|
|
$
|
(9,918)
|
|
|
$
|
13,728
|
|
The accompanying notes are an integral part of the consolidated financial statements.
Humana Inc.
CONSOLIDATED STATEMENTS OF CASH FLOW
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31,
|
|
2020
|
|
2019
|
|
2018
|
|
(in millions)
|
Cash flows from operating activities
|
|
|
|
|
|
Net income
|
$
|
3,367
|
|
|
$
|
2,707
|
|
|
$
|
1,683
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
Loss on sale of business
|
—
|
|
|
—
|
|
|
786
|
|
Gains on investment securities, net
|
(838)
|
|
|
(62)
|
|
|
(90)
|
|
Equity in net earnings
|
(74)
|
|
|
(14)
|
|
|
(11)
|
|
Stock compensation
|
181
|
|
|
163
|
|
|
137
|
|
Depreciation
|
528
|
|
|
505
|
|
|
444
|
|
Amortization
|
88
|
|
|
70
|
|
|
90
|
|
Provision for deferred income taxes
|
195
|
|
|
162
|
|
|
194
|
|
|
|
|
|
|
|
Changes in operating assets and liabilities, net of effect of businesses acquired and dispositions:
|
|
|
|
|
|
Receivables
|
(85)
|
|
|
(32)
|
|
|
(164)
|
|
Other assets
|
(581)
|
|
|
118
|
|
|
(484)
|
|
Benefits payable
|
2,139
|
|
|
1,142
|
|
|
252
|
|
Other liabilities
|
599
|
|
|
471
|
|
|
(676)
|
|
Unearned revenues
|
71
|
|
|
(36)
|
|
|
(95)
|
|
Other
|
49
|
|
|
90
|
|
|
107
|
|
Net cash provided by operating activities
|
5,639
|
|
|
5,284
|
|
|
2,173
|
|
Cash flows from investing activities
|
|
|
|
|
|
Acquisitions, net of cash acquired
|
(709)
|
|
|
—
|
|
|
(354)
|
|
Purchase of equity method investment in Kindred at Home
|
—
|
|
|
—
|
|
|
(1,095)
|
|
Cash transferred in sale of business
|
—
|
|
|
—
|
|
|
(805)
|
|
Purchases of property and equipment
|
(964)
|
|
|
(736)
|
|
|
(612)
|
|
|
|
|
|
|
|
Purchases of investment securities
|
(9,125)
|
|
|
(6,361)
|
|
|
(4,687)
|
|
Maturities of investment securities
|
4,986
|
|
|
1,733
|
|
|
972
|
|
Proceeds from sales of investment securities
|
2,747
|
|
|
4,086
|
|
|
3,494
|
|
Net cash used in investing activities
|
(3,065)
|
|
|
(1,278)
|
|
|
(3,087)
|
|
Cash flows from financing activities
|
|
|
|
|
|
Withdrawals from contract deposits, net
|
(939)
|
|
|
(623)
|
|
|
(640)
|
|
Proceeds from issuance of senior notes, net
|
1,088
|
|
|
987
|
|
|
—
|
|
Repayment of senior notes
|
(400)
|
|
|
(400)
|
|
|
—
|
|
Proceeds (repayments) from issuance of commercial paper, net
|
295
|
|
|
(360)
|
|
|
485
|
|
Proceeds from term loan
|
1,000
|
|
|
—
|
|
|
1,000
|
|
Repayment of term loan
|
(1,000)
|
|
|
(650)
|
|
|
(350)
|
|
Common stock repurchases
|
(1,820)
|
|
|
(1,070)
|
|
|
(1,090)
|
|
Dividends paid
|
(323)
|
|
|
(291)
|
|
|
(265)
|
|
Change in book overdraft
|
95
|
|
|
54
|
|
|
30
|
|
Proceeds from stock option exercises & other
|
49
|
|
|
58
|
|
|
45
|
|
Net cash used in financing activities
|
(1,955)
|
|
|
(2,295)
|
|
|
(785)
|
|
Increase (decrease) in cash and cash equivalents
|
619
|
|
|
1,711
|
|
|
(1,699)
|
|
Cash and cash equivalents at beginning of period
|
4,054
|
|
|
2,343
|
|
|
4,042
|
|
Cash and cash equivalents at end of period
|
$
|
4,673
|
|
|
$
|
4,054
|
|
|
$
|
2,343
|
|
Humana Inc.
CONSOLIDATED STATEMENTS OF CASH FLOW—(Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31,
|
|
2020
|
|
2019
|
|
2018
|
Supplemental cash flow disclosures:
|
(in millions)
|
Interest payments
|
$
|
258
|
|
|
$
|
212
|
|
|
$
|
195
|
|
Income tax payments, net
|
$
|
1,132
|
|
|
$
|
518
|
|
|
$
|
631
|
|
Details of businesses acquired in purchase transactions:
|
|
|
|
|
|
Fair value of assets acquired, net of cash acquired
|
$
|
819
|
|
|
$
|
28
|
|
|
$
|
392
|
|
Less: Fair value of liabilities assumed
|
(110)
|
|
|
(28)
|
|
|
(38)
|
|
Cash paid for acquired businesses, net of cash acquired
|
$
|
709
|
|
|
$
|
—
|
|
|
$
|
354
|
|
The accompanying notes are an integral part of the consolidated financial statements.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. REPORTING ENTITY
Nature of Operations
Humana Inc., headquartered in Louisville, Kentucky, is a leading health and well-being company committed to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and well‐being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large. To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients, our members. Our range of clinical capabilities, resources and tools, such as in‐home care, behavioral health, pharmacy services, data analytics and wellness solutions, combine to produce a simplified experience that makes health care easier to navigate and more effective. References throughout these notes to consolidated financial statements to “we,” “us,” “our,” “Company,” and “Humana,” mean Humana Inc. and its subsidiaries. We derived approximately 83% of our total premiums and services revenue from contracts with the federal government in 2020, including 14% related to our federal government contracts with the Centers for Medicare and Medicaid Services, or CMS, to provide health insurance coverage for individual Medicare Advantage members in Florida. CMS is the federal government’s agency responsible for administering the Medicare program.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
Our financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. Our consolidated financial statements include the accounts of Humana Inc. and subsidiaries that the Company controls, including variable interest entities associated with medical practices for which we are the primary beneficiary. We do not own many of our medical practices but instead enter into exclusive management agreements with the affiliated Professional Associations, or P.A.s, that operate these medical practices. Based upon the provisions of these agreements, these affiliated P.A.s are variable interest entities and we are the primary beneficiary, and accordingly we consolidate the affiliated P.A.s. All significant intercompany balances and transactions have been eliminated.
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.
COVID-19
The emergence and spread of COVID-19 has impacted our business. Beginning in the second half of March 2020, the implementation of stay-at-home and physical distancing orders and other restrictions on movement and economic activity resulted in the temporary deferral of non-essential care and significant reduction in hospital admissions and overall healthcare system utilization during April 2020. Non-COVID utilization then began to increase during May and June 2020, and continued to rebound throughout the third quarter and early in the fourth quarter of 2020, reaching approximately 95% of historic baseline levels as of the end of October 2020. Then, in the latter half of November and accelerating throughout the month of December, we experienced a significant increase in COVID-19 admissions in nearly all of the markets in which we operate across our Medicare Advantage, Medicaid, and group commercial insurance business lines, resulting in higher COVID-19 treatment and testing costs. During this period, we also experienced a corresponding decline in non-COVID utilization in all service categories to well below the near baseline levels of non-COVID utilization witnessed as late as the end of October 2020 (with non-COVID utilization in our Medicare Advantage business running approximately 15%
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
below normal levels at the close of the fourth quarter of 2020). The impact of this decline in non-COVID utilization more than offset the higher COVID-19 treatment and testing costs during this period. Our 2020 results were also impacted by our ongoing pandemic relief efforts and strategic investments in our integrated care delivery model.
Workforce Optimization
We initiated an involuntary workforce reduction program during 2019. This program impacted approximately 1,000 associates. As a result, we recorded charges of $47 million in 2019. Payments under this program were made upon termination during the severance pay period. The remaining 2019 workforce optimization obligation was $45 million as of December 31, 2019 and was fully settled as of December 31, 2020.
Health Care Reform
The Patient Protection and Affordable Care Act and The Health Care and Education Reconciliation Act of 2010 (which we collectively refer to as the Health Care Reform Law) enacted significant reforms to various aspects of the U.S. health insurance industry. Certain of these reforms became effective January 1, 2014, including an annual insurance industry premium-based fee. The Continuing Resolution bill, H.R. 195, enacted on January 22, 2018, included a one year suspension in 2019 of the health insurance industry fee, but the fee resumed in calendar year 2020. The Further Consolidated Appropriations Act, 2020, enacted on December 20, 2019, permanently repealed the health insurance industry fee beginning in calendar year 2021.
The annual premium-based fee on health insurers is not deductible for tax purposes. We estimate a liability for the health insurance industry fee and record it in full once qualifying insurance coverage is provided in the applicable calendar year in which the fee is payable with a corresponding deferred cost that is amortized ratably to expense over the same calendar year. We record the liability for the health insurance industry fee in trade accounts payable and accrued expenses and record the deferred cost in other current assets in our consolidated financial statements. We pay the health insurance industry fee in September or October of each year. We paid the federal government $1.18 billion and $1.04 billion for the annual health insurance industry fee attributed to calendar years 2020 and 2018, respectively.
On November 2, 2017, we filed suit against the United States of America in the United States Court of Federal Claims, on behalf of our health plans seeking recovery from the federal government of approximately $611 million in payments under the risk corridor premium stabilization program established under Health Care Reform, for years 2014, 2015 and 2016. On April 27, 2020, the U.S. Supreme Court ruled that the government is obligated to pay the losses under this risk corridor program, and that Congress did not impliedly repeal the obligation under its appropriations riders. In September 2020, we received a $609 million payment from the U.S Government pursuant to the judgement issued by the Court of Federal Claims on July 7, 2020. The $609 million payment received from the U.S Government and approximately $31 million in related fees and expenses are reflected in Premiums revenue and Operating costs, respectively, in our consolidated statements of income for the year ended December 31, 2020 and reported in the Corporate segment.
Cash and Cash Equivalents
Cash and cash equivalents include cash, time deposits, money market funds, commercial paper, other money market instruments, and certain U.S. Government securities with an original maturity of three months or less. Carrying value approximates fair value due to the short-term maturity of the investments.
Investment Securities
Investment securities, which consist of debt and equity securities, are stated at fair value. Our debt securities have been categorized as available for sale. Debt securities available for current operations are classified as current assets and debt securities available to fund our professional and other self-insurance liability requirements, as well as restricted statutory deposits and equity securities, are classified as long-term assets. For the purpose of determining realized gross gains and losses for debt securities sold, which are included as a component of investment income in
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
the consolidated statements of income, the cost of investment securities sold is based upon specific identification. Unrealized holding gains and losses for debt securities, net of applicable deferred taxes, are included as a component of stockholders’ equity and comprehensive income until realized from a sale or an expected credit loss is recognized. For the purpose of determining gross gains and losses for equity securities, changes in fair value at the reporting date are included as a component of investment income in the consolidated statements of income.
Prior to January 1, 2020, we applied the other-than-temporary impairment model for securities in an unrealized loss position which did not result in any material impairments for 2019 or 2018. Beginning on January 1, 2020, we adopted the new current expected credit losses, or CECL, model which retained many similarities from the previous other-than-temporary impairment model except eliminating from consideration in the impairment analysis the length of time over which the fair value had been less than cost. Also, under the CECL model, expected losses on available for sale debt securities are recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities. For debt securities whose fair value is less than their amortized cost which we do not intend to sell or are not required to sell, we evaluate the expected cash flows to be received as compared to amortized cost and determine if an expected credit loss has occurred. In the event of an expected credit loss, only the amount of the impairment associated with the expected credit loss is recognized in income with the remainder, if any, of the loss recognized in other comprehensive income. To the extent we have the intent to sell the debt security or it is more likely than not we will be required to sell the debt security before recovery of our amortized cost basis, we recognize an impairment loss in income in an amount equal to the full difference between the amortized cost basis and the fair value.
Potential expected credit loss impairment is considered using a variety of factors, including the extent to which the fair value has been less than cost; adverse conditions specifically related to the industry, geographic area or financial condition of the issuer or underlying collateral of a debt security; changes in the quality of the debt security's credit enhancement; payment structure of the debt security; changes in credit rating of the debt security by the rating agencies; failure of the issuer to make scheduled principal or interest payments on the debt security and changes in prepayment speeds. For debt securities, we take into account expectations of relevant market and economic data. For example, with respect to mortgage and asset-backed securities, such data includes underlying loan level data and structural features such as seniority and other forms of credit enhancements. We estimate the amount of the expected credit loss component of a debt security as the difference between the amortized cost and the present value of the expected cash flows of the security. The present value is determined using the best estimate of future cash flows discounted at the implicit interest rate at the date of purchase. The expected credit loss cannot exceed the full difference between the amortized cost basis and the fair value.
Receivables and Revenue Recognition
We generally establish one-year commercial membership contracts with employer groups, subject to cancellation by the employer group on 30-day written notice. Our Medicare contracts with CMS renew annually. Our military services contracts with the federal government and certain contracts with various state Medicaid programs generally are multi-year contracts subject to annual renewal provisions.
Premiums Revenue
We receive monthly premiums from the federal government and various states according to government specified payment rates and various contractual terms. We bill and collect premium from employer groups and members in our Medicare and other individual products monthly. Changes in premium revenues resulting from the periodic changes in risk-adjustment scores derived from medical diagnoses for our membership are estimated by projecting the ultimate annual premium and are recognized ratably during the year, with adjustments each period to reflect changes in the ultimate premium. Receivables or payables are classified as current or long-term in our consolidated balance sheet based on the timing of the expected settlement.
Premiums revenue is estimated by multiplying the membership covered under the various contracts by the contractual rates. Premiums revenue is recognized as income in the period members are entitled to receive services, and is net of estimated uncollectible amounts, retroactive membership adjustments, and adjustments to recognize rebates under the minimum benefit ratios required under the Health Care Reform Law. We estimate policyholder
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
rebates by projecting calendar year minimum benefit ratios for the small group and large group markets, as defined by the Health Care Reform Law using a methodology prescribed by Health and Human Services, or HHS, separately by state and legal entity. Medicare Advantage and Medicaid products are also subject to minimum benefit ratio requirements. Estimated calendar year rebates recognized ratably during the year are revised each period to reflect current experience. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. We routinely monitor the collectability of specific accounts, the aging of receivables, historical retroactivity trends, estimated rebates, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. Premiums received prior to the service period are recorded as unearned revenues.
Medicare Part D
We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with CMS. The payments we receive monthly from CMS and members, which are determined from our annual bid, represent amounts for providing prescription drug insurance coverage. We recognize premiums revenue for providing this insurance coverage ratably over the term of our annual contract. Our CMS payment is subject to risk sharing through the Medicare Part D risk corridor provisions. In addition, receipts for reinsurance and low-income cost subsidies as well as receipts for certain discounts on brand name prescription drugs in the coverage gap represent payments for prescription drug costs for which we are not at risk.
The risk corridor provisions compare costs targeted in our bids to actual prescription drug costs, limited to actual costs that would have been incurred under the standard coverage as defined by CMS. Variances exceeding certain thresholds may result in CMS making additional payments to us or require us to refund to CMS a portion of the premiums we received. As risk corridor provisions are considered in our overall annual bid process, we estimate and recognize an adjustment to premiums revenue related to these provisions based upon pharmacy claims experience. We record a receivable or payable at the contract level and classify the amount as current or long-term in our consolidated balance sheets based on the timing of expected settlement.
Reinsurance and low-income cost subsidies represent funding from CMS in connection with the Medicare Part D program for which we assume no risk. Reinsurance subsidies represent funding from CMS for its portion of prescription drug costs which exceed the member’s out-of-pocket threshold, or the catastrophic coverage level. Low-income cost subsidies represent funding from CMS for all or a portion of the deductible, the coinsurance and co-payment amounts above the out-of-pocket threshold for low-income beneficiaries. Monthly prospective payments from CMS for reinsurance and low-income cost subsidies are based on assumptions submitted with our annual bid. A reconciliation and related settlement of CMS’s prospective subsidies against actual prescription drug costs we paid is made after the end of the year. The Health Care Reform Law mandates consumer discounts of 50% on brand name prescription drugs for Part D plan participants in the coverage gap. These discounts are funded by CMS and pharmaceutical manufacturers while we administer the application of these funds. We account for these subsidies and discounts as a deposit in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits in our consolidated statements of cash flows. For 2020, subsidy and discount payments of $13.3 billion exceeded reimbursements of $12.4 billion by $0.9 billion. For 2019, subsidy and discount payments of $11.8 billion exceeded reimbursements of $11.2 billion by $0.6 billion. For 2018, subsidy and discount payments of $10.3 billion exceeded reimbursements of $9.6 billion by $0.7 billion. We do not recognize premiums revenue or benefit expenses for these subsidies or discounts. Receipt and payment activity is accumulated at the contract level and recorded in our consolidated balance sheets in other current assets or trade accounts payable and accrued expenses depending on the contract balance at the end of the reporting period.
Settlement of the reinsurance and low-income cost subsidies as well as the risk corridor payment is based on a reconciliation made approximately 9 months after the close of each calendar year. Settlement with CMS for brand name prescription drug discounts is based on a reconciliation made approximately 14 to 18 months after the close of each calendar year. We continue to revise our estimates with respect to the risk corridor provisions based on subsequent period pharmacy claims data. See Note 7 for detail regarding amounts recorded to our consolidated balance sheets related to the risk corridor settlement and subsidies from CMS with respect to the Medicare Part D program.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Services Revenue
Patient services revenue
Patient services include injury and illness care and related services as well as other healthcare services related to customer needs or as required by law. Patient services revenues are recognized in the period services are provided to the customer and are net of contractual allowances.
Administrative services fees
Administrative services fees cover the processing of claims, offering access to our provider networks and clinical programs, and responding to customer service inquiries from members of self-funded groups. Revenues from providing administration services, also known as administrative services only, or ASO, are recognized in the period services are performed and are net of estimated uncollectible amounts. ASO fees are estimated by multiplying the membership covered under the various contracts by the contractual rates. Under ASO contracts, self-funded employers retain the risk of financing substantially all of the cost of health benefits. However, many ASO customers purchase stop loss insurance coverage from us to cover catastrophic claims or to limit aggregate annual costs. Accordingly, we have recorded premiums revenue and benefits expense related to these stop loss insurance contracts. We routinely monitor the collectability of specific accounts, the aging of receivables, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. ASO fees received prior to the service period are recorded as unearned revenues.
Under our TRICARE contracts with the Department of Defense (DoD) we provide administrative services, including offering access to our provider networks and clinical programs, claim processing, customer service, enrollment, and other services, while the federal government retains all of the risk of the cost of health benefits. We account for revenues under our contracts net of estimated health care costs similar to an administrative services fee only agreement. Our contracts include fixed administrative services fees and incentive fees and penalties. Administrative services fees are recognized as services are performed.
Our TRICARE members are served by both in-network and out-of-network providers in accordance with our contracts. We pay health care costs related to these services to the providers and are subsequently reimbursed by the DoD for such payments. We account for the payments of the federal government’s claims and the related reimbursements under deposit accounting in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits in our consolidated statements of cash flows. For 2020, health care cost reimbursements and payments were each approximately $6.3 billion with payments exceeding reimbursements by $1 million. For 2019, health care cost payments of approximately $6.5 billion exceeded reimbursements of approximately $6.4 billion by $63 million. For 2018, health care cost reimbursements and payments were each approximately $5.6 billion with reimbursements exceeding payments by $38 million for the year.
Receivables
Receivables, including premium receivables, patient services revenue receivables, and ASO fee receivables, are shown net of allowances for estimated uncollectible accounts, retroactive membership adjustments, and contractual allowances.
At December 31, 2020 and 2019, accounts receivable related to services were $161 million and $141 million, respectively. For the year ended December 31, 2020, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the consolidated balance sheet at December 31, 2020 and 2019.
For the year ended December 31, 2020, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price), was not material. Further, revenue expected to be recognized in any future year related to remaining performance obligations was not material.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Other Current Assets
Other current assets includes amounts associated with Medicare Part D as discussed above and in Note 7, rebates due from pharmaceutical manufacturers and other amounts due within one year. We accrue pharmaceutical rebates as they are earned based on contractual terms and usage of the product. The balance of pharmaceutical rebates receivable was $1.4 billion and $1.3 billion at December 31, 2020 and 2019, respectively.
Policy Acquisition Costs
Policy acquisition costs are those costs that relate directly to the successful acquisition of new and renewal insurance policies. Such costs include commissions, costs of policy issuance and underwriting, and other costs we incur to acquire new business or renew existing business. We expense policy acquisition costs related to our employer-group prepaid health services policies as incurred. These short-duration employer-group prepaid health services policies typically have a 1-year term and may be canceled upon 30 days notice by the employer group.
Long-Lived Assets
Property and equipment is recorded at cost. Gains and losses on sales or disposals of property and equipment are included in operating costs. Certain costs related to the development or purchase of internal-use software are capitalized. Depreciation is computed using the straight-line method over estimated useful lives ranging from 3 to 10 years for equipment, 3 to 5 years for computer software, and 10 to 20 years for buildings. Improvements to leased facilities are depreciated over the shorter of the remaining lease term or the anticipated life of the improvement.
We periodically review long-lived assets, including property and equipment and definite-lived intangible assets, for impairment whenever adverse events or changes in circumstances indicate the carrying value of the asset may not be recoverable. Losses are recognized for a long-lived asset to be held and used in our operations when the undiscounted future cash flows expected to result from the use of the asset are less than its carrying value. We recognize an impairment loss based on the excess of the carrying value over the fair value of the asset. A long-lived asset held for sale is reported at the lower of the carrying amount or fair value less costs to sell. Depreciation expense is not recognized on assets held for sale. Losses are recognized for a long-lived asset to be abandoned when the asset ceases to be used. In addition, we periodically review the estimated lives of all long-lived assets for reasonableness.
Equity Method Investments
We use the equity method of accounting for equity investments in companies where we are able to exercise significant influence, but not control, over operating and financial policies of the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as our ownership interest, representation on the board of directors, organizational structure, participation in policy-making decisions and material intra-entity transactions.
Generally, under the equity method, original investments in these entities are recorded at cost and subsequently adjusted by our share of equity in income or losses after the date of acquisition as well as capital contributions to and distributions from these companies. Our proportionate share of the net income or loss of these companies is included in consolidated net income. Investment amounts in excess of our share of an investee’s net assets are amortized over the life of the related asset creating the excess. Excess goodwill is not amortized.
We evaluate equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered by us when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than carrying value, the investee’s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
See Note 4 for further information.
Goodwill and Definite-Lived Intangible Assets
Goodwill represents the unamortized excess of cost over the fair value of the net tangible and other intangible assets acquired. We are required to test at least annually for impairment at a level of reporting referred to as the reporting unit, and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. A reporting unit either is our operating segments or one level below the operating segments, referred to as a component, which comprise our reportable segments. A component is considered a reporting unit if the component constitutes a business for which discrete financial information is available that is regularly reviewed by management. We aggregate the components of an operating segment into one reporting unit if they have similar economic characteristics. Goodwill is assigned to the reporting units that are expected to benefit from the specific synergies of the business combination.
We use the one-step process to review goodwill for impairment to determine both the existence and amount of goodwill impairment, if any. Impairment tests are performed, at a minimum, in the fourth quarter of each year supported by our long-range business plan and annual planning process. We rely on an evaluation of future discounted cash flows to determine fair value of our reporting units. The fair value of our reporting units with significant goodwill exceeded carrying amounts by a substantial margin. However, unfavorable changes in key assumptions or combinations of assumptions including a significant increase in the discount rate, decrease in the long-term growth rate or substantial reduction in our underlying cash flow assumptions, including revenue growth rates, medical and operating cost trends, and projected operating income could have a significant negative impact on the estimated fair value of our clinical and provider reporting units, which accounted for $524 million and $761 million of goodwill, respectively. Impairment tests completed for 2020, 2019, and 2018 did not result in an impairment loss.
Definite-lived intangible assets primarily relate to acquired customer contracts/relationships and are included with other long-term assets in the consolidated balance sheets. Definite-lived intangible assets are amortized over the useful life generally using the straight-line method. We review definite-lived intangible assets for impairment under our long-lived asset policy.
Benefits Payable and Benefits Expense Recognition
Benefits expense includes claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care and other supplemental benefits provided on or prior to the balance sheet date. Capitation payments represent monthly contractual fees disbursed to primary care and other providers who are responsible for providing medical care to members. Pharmacy costs represent payments for members’ prescription drug benefits, net of rebates from drug manufacturers. Receivables for such pharmacy rebates are included in other current assets in our consolidated balance sheets. Other supplemental benefits include dental, vision, and other supplemental health products.
We estimate the costs of our benefits expense payments using actuarial methods and assumptions based upon claim payment patterns, medical cost inflation, historical developments such as claim inventory levels and claim receipt patterns, and other relevant factors, and record benefit reserves for future payments. We continually review estimates of future payments relating to claims costs for services incurred in the current and prior periods and make necessary adjustments to our reserves.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Benefits expense is recognized in the period in which services are provided and includes an estimate of the cost of services which have been incurred but not yet reported, or IBNR. Our reserving practice is to consistently recognize the actuarial best point estimate within a level of confidence required by actuarial standards. Actuarial standards of practice generally require a level of confidence such that the liabilities established for IBNR have a greater probability of being adequate versus being insufficient, or such that the liabilities established for IBNR are sufficient to cover obligations under an assumption of moderately adverse conditions. Adverse conditions are situations in which the actual claims are expected to be higher than the otherwise estimated value of such claims at the time of the estimate. Therefore, in many situations, the claim amounts ultimately settled will be less than the estimate that satisfies the actuarial standards of practice.
We develop our estimate for IBNR using actuarial methodologies and assumptions, primarily based upon historical claim experience. Depending on the period for which incurred claims are estimated, we apply a different method in determining our estimate. For periods prior to the most recent two months, a completion factor method uses historical paid claims patterns to estimate the percentage of claims incurred during a given period that have historically been adjudicated as of the reporting period. Changes in claim inventory levels and known changes in claim payment processes are taken into account in these estimates. For the most recent two months, the incurred claims are estimated primarily from a trend analysis based upon per member per month claims trends developed from our historical experience in the preceding months, adjusted for known changes in estimates of hospital admissions, recent hospital and drug utilization data, provider contracting changes, changes in benefit levels, changes in member cost sharing, changes in medical management processes, product mix, and workday seasonality.
The completion factor method is used for the months of incurred claims prior to the most recent two months because the historical percentage of claims processed for those months is at a level sufficient to produce a consistently reliable result. Conversely, for the most recent two months of incurred claims, the volume of claims processed historically is not at a level sufficient to produce a reliable result, which therefore requires us to examine historical trend patterns as the primary method of evaluation. Changes in claim processes, including recoveries of overpayments, receipt cycle times, claim inventory levels, outsourcing, system conversions, and processing disruptions due to weather or other events affect views regarding the reasonable choice of completion factors. Claim payments to providers for services rendered are often net of overpayment recoveries for claims paid previously, as contractually allowed. Claim overpayment recoveries can result from many different factors, including retroactive enrollment activity, audits of provider billings, and/or payment errors. Changes in patterns of claim overpayment recoveries can be unpredictable and result in completion factor volatility, as they often impact older dates of service. The receipt cycle time measures the average length of time between when a medical claim was initially incurred and when the claim form was received. Increases in electronic claim submissions from providers decrease the receipt cycle time. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claim may be more (less) complete than originally estimated using our completion factors, which may result in reserves that are higher (lower) than required.
Medical cost trends potentially are more volatile than other segments of the economy. The drivers of medical cost trends include increases in the utilization of hospital facilities, physician services, new higher priced technologies and medical procedures, and new prescription drugs and therapies, as well as the inflationary effect on the cost per unit of each of these expense components. Other external factors such as government-mandated benefits or other regulatory changes, the tort liability system, increases in medical services capacity, direct to consumer advertising for prescription drugs and medical services, an aging population, lifestyle changes including diet and smoking, catastrophes, public health emergencies, epidemics and pandemics (such as the spread of COVID-19) also may impact medical cost trends. Internal factors such as system conversions, claims processing cycle times, changes in medical management practices and changes in provider contracts also may impact our ability to accurately predict estimates of historical completion factors or medical cost trends. All of these factors are considered in estimating IBNR and in estimating the per member per month claims trend for purposes of determining the reserve for the most recent two months. Additionally, we continually prepare and review follow-up studies to assess the reasonableness of the estimates generated by our process and methods over time. The results of these studies are also considered in determining the reserve for the most recent two months. Each of these factors requires significant judgment by management.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
We reassess the profitability of our contracts for providing insurance coverage to our members when current operating results or forecasts indicate probable future losses. We establish a premium deficiency reserve in current operations to the extent that the sum of expected future costs, claim adjustment expenses, and maintenance costs exceeds related future premiums under contracts without consideration of investment income. For purposes of determining premium deficiencies, contracts are grouped in a manner consistent with our method of acquiring, servicing, and measuring the profitability of such contracts. Losses recognized as a premium deficiency result in a beneficial effect in subsequent periods as operating losses under these contracts are charged to the liability previously established. Because the majority of our member contracts renew annually, we would not record a material premium deficiency reserve, except when unanticipated adverse events or changes in circumstances indicate otherwise.
We believe our benefits payable are adequate to cover future claims payments required. However, such estimates are based on knowledge of current events and anticipated future events. Therefore, the actual liability could differ materially from the amounts provided.
Future policy benefits payable
Future policy benefits payable include liabilities for long-duration insurance policies primarily related to certain blocks of insurance assumed in acquisitions, primarily life and annuities in run-off status, and are included in our consolidated balance sheet with other long-term liabilities. Prior period future policy benefits payable previously included as a separate line item has been reclassified to conform to the 2020 presentation. Most of these policies are subject to reinsurance as detailed in Note 19.
Book Overdraft
Under our cash management system, checks issued but not yet presented to banks that would result in negative bank balances when presented are classified as a current liability in the consolidated balance sheets. Changes in book overdrafts from period to period are reported in the consolidated statement of cash flows as a financing activity.
Income Taxes
We recognize an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets or liabilities and their reported amounts in the consolidated financial statements. These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. We also recognize the future tax benefits such as net operating and capital loss carryforwards as deferred tax assets. A valuation allowance is provided against these deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized. Future years’ tax expense may be increased or decreased by adjustments to the valuation allowance or to the estimated accrual for income taxes. Deferred tax assets and deferred tax liabilities are further adjusted for changes in the enacted tax rates.
We record tax benefits when it is more likely than not that the tax return position taken with respect to a particular transaction will be sustained. A liability, if recorded, is not considered resolved until the statute of limitations for the relevant taxing authority to examine and challenge the tax position has expired, or the tax position is ultimately settled through examination, negotiation, or litigation. We classify interest and penalties associated with uncertain tax positions in our provision for income taxes.
Stock-Based Compensation
We generally recognize stock-based compensation expense, as determined on the date of grant at fair value, on a straight-line basis over the period during which an employee is required to provide service in exchange for the award (the vesting period). In addition, for awards with both time and performance-based conditions, we generally recognize compensation expense on a straight line basis over the vesting period when it is probable that the performance condition will be achieved. We estimate expected forfeitures and recognize compensation expense only
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
for those awards which are expected to vest. We estimate the grant-date fair value of stock options using the Black-Scholes option-pricing model.
Additional detail regarding our stock-based compensation plans is included in Note 14.
Earnings Per Common Share
We compute basic earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding. Diluted earnings per common share is computed on the basis of the weighted-average number of unrestricted common shares outstanding plus the dilutive effect of outstanding employee stock options and restricted shares, or units, using the treasury stock method.
Additional detail regarding earnings per common share is included in Note 15.
Fair Value
Assets and liabilities measured at fair value are categorized into a fair value hierarchy based on whether the inputs to valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our own assumptions about the assumptions market participants would use. The fair value hierarchy includes three levels of inputs that may be used to measure fair value as described below.
Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include securities that are traded in an active exchange market.
Level 2 – Observable inputs other than Level 1 prices such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less frequently than exchange-traded instruments as well as debt securities whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.
Level 3 – Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes assets and liabilities whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting our own assumptions about the assumptions market participants would use as well as those requiring significant management judgment.
Fair value of actively traded debt and equity securities are based on quoted market prices. Fair value of other debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates generally using a market valuation approach, or, less frequently, an income valuation approach and are generally classified as Level 2. We obtain at least one price for each security from a third party pricing service. These prices are generally derived from recently reported trades for identical or similar securities, including adjustments through the reporting date based upon observable market information. When quoted prices are not available, the third party pricing service may use quoted market prices of comparable securities or discounted cash flow analysis, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include benchmark yields, reported trades, credit spreads, broker quotes, default rates, and prepayment speeds. We are responsible for the determination of fair value and as such we perform analysis on the prices received from the third party pricing service to determine whether the prices are reasonable estimates of fair value. Our analysis includes a review of monthly price fluctuations as well as a quarterly comparison of the prices received from the pricing service to prices reported by our third party investment adviser. In addition, on a quarterly basis we examine the underlying inputs and assumptions for a sample of individual securities across asset classes, credit rating levels, and various durations.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Fair value of privately held debt securities are estimated using a variety of valuation methodologies, including both market and income approaches, where an observable quoted market does not exist and are generally classified as Level 3. For privately-held debt securities, such methodologies include reviewing the value ascribed to the most recent financing, comparing the security with securities of publicly-traded companies in similar lines of business, and reviewing the underlying financial performance including estimating discounted cash flows.
Recently Issued Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In June 2016, the FASB issued guidance introducing a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The guidance was effective for us beginning January 1, 2020. The new current expected credit losses (CECL) model generally calls for the immediate recognition of all expected credit losses and applies to loans, accounts and trade receivables as well as other financial assets measured at amortized cost, loan commitments and off-balance sheet credit exposures, debt securities and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The new guidance replaces the current incurred loss model for measuring expected credit losses, requires expected losses on available for sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities, and provides for additional disclosure requirements. Our investment portfolio consists primarily of available for sale debt securities. We adopted the new standard effective January 1, 2020. Due to the high concentration of our financial assets measured at amortized cost being with the federal government resulting in zero nonpayment risk as well as our available for sale debt securities primarily being in an unrealized gain position, the adoption of the new standard did not have a material impact on our results of operations, financial condition, or cash flows.
Accounting Pronouncements Effective in Future Periods
In September 2018, the FASB issued new guidance related to accounting for long-duration contracts of insurers which revises key elements of the measurement models and disclosure requirements for long-duration contracts issued by insurers and reinsurers. The new guidance is effective for us beginning with annual and interim periods in 2023, with earlier adoption permitted, and requires retrospective application to previously issued annual and interim financial statements. We are currently evaluating the impact on our results of operations, financial position and cash flows.
There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.
3. ACQUISITIONS AND DIVESTITURES
Acquisitions
In the first quarter of 2020, we acquired privately held Enclara Healthcare, or Enclara, one of the nation’s largest hospice pharmacy and benefit management providers for cash consideration of approximately $709 million, net of cash received. This resulted in a purchase price allocation to goodwill of $517 million, other intangible assets of $240 million, and net tangible liabilities assumed of $13 million. The goodwill was assigned to the Healthcare Services segment. The other intangible assets, which primarily consist of customer contracts, have an estimated weighted average useful life of 11 years. Enclara's goodwill is not amortizable as deductible expense for tax purposes.
Also in the first quarter of 2020, our Partners in Primary Care wholly-owned subsidiary entered into a strategic partnership with Welsh, Carson, Anderson & Stowe, or WCAS, to accelerate the expansion of our primary care model. The WCAS partnership opened 20 payor-agnostic, senior-focused primary care centers during 2020, and is expected to open an additional 30 over the next 2 years. Partners in Primary Care committed to the acquisition of a non-controlling interest in the approximately $600 million entity. In addition, the agreement includes a series of put
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
and call options through which WCAS may require us to purchase their interest in the entity and, through which we may acquire WCAS’s interest over the next 5 to 10 years.
In the first quarter of 2018, we acquired the remaining equity interest in MCCI Holdings, LLC, or MCCI, a privately held management service organization and healthcare provider headquartered in Miami, Florida, that primarily coordinates medical care for Medicare Advantage beneficiaries in Florida and Texas. The purchase price consisted primarily of $169 million cash, as well as our existing investment in MCCI and a note receivable and a revolving note with an aggregate balance of $383 million. This resulted in a purchase price allocation to goodwill of $483 million, other intangible assets of $80 million, and net tangible assets of $24 million. The goodwill was assigned to the Retail and Healthcare Services segments. The other intangible assets, which primarily consist of customer contracts, have an estimated weighted average useful life of 8 years. Goodwill is amortizable as deductible expense for tax purposes.
In the second quarter of 2018, we acquired Family Physicians Group, or FPG, for cash consideration of approximately $185 million, net of cash received. FPG serves Medicare Advantage and Managed Medicaid HMO patients in Greater Orlando, Florida with a footprint that includes clinics located in Lake, Orange, Osceola and Seminole counties. This resulted in a purchase price allocation to goodwill of $133 million, other intangible assets of $38 million and net tangible assets of $14 million. The goodwill was assigned to the Retail and Healthcare Services segments. The other intangible assets, which primarily consist of customer contracts, have an estimated weighted average useful life of 5 years. The purchase price allocations for Enclara, MCCI and FPG are final.
During 2020 and 2019, we acquired other health and wellness related businesses which, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses have been included in our consolidated statements of income and consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in each of 2020, 2019 and 2018 were not material to our results of operations. For asset acquisitions the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the year of acquisition, were not material for disclosure purposes.
Sale of Closed Block of Commercial Long-Term Care Insurance Business
On August 9, 2018, we completed the sale of KMG to Continental General Insurance Company, or CGIC, a Texas-based insurance company wholly owned by HC2 Holdings, Inc., a diversified holding company. KMG's subsidiary, Kanawha Insurance Company, or KIC, included our closed block of non-strategic commercial long-term care policies. Upon closing, we funded the transaction with approximately $190 million of parent company cash contributed into KMG, subject to customary adjustments, in addition to the transfer of approximately $160 million of statutory capital with the sale. In connection with the sale of KMG, we recognized a pretax loss, including transaction costs, of $786 million and a corresponding $452 million tax benefit.
Prior to the sale of KMG, we entered into reinsurance contracts to transfer the risk associated with certain voluntary benefit and financial protection products previously issued primarily by KIC to a third party. We transferred approximately $245 million of cash to the third party and recorded a commensurate reinsurance recoverable as a result of these transactions. The reinsurance recoverable was included as part of the net assets disposed. There was no material impact to operating results from these reinsurance transactions.
KMG revenues and net income for the 2018 period prior to the date of sale were $182 million and $47 million, respectively.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
4. EQUITY METHOD INVESTMENT
In the third quarter of 2018, we, along with TPG Capital, or TPG, and Welsh, Carson, Anderson & Stowe, or WCAS (together, the "Sponsors"), completed the acquisitions of Kindred Healthcare, Inc., or Kindred, and privately-held Curo Health Services, or Curo, respectively, merging Curo with the hospice business of the Kindred at Home Division, or Kindred at Home. As part of these transactions, we acquired a 40% minority interest in Kindred at Home, a leading home health and hospice company, for total cash consideration of approximately $1.1 billion.
We account for our 40% investment in Kindred at Home using the equity method of accounting. This investment is reflected in Equity method investments in our consolidated balance sheets, with our share of income or loss reported as Equity in net earnings in our consolidated statements of income.
We entered into a shareholders agreement with the Sponsors that provides for certain rights and obligations of each party. The shareholders agreement with the Sponsors includes a put option under which they have the right to require us to purchase their interest in the joint venture beginning on July 2, 2021 and ending on July 1, 2022. Likewise, we have a call option under which we have the right to require the Sponsors to sell their interest in the joint venture to Humana beginning on July 2, 2022 and ending on July 1, 2023. The put and call options, which are exercisable at a fixed EBITDA multiple and provide a minimum return on the Sponsor's investment if exercised, are measured at fair value each period using a Monte Carlo simulation. The simulation relies on assumptions around Kindred at Home's equity value, risk free interest rates, volatility, and the details specific to the put and call options. The fair values of the put option and call option were $45 million and $503 million, respectively, at December 31, 2020 and were $28 million and $557 million, respectively, at December 31, 2019.
The put option is included within other long-term liabilities and the call option is included within other long-term assets. The change in fair value of the put and call options for the years ended December 31, 2020 and 2019 of $71 million and $(506) million, respectively, are reported as Other expense (income), net in our consolidated statements of income.
The summarized balance sheets and statements of income at December 31, 2020 and 2019 of Kindred at Home were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance sheets
|
December 31, 2020
|
December 31, 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in millions)
|
|
|
|
|
|
|
|
|
Current assets
|
$
|
844
|
|
$
|
563
|
|
|
|
|
|
|
|
|
|
Non-current assets
|
4,858
|
|
4,967
|
|
|
|
|
|
|
|
|
|
Current liabilities
|
556
|
|
405
|
|
|
|
|
|
|
|
|
|
Non-current liabilities
|
2,445
|
|
2,637
|
|
|
|
|
|
|
|
|
|
Shareholders' equity
|
2,700
|
|
2,488
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Statements of income
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2020
|
For the year ended December 31, 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in millions)
|
|
|
|
|
|
|
|
|
Revenues
|
$
|
2,972
|
|
$
|
3,100
|
|
|
|
|
|
|
|
|
|
Expenses
|
2,552
|
|
2,835
|
|
|
|
|
|
|
|
|
|
Net income
|
207
|
|
54
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
5. INVESTMENT SECURITIES
Investment securities classified as current and long-term were as follows at December 31, 2020 and 2019, respectively:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized
Cost
|
|
Gross
Unrealized
Gains
|
|
Gross
Unrealized
Losses
|
|
Fair
Value
|
|
(in millions)
|
December 31, 2020
|
|
|
|
|
|
|
|
U.S. Treasury and other U.S. government
corporations and agencies:
|
|
|
|
|
|
|
|
U.S. Treasury and agency obligations
|
$
|
616
|
|
|
$
|
1
|
|
|
$
|
(1)
|
|
|
$
|
616
|
|
Mortgage-backed securities
|
3,115
|
|
|
140
|
|
|
(1)
|
|
|
3,254
|
|
Tax-exempt municipal securities
|
1,393
|
|
|
54
|
|
|
—
|
|
|
1,447
|
|
Mortgage-backed securities:
|
|
|
|
|
|
|
|
Residential
|
17
|
|
|
—
|
|
|
—
|
|
|
17
|
|
Commercial
|
1,260
|
|
|
59
|
|
|
(1)
|
|
|
1,318
|
|
Asset-backed securities
|
1,364
|
|
|
10
|
|
|
(2)
|
|
|
1,372
|
|
Corporate debt securities
|
4,672
|
|
|
256
|
|
|
(1)
|
|
|
4,927
|
|
Total debt securities
|
$
|
12,437
|
|
|
$
|
520
|
|
|
$
|
(6)
|
|
|
12,951
|
|
Common stock
|
|
|
|
|
|
|
815
|
|
Total investment securities
|
|
|
|
|
|
|
$
|
13,766
|
|
|
|
|
|
|
|
|
|
December 31, 2019
|
|
|
|
|
|
|
|
U.S. Treasury and other U.S. government
corporations and agencies:
|
|
|
|
|
|
|
|
U.S. Treasury and agency obligations
|
$
|
353
|
|
|
$
|
1
|
|
|
$
|
—
|
|
|
$
|
354
|
|
Mortgage-backed securities
|
3,628
|
|
|
85
|
|
|
(3)
|
|
|
3,710
|
|
Tax-exempt municipal securities
|
1,433
|
|
|
30
|
|
|
—
|
|
|
1,463
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial mortgage-backed securities
|
786
|
|
|
18
|
|
|
—
|
|
|
804
|
|
Asset-backed securities
|
1,093
|
|
|
3
|
|
|
(3)
|
|
|
1,093
|
|
Corporate debt securities
|
3,867
|
|
|
82
|
|
|
(2)
|
|
|
3,947
|
|
Total debt securities
|
$
|
11,160
|
|
|
$
|
219
|
|
|
$
|
(8)
|
|
|
11,371
|
|
Common stock
|
|
|
|
|
|
|
7
|
|
Total investment securities
|
|
|
|
|
|
|
$
|
11,378
|
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Gross unrealized losses and fair values aggregated by investment category and length of time that individual debt securities have been in a continuous unrealized loss position were as follows at December 31, 2020 and 2019, respectively:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less than 12 months
|
|
12 months or more
|
|
Total
|
|
Fair
Value
|
|
Gross
Unrealized
Losses
|
|
Fair
Value
|
|
Gross
Unrealized
Losses
|
|
Fair
Value
|
|
Gross
Unrealized
Losses
|
|
|
(in millions)
|
December 31, 2020
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Treasury and other U.S. government
corporations and agencies:
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Treasury and agency obligations
|
$
|
225
|
|
|
$
|
(1)
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
225
|
|
|
$
|
(1)
|
|
Mortgage-backed securities
|
199
|
|
|
(1)
|
|
|
—
|
|
|
—
|
|
|
199
|
|
|
(1)
|
|
Tax-exempt municipal securities
|
16
|
|
|
—
|
|
|
19
|
|
|
—
|
|
|
35
|
|
|
—
|
|
Mortgage-backed securities:
|
|
|
|
|
|
|
|
|
|
|
|
Residential
|
17
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
17
|
|
|
—
|
|
Commercial
|
193
|
|
|
(1)
|
|
|
43
|
|
|
—
|
|
|
236
|
|
|
(1)
|
|
Asset-backed securities
|
65
|
|
|
—
|
|
|
498
|
|
|
(2)
|
|
|
563
|
|
|
(2)
|
|
Corporate debt securities
|
342
|
|
|
(1)
|
|
|
16
|
|
|
—
|
|
|
358
|
|
|
(1)
|
|
Total debt securities
|
$
|
1,057
|
|
|
$
|
(4)
|
|
|
$
|
576
|
|
|
$
|
(2)
|
|
|
$
|
1,633
|
|
|
$
|
(6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2019
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Treasury and other U.S. government
corporations and agencies:
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Treasury and agency obligations
|
$
|
48
|
|
|
$
|
—
|
|
|
$
|
23
|
|
|
$
|
—
|
|
|
$
|
71
|
|
|
$
|
—
|
|
Mortgage-backed securities
|
315
|
|
|
(1)
|
|
|
204
|
|
|
(2)
|
|
|
519
|
|
|
(3)
|
|
Tax-exempt municipal securities
|
58
|
|
|
—
|
|
|
75
|
|
|
—
|
|
|
133
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial mortgage-backed securities
|
118
|
|
|
—
|
|
|
36
|
|
|
—
|
|
|
154
|
|
|
—
|
|
Asset-backed securities
|
20
|
|
|
—
|
|
|
607
|
|
|
(3)
|
|
|
627
|
|
|
(3)
|
|
Corporate debt securities
|
589
|
|
|
(2)
|
|
|
155
|
|
|
—
|
|
|
744
|
|
|
(2)
|
|
Total debt securities
|
$
|
1,148
|
|
|
$
|
(3)
|
|
|
$
|
1,100
|
|
|
$
|
(5)
|
|
|
$
|
2,248
|
|
|
$
|
(8)
|
|
Approximately 96% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by S&P at December 31, 2020. Most of the debt securities that were below investment-grade were rated BB, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types.
Our unrealized loss from all debt securities was generated from approximately 150 positions out of a total of approximately 1,520 positions at December 31, 2020. All issuers of debt securities we own that were trading at an unrealized loss at December 31, 2020 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time the debt securities were purchased. At December 31, 2020, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position at December 31, 2020.
The detail of realized gains (losses) related to investment securities and included within investment income was as follows for the years ended December 31, 2020, 2019, and 2018:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
2018
|
|
(in millions)
|
Gross gains on investment securities
|
$
|
947
|
|
|
$
|
129
|
|
|
$
|
106
|
|
Gross losses on investment securities
|
(109)
|
|
|
(67)
|
|
|
(16)
|
|
Net realized gains on investment securities
|
$
|
838
|
|
|
$
|
62
|
|
|
$
|
90
|
|
Gross gains and gross losses on investment securities include both the gain resulting from the initial conversion of our prior ownership interest in certain privately held companies into common stock upon such companies' initial public offering, or IPO, and subsequent changes in the market value of such securities from the IPO through December 31, 2020, which combined to total $837 million and $91 million, respectively.
All purchases of and proceeds from investment securities for the years ended December 31, 2020 and 2019 relate to debt securities.
There were no material other-than-temporary impairments in 2019 or 2018.
The contractual maturities of debt securities available for sale at December 31, 2020, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized
Cost
|
|
Fair
Value
|
|
(in millions)
|
Due within one year
|
$
|
802
|
|
|
$
|
805
|
|
Due after one year through five years
|
2,145
|
|
|
2,236
|
|
Due after five years through ten years
|
2,247
|
|
|
2,396
|
|
Due after ten years
|
1,487
|
|
|
1,553
|
|
Mortgage and asset-backed securities
|
5,756
|
|
|
5,961
|
|
Total debt securities
|
$
|
12,437
|
|
|
$
|
12,951
|
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
6. FAIR VALUE
Financial Assets
The following table summarizes our fair value measurements at December 31, 2020 and 2019, respectively, for financial assets measured at fair value on a recurring basis:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements Using
|
|
Fair Value
|
|
Quoted Prices
in Active
Markets
(Level 1)
|
|
Other
Observable
Inputs
(Level 2)
|
|
Unobservable
Inputs
(Level 3)
|
|
(in millions)
|
December 31, 2020
|
|
|
|
|
|
|
|
Cash equivalents
|
$
|
4,548
|
|
|
$
|
4,548
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Debt securities:
|
|
|
|
|
|
|
|
U.S. Treasury and other U.S. government corporations and agencies:
|
|
|
|
|
|
|
|
U.S. Treasury and agency obligations
|
616
|
|
|
—
|
|
|
616
|
|
|
—
|
|
Mortgage-backed securities
|
3,254
|
|
|
—
|
|
|
3,254
|
|
|
—
|
|
Tax-exempt municipal securities
|
1,447
|
|
|
—
|
|
|
1,447
|
|
|
—
|
|
Mortgage-backed securities:
|
|
|
|
|
|
|
|
Residential
|
17
|
|
|
—
|
|
|
17
|
|
|
—
|
|
Commercial
|
1,318
|
|
|
—
|
|
|
1,318
|
|
|
—
|
|
Asset-backed securities
|
1,372
|
|
|
—
|
|
|
1,372
|
|
|
—
|
|
Corporate debt securities
|
4,927
|
|
|
—
|
|
|
4,927
|
|
|
—
|
|
Total debt securities
|
12,951
|
|
|
—
|
|
|
12,951
|
|
|
—
|
|
Common stock
|
815
|
|
|
815
|
|
|
—
|
|
|
—
|
|
Total invested assets
|
$
|
18,314
|
|
|
$
|
5,363
|
|
|
$
|
12,951
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
December 31, 2019
|
|
|
|
|
|
|
|
Cash equivalents
|
$
|
3,660
|
|
|
$
|
3,660
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Debt securities:
|
|
|
|
|
|
|
|
U.S. Treasury and other U.S. government corporations and agencies:
|
|
|
|
|
|
|
|
U.S. Treasury and agency obligations
|
354
|
|
|
—
|
|
|
354
|
|
|
—
|
|
Mortgage-backed securities
|
3,710
|
|
|
—
|
|
|
3,710
|
|
|
—
|
|
Tax-exempt municipal securities
|
1,463
|
|
|
—
|
|
|
1,463
|
|
|
—
|
|
Mortgage-backed securities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial
|
804
|
|
|
—
|
|
|
804
|
|
|
—
|
|
Asset-backed securities
|
1,093
|
|
|
—
|
|
|
1,093
|
|
|
—
|
|
Corporate debt securities
|
3,947
|
|
|
—
|
|
|
3,947
|
|
|
—
|
|
Total debt securities
|
11,371
|
|
|
—
|
|
|
11,371
|
|
|
—
|
|
Common stock
|
7
|
|
|
7
|
|
|
—
|
|
|
—
|
|
Total invested assets
|
$
|
15,038
|
|
|
$
|
3,667
|
|
|
$
|
11,371
|
|
|
$
|
—
|
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Financial Liabilities
Our debt is recorded at carrying value in our consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $6,060 million at December 31, 2020 and $5,366 million at December 31, 2019. The fair value of our senior note debt was $7,352 million at December 31, 2020 and $5,916 million at December 31, 2019. The fair value of our senior note debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities.
Due to the short-term nature, carrying value approximates fair value for commercial paper borrowings. The commercial paper borrowings were $600 million and $300 million at December 31, 2020 and December 31, 2019, respectively.
Put and Call Options Measured at Fair Value
The put and call options associated with our investment in Kindred at Home, which are exercisable at a fixed EBITDA multiple and provide a minimum return on the Sponsor's investment if exercised, are measured at fair value each period using a Monte Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $45 million and $503 million, respectively, at December 31, 2020 and $28 million and $557 million, respectively, at December 31, 2019.
The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value of Kindred at Home, annualized volatility and secured credit rate. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term net operating profit after tax margin, or NOPAT, to measure underlying cash flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for each reporting period.
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2020
|
December 31, 2019
|
|
|
Annualized volatility
|
29.9
|
%
|
19.8
|
%
|
|
|
Secured credit rate
|
0.4
|
%
|
2.2
|
%
|
|
|
NOPAT
|
12.0
|
%
|
12.0
|
%
|
|
|
Weighted average cost of capital
|
9.5
|
%
|
10.0
|
%
|
|
|
Long term growth rate
|
3.0
|
%
|
3.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The calculation of NOPAT utilized net income plus after tax interest expense. We regularly evaluate each of the assumptions used in establishing these assets and liabilities. Significant changes in assumptions for weighted average cost of capital, long term growth rates, NOPAT, volatility, credit spreads, risk free rate, and underlying cash flow estimates, could result in significantly lower or higher fair value measurements. A change in one of these assumptions is not necessarily accompanied by a change in another assumption.
Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
As disclosed in Note 3, we acquired Enclara, MCCI, FPG, and other health and wellness related businesses during 2020, 2019, and 2018. The values of net tangible assets acquired and the resulting goodwill and other intangible assets were recorded at fair value using Level 3 inputs. The majority of the tangible assets acquired and liabilities assumed were recorded at their carrying values as of the respective dates of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in these acquisitions were internally estimated primarily based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets are expected to generate in the future. We developed internal estimates for the expected future cash flows and discount rates used in the present value calculations. Other than assets acquired and liabilities assumed in these acquisitions, there were no material assets or liabilities measured at fair value on a nonrecurring basis during 2020, 2019, or 2018.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
7. MEDICARE PART D
As discussed in Note 2, we cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with CMS. The accompanying consolidated balance sheets include the following amounts associated with Medicare Part D as of December 31, 2020 and 2019. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
|
Risk
Corridor
Settlement
|
|
CMS
Subsidies/
Discounts
|
|
Risk
Corridor
Settlement
|
|
CMS
Subsidies/
Discounts
|
|
|
(in millions)
|
Other current assets
|
|
$
|
216
|
|
|
$
|
1,420
|
|
|
$
|
5
|
|
|
$
|
585
|
|
Trade accounts payable and accrued expenses
|
|
(39)
|
|
|
(253)
|
|
|
(120)
|
|
|
(356)
|
|
Net current asset (liability)
|
|
177
|
|
|
1,167
|
|
|
(115)
|
|
|
229
|
|
Other long-term assets
|
|
8
|
|
|
—
|
|
|
6
|
|
|
—
|
|
Other long-term liabilities
|
|
(90)
|
|
|
—
|
|
|
(61)
|
|
|
—
|
|
Net long-term liability
|
|
(82)
|
|
|
—
|
|
|
(55)
|
|
|
—
|
|
Total net asset (liability)
|
|
$
|
95
|
|
|
$
|
1,167
|
|
|
$
|
(170)
|
|
|
$
|
229
|
|
8. PROPERTY AND EQUIPMENT, NET
Property and equipment was comprised of the following at December 31, 2020 and 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
|
(in millions)
|
Land
|
|
$
|
19
|
|
|
$
|
20
|
|
Buildings and leasehold improvements
|
|
952
|
|
|
874
|
|
Equipment
|
|
1,009
|
|
|
922
|
|
Computer software
|
|
3,514
|
|
|
2,799
|
|
|
|
5,494
|
|
|
4,615
|
|
Accumulated depreciation
|
|
(3,123)
|
|
|
(2,660)
|
|
Property and equipment, net
|
|
$
|
2,371
|
|
|
$
|
1,955
|
|
Depreciation expense was $528 million in 2020, $505 million in 2019, and $444 million in 2018, including amortization expense for capitalized internally developed and purchased software of $351 million in 2020, $343 million in 2019, and $298 million in 2018.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
9. GOODWILL AND OTHER INTANGIBLE ASSETS
Changes in the carrying amount of goodwill for our reportable segments for the years ended December 31, 2020 and 2019 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retail
|
|
Group and Specialty
|
|
Healthcare Services
|
|
|
|
Total
|
|
|
(in millions)
|
Balance at January 1, 2019
|
|
$
|
1,535
|
|
|
$
|
261
|
|
|
$
|
2,101
|
|
|
|
|
$
|
3,897
|
|
Acquisitions
|
|
—
|
|
|
—
|
|
|
31
|
|
|
|
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2019
|
|
1,535
|
|
|
261
|
|
|
2,132
|
|
|
|
|
3,928
|
|
Acquisitions
|
|
—
|
|
|
—
|
|
|
519
|
|
|
|
|
519
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2020
|
|
$
|
1,535
|
|
|
$
|
261
|
|
|
$
|
2,651
|
|
|
|
|
$
|
4,447
|
|
The following table presents details of our other intangible assets included in other long-term assets in the accompanying consolidated balance sheets at December 31, 2020 and 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
Average
Life
|
|
2020
|
|
2019
|
|
|
Cost
|
|
Accumulated
Amortization
|
|
Net
|
|
Cost
|
|
Accumulated
Amortization
|
|
Net
|
|
|
|
|
(in millions)
|
Other intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Customer contracts/relationships
|
|
9.5 years
|
|
$
|
849
|
|
|
$
|
572
|
|
|
$
|
277
|
|
|
$
|
646
|
|
|
$
|
496
|
|
|
$
|
150
|
|
Trade names and technology
|
|
7.0 years
|
|
122
|
|
|
89
|
|
|
33
|
|
|
84
|
|
|
84
|
|
|
—
|
|
Provider contracts
|
|
11.8 years
|
|
69
|
|
|
50
|
|
|
19
|
|
|
70
|
|
|
44
|
|
|
26
|
|
Noncompetes and other
|
|
7.3 years
|
|
29
|
|
|
29
|
|
|
—
|
|
|
29
|
|
|
28
|
|
|
1
|
|
Total other intangible assets
|
|
9.3 years
|
|
$
|
1,069
|
|
|
$
|
740
|
|
|
$
|
329
|
|
|
$
|
829
|
|
|
$
|
652
|
|
|
$
|
177
|
|
Amortization expense for other intangible assets was approximately $88 million in 2020, $70 million in 2019, and $90 million in 2018. Amortization expense for 2018 included $12 million associated with the write-off of a trade name value reflecting the re-branding of certain provider assets.
The following table presents our estimate of amortization expense for each of the five next succeeding fiscal years:
|
|
|
|
|
|
|
(in millions)
|
For the years ending December 31,
|
|
2021
|
$
|
56
|
|
2022
|
53
|
|
2023
|
40
|
|
2024
|
33
|
|
2025
|
33
|
|
10. LEASES
We determine if a contract contains a lease by evaluating the nature and substance of the agreement. We lease facilities, computer hardware, and other furniture and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. For new lease agreements, we combine lease and nonlease components for all of our asset classes.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
When portions of the lease payments are not fixed or depend on an index or rate, we consider those payments to be variable in nature. Our variable lease payments include, but are not limited to, common area maintenance, taxes and insurance which are not dependent upon an index or rate. Variable lease payments are recorded in the period in which the obligation for the payment is incurred. Most leases include options to renew, with renewal terms that can extend the lease term. The exercise of lease renewal options is at our sole discretion. Certain leases also include options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.
Right-of-use assets included within other long-term assets in our consolidated balance sheets were $437 million and $410 million at December 31, 2020 and 2019, respectively. Operating lease liabilities included within trade accounts payable and accrued expenses were $129 million and $116 million at December 31, 2020 and December 31, 2019, respectively. Additionally, operating lease liabilities included within other long-term liabilities were $355 million and $332 million at December 31, 2020 and December 31, 2019, respectively. The classification of our operating lease liabilities is based on the remaining lease term.
For the years ended December 31, 2020 and December 31, 2019, total fixed operating lease costs, excluding short-term lease costs, were $141 million and $154 million, respectively, and are included within operating costs in our consolidated statements of income. Short-term lease costs were not material for the years ended December 31, 2020 and December 31, 2019. In addition, for the years ended December 31, 2020 and December 31, 2019, total variable operating lease costs were $92 million and $82 million, respectively, and are included within operating costs in our consolidated statements of income.
We sublease facilities or partial facilities to third party tenants for space not used in our operations. For the years ended December 31, 2020 and December 31, 2019, sublease rental income was $36 million and $45 million, respectively, and is included within operating costs in our consolidated statements of income.
The weighted average remaining lease term is 5.2 years and 4.9 years with a weighted average discount rate of 3.7% and 4.1% at December 31, 2020 and December 31, 2019, respectively. For the year-ended December 31, 2020 and December 31, 2019, cash paid for amounts included in the measurement of lease liabilities included within our operating cash flows was $146 million and $151 million, respectively.
|
|
|
|
|
|
|
|
|
Maturity of Lease Liabilities
|
|
December 31, 2020
|
|
|
(in millions)
|
2021
|
|
$
|
146
|
|
2022
|
|
129
|
|
2023
|
|
82
|
|
2024
|
|
59
|
|
2025
|
|
41
|
|
After 2025
|
|
87
|
|
Total lease payments
|
|
544
|
|
Less: Interest
|
|
60
|
|
Present value of lease liabilities
|
|
$
|
484
|
|
As most of our leases do not provide an implicit rate, we use our incremental borrowing rate, as adjusted for collateralized borrowings, based on the information available at date of adoption or commencement date in determining the present value of lease payments.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
For the year ended 2018, under prior lease disclosure requirements
We lease facilities, computer hardware, and other furniture and equipment under long-term operating leases that are noncancellable and expire on various dates through 2046. We sublease facilities or partial facilities to third party tenants for space not used in our operations. Rent with scheduled escalation terms are accounted for on a straight-line basis over the lease term. Rent expense and sublease rental income, which are recorded net as an operating cost, for all operating leases were as follows for the year ended December 31, 2018:
|
|
|
|
|
|
|
|
|
2018
|
|
|
|
(in millions)
|
Rent expense
|
$
|
167
|
|
|
|
Sublease rental income
|
(32)
|
|
|
|
Net rent expense
|
$
|
135
|
|
|
|
11. BENEFITS PAYABLE
On a consolidated basis, activity in benefits payable was as follows for the years ended December 31, 2020, 2019 and 2018:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
2018
|
|
|
(in millions)
|
Balances at January 1
|
|
$
|
6,004
|
|
|
$
|
4,862
|
|
|
$
|
4,668
|
|
|
|
|
|
|
|
|
Less: Reinsurance recoverables
|
|
(68)
|
|
|
(95)
|
|
|
(70)
|
|
Balances at January 1, net
|
|
5,936
|
|
|
4,767
|
|
|
4,598
|
|
|
|
|
|
|
|
|
Incurred related to:
|
|
|
|
|
|
|
Current year
|
|
61,941
|
|
|
54,193
|
|
|
46,385
|
|
Prior years
|
|
(313)
|
|
|
(336)
|
|
|
(503)
|
|
Total incurred
|
|
61,628
|
|
|
53,857
|
|
|
45,882
|
|
Paid related to:
|
|
|
|
|
|
|
Current year
|
|
(54,003)
|
|
|
(48,421)
|
|
|
(41,736)
|
|
Prior years
|
|
(5,418)
|
|
|
(4,267)
|
|
|
(3,977)
|
|
Total paid
|
|
(59,421)
|
|
|
(52,688)
|
|
|
(45,713)
|
|
|
|
|
|
|
|
|
Reinsurance recoverable
|
|
—
|
|
|
68
|
|
|
95
|
|
Balances at December 31
|
|
$
|
8,143
|
|
|
$
|
6,004
|
|
|
$
|
4,862
|
|
Amounts incurred related to prior years vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
As previously discussed, our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. We experienced favorable medical claims reserve development related to prior fiscal years of $313 million in 2020, $336 million in 2019, and $503 million in 2018. The table below details our favorable medical claims reserve development related to prior fiscal years by segment for 2020, 2019, and 2018.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Favorable) Unfavorable Medical Claims Reserve
Development
|
|
2020
|
|
2019
|
|
2018
|
|
|
Retail Segment
|
$
|
(266)
|
|
|
$
|
(386)
|
|
|
$
|
(398)
|
|
Group and Specialty Segment
|
(47)
|
|
|
50
|
|
|
(46)
|
|
Individual Commercial Segment
|
—
|
|
|
—
|
|
|
(57)
|
|
Other Businesses
|
—
|
|
|
—
|
|
|
(2)
|
|
Total
|
$
|
(313)
|
|
|
$
|
(336)
|
|
|
$
|
(503)
|
|
The medical claims reserve development for 2020, 2019, and 2018 primarily reflects the consistent application of trend and completion factors estimated using an assumption of moderately adverse conditions. Favorable prior period development is primarily attributed to our Medicare Advantage medical business.
Incurred and Paid Claims Development
The following discussion provides information about incurred and paid claims development for our segments as of December 31, 2020, net of reinsurance, as well as cumulative claim frequency and the total of IBNR included within the net incurred claims amounts. The information about incurred and paid claims development for the years ended December 31, 2019 and 2018 is presented as supplementary information.
Claims frequency is measured as medical fee-for-service claims for each service encounter with a unique provider identification number. Our claims frequency measure includes claims covered by deductibles as well as claims under capitated arrangements. Claim counts may vary based on product mix and the percentage of delegated capitation arrangements.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Retail Segment
Activity in benefits payable for our Retail segment was as follows for the years ended December 31, 2020, 2019 and 2018:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
2018
|
|
|
(in millions)
|
Balances at January 1
|
|
$
|
5,363
|
|
|
$
|
4,338
|
|
|
$
|
3,963
|
|
|
|
|
|
|
|
|
Less: Reinsurance recoverables
|
|
(68)
|
|
|
(95)
|
|
|
(70)
|
|
Balances at January 1, net
|
|
5,295
|
|
|
4,243
|
|
|
3,893
|
|
|
|
|
|
|
|
|
Incurred related to:
|
|
|
|
|
|
|
Current year
|
|
56,821
|
|
|
48,983
|
|
|
41,323
|
|
Prior years
|
|
(266)
|
|
|
(386)
|
|
|
(398)
|
|
Total incurred
|
|
56,555
|
|
|
48,597
|
|
|
40,925
|
|
Paid related to:
|
|
|
|
|
|
|
Current year
|
|
(49,586)
|
|
|
(43,831)
|
|
|
(37,189)
|
|
Prior years
|
|
(4,836)
|
|
|
(3,714)
|
|
|
(3,386)
|
|
Total paid
|
|
(54,422)
|
|
|
(47,545)
|
|
|
(40,575)
|
|
|
|
|
|
|
|
|
Reinsurance recoverable
|
|
—
|
|
|
68
|
|
|
95
|
|
Balances at December 31
|
|
$
|
7,428
|
|
|
$
|
5,363
|
|
|
$
|
4,338
|
|
At December 31, 2020, benefits payable for our Retail segment included IBNR of approximately $4.7 billion, primarily associated with claims incurred in 2020. The cumulative number of reported claims as of December 31, 2020 was approximately 133.0 million for claims incurred in 2020, 128.8 million for claims incurred in 2019, and 109.9 million for claims incurred in 2018.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
The following tables provide information about incurred and paid claims development for the Retail segment as of December 31, 2020, net of reinsurance.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incurred Claims, Net of Reinsurance
|
|
|
|
|
For the Years Ended December 31,
|
|
|
|
|
Claims Incurred Year
|
|
2018
Unaudited
|
|
2019
Unaudited
|
|
2020
|
|
|
|
|
(in millions)
|
|
|
|
|
2018
|
|
$
|
41,323
|
|
|
$
|
40,984
|
|
|
$
|
40,946
|
|
|
|
|
|
2019
|
|
|
|
48,983
|
|
|
48,820
|
|
|
|
|
|
2020
|
|
|
|
|
|
56,821
|
|
|
|
|
|
Total
|
|
|
|
|
|
$
|
146,587
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cumulative Paid Claims, Net of Reinsurance
|
|
|
For the Years Ended December 31,
|
Claims Incurred Year
|
|
2018
Unaudited
|
|
2019
Unaudited
|
|
2020
|
|
|
(in millions)
|
2018
|
|
$
|
37,189
|
|
|
$
|
40,841
|
|
|
$
|
40,946
|
|
2019
|
|
|
|
43,831
|
|
|
48,627
|
|
2020
|
|
|
|
|
|
49,586
|
|
Total
|
|
|
|
|
|
139,159
|
|
All outstanding benefit liabilities before 2018, net of reinsurance
|
|
N/A
|
Benefits payable, net of reinsurance
|
|
$
|
7,428
|
|
Group and Specialty Segment
Activity in benefits payable for our Group and Specialty segment, excluding military services, was as follows for the years ended December 31, 2020, 2019 and 2018:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
2018
|
|
|
(in millions)
|
Balances at January 1
|
|
$
|
641
|
|
|
$
|
517
|
|
|
$
|
568
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incurred related to:
|
|
|
|
|
|
|
Current year
|
|
5,576
|
|
|
5,708
|
|
|
5,466
|
|
Prior years
|
|
(47)
|
|
|
50
|
|
|
(46)
|
|
Total incurred
|
|
5,529
|
|
|
5,758
|
|
|
5,420
|
|
Paid related to:
|
|
|
|
|
|
|
Current year
|
|
(4,873)
|
|
|
(5,081)
|
|
|
(4,957)
|
|
Prior years
|
|
(582)
|
|
|
(553)
|
|
|
(514)
|
|
Total paid
|
|
(5,455)
|
|
|
(5,634)
|
|
|
(5,471)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balances at December 31
|
|
$
|
715
|
|
|
$
|
641
|
|
|
$
|
517
|
|
At December 31, 2020, benefits payable for our Group and Specialty segment included IBNR of approximately $594 million, primarily associated with claims incurred in 2020. The cumulative number of reported claims as of December 31, 2020 was approximately 8.6 million for claims incurred in 2020, 10.0 million for claims incurred in 2019, and 10.9 million for claims incurred in 2018.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
The following tables provide information about incurred and paid claims development for the Group and Specialty segment as of December 31, 2020, net of reinsurance.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incurred Claims, Net of Reinsurance
|
|
|
|
|
For the Years Ended December 31,
|
|
|
|
|
Claims Incurred Year
|
|
2018
Unaudited
|
|
2019
Unaudited
|
|
2020
|
|
|
|
|
(in millions)
|
|
|
|
|
2018
|
|
$
|
5,466
|
|
|
$
|
5,501
|
|
|
$
|
5,505
|
|
|
|
|
|
2019
|
|
|
|
5,708
|
|
|
5,657
|
|
|
|
|
|
2020
|
|
|
|
|
|
5,576
|
|
|
|
|
|
Total
|
|
|
|
|
|
$
|
16,738
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cumulative Paid Claims, Net of Reinsurance
|
|
|
For the Years Ended December 31,
|
Claims Incurred Year
|
|
2018
Unaudited
|
|
2019
Unaudited
|
|
2020
|
|
|
(in millions)
|
2018
|
|
$
|
4,957
|
|
|
$
|
5,487
|
|
|
$
|
5,505
|
|
2019
|
|
|
|
5,081
|
|
|
5,645
|
|
2020
|
|
|
|
|
|
4,873
|
|
Total
|
|
|
|
|
|
16,023
|
|
All outstanding benefit liabilities before 2018, net of reinsurance
|
|
N/A
|
Benefits payable, net of reinsurance
|
|
$
|
715
|
|
Reconciliation to Consolidated
The reconciliation of the net incurred and paid claims development tables to benefits payable in the consolidated statement of financial position is as follows:
|
|
|
|
|
|
|
December 31,
2020
|
Net outstanding liabilities
|
|
Retail
|
$
|
7,428
|
|
Group and Specialty
|
715
|
|
Benefits payable, net of reinsurance
|
8,143
|
|
Reinsurance recoverable on unpaid claims
|
|
Retail
|
—
|
|
|
|
|
|
Total benefits payable, gross
|
$
|
8,143
|
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
12. INCOME TAXES
The provision for income taxes consisted of the following for the years ended December 31, 2020, 2019 and 2018:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
2018
|
|
(in millions)
|
Current provision:
|
|
|
|
|
|
Federal
|
$
|
1,019
|
|
|
$
|
560
|
|
|
$
|
139
|
|
States and Puerto Rico
|
93
|
|
|
41
|
|
|
58
|
|
Total current provision
|
1,112
|
|
|
601
|
|
|
197
|
|
Deferred expense
|
195
|
|
|
162
|
|
|
194
|
|
Provision for income taxes
|
$
|
1,307
|
|
|
$
|
763
|
|
|
$
|
391
|
|
The provision for income taxes was different from the amount computed using the federal statutory rate for the years ended December 31, 2020, 2019 and 2018 due to the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
2018
|
|
(in millions)
|
Income tax provision at federal statutory rate
|
$
|
982
|
|
|
$
|
729
|
|
|
$
|
436
|
|
States, net of federal benefit, and Puerto Rico
|
63
|
|
|
49
|
|
|
42
|
|
Tax exempt investment income
|
(5)
|
|
|
(6)
|
|
|
(11)
|
|
Health insurance industry fee
|
268
|
|
|
—
|
|
|
243
|
|
Nondeductible executive compensation
|
19
|
|
|
25
|
|
|
17
|
|
Tax reform
|
—
|
|
|
—
|
|
|
(39)
|
|
KMG sale
|
—
|
|
|
—
|
|
|
(272)
|
|
Other, net
|
(20)
|
|
|
(34)
|
|
|
(25)
|
|
Provision for income taxes
|
$
|
1,307
|
|
|
$
|
763
|
|
|
$
|
391
|
|
The tax reform law enacted on December 22, 2017, or Tax Reform Law, reduced the statutory federal corporate income tax rate to 21 percent from 35 percent, beginning in 2018, and required a mandatory deemed repatriation of undistributed foreign earnings. The rate reduction required a remeasurement of our net deferred tax asset. Revisions to our prior estimate for the income tax effects of the Tax Reform Law decreased our 2018 tax provision by approximately $39 million.
Due to a higher tax basis in KMG than book basis the incremental tax benefit on the sale of KMG of $272 million resulted from a tax loss higher than the loss recorded in the statement of income for the year ended December 31, 2018. In addition, the amount reflects our ability to carryback the capital loss to tax years 2015, 2016 and 2017 at the historical tax rate of 35 percent instead of the current tax rate of 21 percent.
Deferred income tax balances reflect the impact of temporary differences between the tax bases of assets or liabilities and their reported amounts in our consolidated financial statements, and are stated at enacted tax rates expected to be in effect when the reported amounts are actually recovered or settled.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Principal components of our net deferred tax balances at December 31, 2020 and 2019 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets (Liabilities)
|
|
2020
|
|
2019
|
|
(in millions)
|
Compensation and other accrued expense
|
$
|
171
|
|
|
$
|
111
|
|
Benefits payable
|
87
|
|
|
89
|
|
Net operating loss carryforward
|
32
|
|
|
42
|
|
Deferred acquisition costs
|
26
|
|
|
22
|
|
Unearned revenues
|
12
|
|
|
8
|
|
Other
|
11
|
|
|
8
|
|
Capital loss carryforward
|
—
|
|
|
1
|
|
|
|
|
|
|
|
|
|
Total deferred income tax assets
|
339
|
|
|
281
|
|
Valuation allowance
|
(37)
|
|
|
(45)
|
|
Total deferred income tax assets, net of valuation allowance
|
302
|
|
|
236
|
|
Depreciable property and intangible assets
|
(449)
|
|
|
(329)
|
|
Investment securities
|
(418)
|
|
|
(181)
|
|
Prepaid expenses
|
(91)
|
|
|
(64)
|
|
Future policy benefits payable
|
(3)
|
|
|
(3)
|
|
Total deferred income tax liabilities
|
(961)
|
|
|
(577)
|
|
Total net deferred income tax liabilities
|
$
|
(659)
|
|
|
$
|
(341)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All deferred tax liabilities and assets are classified as noncurrent in our consolidated balance sheets as other long-term liabilities at December 31, 2020 and 2019.
At December 31, 2020, we had approximately $86 million of net operating losses to carry forward. These loss carryforwards, if not used to offset future taxable income, will expire from 2024 through 2031. Due to limitations and uncertainty regarding our ability to use some of the loss carryforwards and certain other deferred tax assets, a valuation allowance of $37 million was established. For the remainder of the net operating loss carryforwards and other cumulative temporary differences, based on our historical record of producing taxable income and profitability, we have concluded that future operating income will be sufficient to recover these deferred tax assets.
We file income tax returns in the United States and Puerto Rico. The U.S. Internal Revenue Service, or IRS, has completed its examinations of our consolidated income tax returns for 2017 and prior years. Our 2018 and 2019 tax returns are in the post-filing review period under the Compliance Assurance Process, or CAP. Our 2020 tax return is under advance review by the IRS under CAP. With a few exceptions, which are immaterial in the aggregate, we no longer are subject to state, local and foreign tax examinations for years before 2017. We are not aware of any material adjustments that may be proposed as a result of any ongoing or future examinations. We do not have material uncertain tax positions reflected in our consolidated balance sheets.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
13. DEBT
The carrying value of debt outstanding was as follows at December 31, 2020 and 2019:
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
(in millions)
|
Short-term debt:
|
|
Commercial paper
|
$
|
600
|
|
|
$
|
300
|
|
Senior notes:
|
|
|
|
$400 million, 2.50% due December 15, 2020
|
—
|
|
|
399
|
|
Total short-term debt
|
$
|
600
|
|
|
$
|
699
|
|
|
|
Long-term debt:
|
|
Senior notes:
|
|
|
|
|
|
$600 million, 3.15% due December 1, 2022
|
$
|
598
|
|
|
$
|
598
|
|
$400 million, 2.90% due December 15, 2022
|
398
|
|
|
397
|
|
$600 million, 3.85% due October 1, 2024
|
598
|
|
|
597
|
|
$600 million, 4.50% due April 1, 2025
|
595
|
|
|
—
|
|
$600 million, 3.95% due March 15, 2027
|
596
|
|
|
595
|
|
$500 million, 3.125% due August 15, 2029
|
495
|
|
|
495
|
|
$500 million, 4.875% due April 1, 2030
|
494
|
|
|
—
|
|
$250 million, 8.15% due June 15, 2038
|
262
|
|
|
262
|
|
$400 million, 4.625% due December 1, 2042
|
396
|
|
|
396
|
|
$750 million, 4.95% due October 1, 2044
|
739
|
|
|
739
|
|
$400 million, 4.80% due March 15, 2047
|
396
|
|
|
396
|
|
$500 million, 3.95% due August 15, 2049
|
493
|
|
|
492
|
|
Total long-term debt
|
$
|
6,060
|
|
|
$
|
4,967
|
|
Maturities of the short-term and long-term debt for the years ending December 31, are as follows:
|
|
|
|
|
|
For the years ending December 31,
|
(in millions)
|
2021
|
$
|
600
|
|
2022
|
1,000
|
|
2023
|
—
|
|
2024
|
600
|
|
2025
|
600
|
|
Thereafter
|
3,900
|
|
Senior Notes
In December 2020, we repaid $400 million aggregate principal amount of our 2.5% senior notes due on their maturity date of December 15, 2020.
In March 2020, we issued $600 million of 4.500% senior notes due April 1, 2025 and $500 million of 4.875% senior notes due April 1, 2030. Our net proceeds, reduced for the underwriters' discount and commission and offering expenses paid, were approximately $1,088 million as of December 31, 2020. We used the net proceeds for general corporate purposes.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Our senior notes, which are unsecured, may be redeemed at our option at any time at 100% of the principal amount plus accrued interest and a specified make-whole amount. The 8.15% senior notes are subject to an interest rate adjustment if the debt ratings assigned to the notes are downgraded (or subsequently upgraded). In addition, our senior notes contain a change of control provision that may require us to purchase the notes under certain circumstances.
Credit Agreement
Our 5-year, $2.0 billion unsecured revolving credit agreement expires May 2022. Under the credit agreement, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at either LIBOR plus a spread or the base rate plus a spread. If drawn upon, the revolving credit would revert to using the alternative base rate once LIBOR is discontinued. The LIBOR spread, currently 110.0 basis points, varies depending on our credit ratings ranging from 91.0 to 150.0 basis points. We also pay an annual facility fee regardless of utilization. This facility fee, currently 15.0 basis points, may fluctuate between 9.0 and 25.0 basis points, depending upon our credit ratings. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based on LIBOR, at our option.
The terms of the credit agreement include standard provisions related to conditions of borrowing which could limit our ability to borrow additional funds. In addition, the credit agreement contains customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 50% as well as customary events of default. We are in compliance with this financial covenant, with an actual debt to capitalization of 33% as measured in accordance with the credit agreement as of December 31, 2020. Upon our agreement with one or more financial institutions, we may expand the aggregate commitments under the credit agreement to a maximum of $2.5 billion, through a $500 million incremental loan facility.
At December 31, 2020, we had no borrowings and no letters of credit outstanding under the credit agreement. Accordingly, as of December 31, 2020, we had $2 billion of remaining borrowing capacity (which excludes the uncommitted $500 million incremental loan facility under the credit agreement), none of which would be restricted by our financial covenant compliance requirement. We have other customary, arms-length relationships, including financial advisory and banking, with some parties to the credit agreement.
Commercial Paper
Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time not to exceed $2 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the year ended December 31, 2020 was $600 million, with $600 million outstanding at December 31, 2020 compared to $300 million outstanding at December 31, 2019. The outstanding commercial paper at December 31, 2020 had a weighted average annual interest rate of 0.34%.
Term Note
In February 2020, we entered into a new $1 billion term loan commitment with a bank that matures 1 year after the first draw, subject to a 1 year extension. In March 2020, we made a draw on the entire term loan commitment of $1 billion. The facility fee, interest rate and financial covenants are consistent with those of our revolving credit agreement. The note was prepayable without penalty. We repaid the $1 billion outstanding balance in November 2020.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
14. EMPLOYEE BENEFIT PLANS
Employee Savings Plan
We have defined contribution retirement savings plans covering eligible employees which include matching contributions based on the amount of our employees’ contributions to the plans. The cost of these plans amounted to approximately $236 million in 2020, $221 million in 2019, and $197 million in 2018. The Company’s cash match is invested pursuant to the participant’s contribution direction. Based on the closing price of our common stock of $410.27 on December 31, 2020, approximately 10% of the retirement and savings plan’s assets were invested in our common stock, or approximately 1.5 million shares, representing approximately 1.2% of the shares outstanding as of December 31, 2020. At December 31, 2020, approximately 1.3 million shares of our common stock were reserved for issuance under our defined contribution retirement savings plans.
Stock-Based Compensation
We have plans under which options to purchase our common stock and restricted stock units have been granted to executive officers, directors and key employees. Awards generally require both a change in control and termination of employment within 2 years of the date of the change in control to accelerate the vesting, including those granted to retirement-eligible participants.
The terms and vesting schedules for stock-based awards vary by type of grant. Generally, the awards vest upon time-based conditions. We have also granted awards to certain employees that vest upon a combination of time and performance-based conditions. The stock awards of retirement-eligible participants are generally earned ratably over the service period for each tranche. Accordingly, upon retirement the earned portion of the current tranche will continue to vest on the originally scheduled vest date and any remaining unearned portion of the award will be forfeited. Our equity award program includes a retirement provision that generally treats employees with a combination of age and years of services with the Company totaling 65 or greater, with a minimum required age of 55 and a minimum requirement of 5 years of service, as retirement-eligible. Upon exercise, stock-based compensation awards are settled with authorized but unissued company stock or treasury stock.
The compensation expense that has been charged against income for these plans was as follows for the years ended December 31, 2020, 2019, and 2018:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
2018
|
|
(in millions)
|
Stock-based compensation expense by type:
|
|
|
|
|
|
Restricted stock
|
$
|
171
|
|
|
$
|
152
|
|
|
$
|
124
|
|
Stock options
|
10
|
|
|
11
|
|
|
13
|
|
Total stock-based compensation expense
|
181
|
|
|
163
|
|
|
137
|
|
Tax benefit recognized
|
(29)
|
|
|
(35)
|
|
|
(21)
|
|
Stock-based compensation expense, net of tax
|
$
|
152
|
|
|
$
|
128
|
|
|
$
|
116
|
|
The tax benefit recognized in our consolidated financial statements is based on the amount of compensation expense recorded for book purposes, subject to limitations on the deductibility of annual compensation in excess of $500,000 per employee as mandated by the Health Care Reform Law. The actual tax benefit realized in our tax return is based on the intrinsic value, or the excess of the market value over the exercise or purchase price, of stock options exercised and restricted stock vested during the period, subject to limitations on the deductibility of annual compensation in excess of $500,000 per employee as mandated by the Health Care Reform Law. The actual tax benefit realized for the deductions taken on our tax returns from option exercises and restricted stock vesting totaled $32 million in 2020, $25 million in 2019, and $49 million in 2018. There was no capitalized stock-based compensation expense during these years.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
At December 31, 2020, there were 11.7 million shares reserved for stock award plans under the Humana Inc. 2011 Stock Incentive Plan, or 2011 Plan, and 15.9 million shares reserved for stock award plans under the Humana Inc. 2019 Stock Incentive Plan, or 2019 Plan. These reserved shares included giving effect to, under the 2011 Plan, 3.9 million shares of common stock available for future grants assuming all stock options were granted or 1.7 million shares available for future grants assuming all restricted stock were granted. These reserved shares included giving effect to, under the 2019 Plan, 14.4 million shares of common stock available for future grants assuming all stock options were granted or 4.3 million shares available for future grants assuming all restricted stock were granted. Shares may be issued from authorized but unissued company stock or treasury stock.
Restricted Stock
Restricted stock is granted with a fair value equal to the market price of our common stock on the date of grant and generally vests in equal annual tranches over a three year period from the date of grant. Certain of our restricted stock grants also include performance-based conditions generally associated with return on invested capital and strategic membership growth. Restricted stock units have forfeitable dividend equivalent rights equal to the dividend paid on common stock. The weighted-average grant date fair value of our restricted stock was $354.66 in 2020, $302.09 in 2019, and $276.62 in 2018. Activity for our restricted stock was as follows for the year ended December 31, 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
|
|
Weighted-
Average
Grant-Date
Fair Value
|
|
(shares in thousands)
|
Nonvested restricted stock at December 31, 2019
|
976
|
|
|
$
|
245.21
|
|
Granted
|
471
|
|
|
354.66
|
|
Vested
|
(486)
|
|
|
274.80
|
|
Forfeited
|
(50)
|
|
|
303.74
|
|
Nonvested restricted stock at December 31, 2020
|
911
|
|
|
$
|
282.81
|
|
Approximately 33% of the nonvested restricted stock at December 31, 2020 included performance-based conditions.
The fair value of shares vested was $191 million during 2020, $141 million during 2019, and $298 million during 2018. Total compensation expense not yet recognized related to nonvested restricted stock was $175 million at December 31, 2020. We expect to recognize this compensation expense over a weighted-average period of approximately 1.7 years. There are no other contractual terms covering restricted stock once vested.
Stock Options
Stock options are granted with an exercise price equal to the fair market value of the underlying common stock on the date of grant. Our stock plans, as approved by the Board of Directors and stockholders, define fair market value as the average of the highest and lowest stock prices reported on the composite tape by the New York Stock Exchange on a given date. Exercise provisions vary, but most options vest in whole or in part 1 to 3 years after grant and expire 7 years after grant.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
The weighted-average fair value of each option granted during 2020, 2019, and 2018 is provided below. The fair value was estimated on the date of grant using the Black-Scholes pricing model with the weighted-average assumptions indicated below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
2018
|
Weighted-average fair value at grant date
|
$
|
69.73
|
|
|
$
|
68.53
|
|
|
$
|
63.67
|
|
Expected option life (years)
|
4.0 years
|
|
4.1 years
|
|
4.1 years
|
Expected volatility
|
24.9
|
%
|
|
25.5
|
%
|
|
26.1
|
%
|
Risk-free interest rate at grant date
|
1.2
|
%
|
|
2.4
|
%
|
|
2.5
|
%
|
Dividend yield
|
0.7
|
%
|
|
0.7
|
%
|
|
0.7
|
%
|
We calculate the expected term for our employee stock options based on historical employee exercise behavior and base the risk-free interest rate on a traded zero-coupon U.S. Treasury bond with a term substantially equal to the option’s expected term.
The volatility used to value employee stock options is based on historical volatility. We calculate historical volatility using a simple-average calculation methodology based on daily price intervals as measured over the expected term of the option.
Activity for our option plans was as follows for the year ended December 31, 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares Under
Option
|
|
Weighted-Average
Exercise Price
|
|
(shares in thousands)
|
Options outstanding at December 31, 2019
|
493
|
|
|
$
|
250.46
|
|
Granted
|
111
|
|
|
350.79
|
|
Exercised
|
(276)
|
|
|
221.15
|
|
Forfeited
|
(5)
|
|
|
307.96
|
|
Options outstanding at December 31, 2020
|
323
|
|
|
$
|
309.04
|
|
Options exercisable at December 31, 2020
|
100
|
|
|
$
|
277.51
|
|
As of December 31, 2020, outstanding stock options, substantially all of which are expected to vest, had an aggregate intrinsic value of $32 million, and a weighted-average remaining contractual term of 4.9 years. As of December 31, 2020, exercisable stock options had an aggregate intrinsic value of $13 million, and a weighted-average remaining contractual term of 3.8 years. The total intrinsic value of stock options exercised during 2020 was $51 million, compared with $43 million during 2019 and $43 million during 2018. Cash received from stock option exercises totaled $61 million in 2020, $58 million in 2019, and $50 million in 2018.
Total compensation expense not yet recognized related to nonvested options was $9 million at December 31, 2020. We expect to recognize this compensation expense over a weighted-average period of approximately 1.7 years.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
15. EARNINGS PER COMMON SHARE COMPUTATION
Detail supporting the computation of basic and diluted earnings per common share was as follows for the years ended December 31, 2020, 2019 and 2018:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
2018
|
|
(dollars in millions, except per
common share results, number of
shares/options in thousands)
|
Net income available for common stockholders
|
$
|
3,367
|
|
|
$
|
2,707
|
|
|
$
|
1,683
|
|
Weighted-average outstanding shares of common stock used to
compute basic earnings per common share
|
132,199
|
|
|
134,055
|
|
|
137,486
|
|
Dilutive effect of:
|
|
|
|
|
|
Employee stock options
|
92
|
|
|
107
|
|
|
194
|
|
Restricted stock
|
721
|
|
|
565
|
|
|
723
|
|
Shares used to compute diluted earnings per common share
|
133,012
|
|
|
134,727
|
|
|
138,403
|
|
Basic earnings per common share
|
$
|
25.47
|
|
|
$
|
20.20
|
|
|
$
|
12.24
|
|
Diluted earnings per common share
|
$
|
25.31
|
|
|
$
|
20.10
|
|
|
$
|
12.16
|
|
Number of antidilutive stock options and restricted stock awards
excluded from computation
|
238
|
|
|
478
|
|
|
223
|
|
16. STOCKHOLDERS’ EQUITY
Dividends
The following table provides details of dividend payments, excluding dividend equivalent rights, in 2018, 2019, and 2020 under our Board approved quarterly cash dividend policy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payment
Date
|
|
Amount
per Share
|
|
Total
Amount
|
|
|
|
|
(in millions)
|
2018
|
|
$1.90
|
|
$262
|
2019
|
|
$2.15
|
|
$289
|
2020
|
|
$2.43
|
|
$322
|
In November 2020, the Board declared a cash dividend of $0.625 per share that was paid on January 29, 2021 to stockholders of record on December 31, 2020, for an aggregate amount of $81 million. Declaration and payment of future quarterly dividends is at the discretion of our Board and may be adjusted as business needs or market conditions change.
In February 2021, the Board declared a cash dividend of $0.70 per share payable on April 30, 2021 to stockholders of record on March 31, 2021.
Stock Repurchases
Our Board of Directors may authorize the purchase of our common shares. Under our share repurchase authorization, shares may have been purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or in privately-negotiated transactions (including pursuant to accelerated share repurchase agreements with investment banks), subject to certain regulatory restrictions on volume, pricing, and timing.
On December 14, 2017, our Board of Directors authorized the repurchase of up to $3.0 billion of our common shares expiring on December 31, 2020, exclusive of shares repurchased in connection with employee stock plans.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
On December 21, 2017, we entered into an accelerated stock repurchase agreement, the December 2017 ASR, with Bank of America, N.A., or BofA, to repurchase $1.0 billion of our common stock as part of the $3.0 billion share repurchase program authorized on December 14, 2017. On December 22, 2017, we made a payment of $1.0 billion to BofA from available cash on hand and received an initial delivery of 3.28 million shares of our common stock from BofA based on the then current market price of Humana common stock. The payment to BofA was recorded as a reduction to stockholders’ equity, consisting of an $800 million increase in treasury stock, which reflected the value of the initial 3.28 million shares received upon initial settlement, and a $200 million decrease in capital in excess of par value, which reflected the value of stock held back by BofA pending final settlement of the December 2017 ASR. Upon settlement of the ASR on March 26, 2018, we received an additional 0.46 million shares as determined by the average daily volume weighted-average share price of our common stock during the term of the ASR Agreement, less a discount, of $267.55, bringing the total shares received under this program to 3.74 million. In addition, upon settlement we reclassified the $200 million value of stock initially held back by BofA from capital in excess of par value to treasury stock.
On November 28, 2018, we entered into an accelerated stock repurchase agreement, the November 2018 ASR, with Goldman Sachs to repurchase $750 million of our common stock as part of the $3.0 billion share repurchase program authorized by the Board of Directors on December 14, 2017. On November 29, 2018, we made a payment of $750 million to Goldman Sachs from available cash on hand and received an initial delivery of 1.94 million shares of our common stock from Goldman Sachs. The payment to Goldman Sachs was recorded as a reduction to stockholders’ equity, consisting of a $600 million increase in treasury stock, which reflected the value of the initial 1.94 million shares received upon initial settlement, and a $150 million decrease in capital in excess of par value, which reflected the value of stock held back by Goldman Sachs pending final settlement of the November 2018 ASR. Upon final settlement of the November 2018 ASR on February 28, 2019, we received an additional 0.6 million shares as determined by the average daily volume weighted-averages share price of our common stock during the term of the agreement, less a discount, of $295.15, bringing the total shares received under this program to 2.54 million. In addition, upon settlement we reclassified the $150 million value of stock initially held back by Goldman Sachs from capital in excess of par value to treasury stock.
On July 30, 2019, the Board of Directors replaced a previous share repurchase authorization of up to $3 billion (of which approximately $1.03 billion remained unused) with a new authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring on June 30, 2022.
On July 31, 2019, we entered into an accelerated stock repurchase agreement, the July 2019 ASR, with Citibank, N.A., or Citi, to repurchase $1 billion of our common stock as part of the $3 billion repurchase program authorized by the Board of Directors on July 30, 2019. On August 2, 2019, we made a payment of $1 billion to Citi and received an initial delivery of 2.7 million shares of our common stock. We recorded the payment to Citi as a reduction to stockholders’ equity, consisting of an $800 million increase in treasury stock, which reflected the value of the initial 2.7 million shares received upon initial settlement, and a $200 million decrease in capital in excess of par value, which reflected the value of stock held back by Citi pending final settlement of the July 2019 ASR. Upon final settlement of the July 2019 ASR on December 26, 2019, we received an additional 0.7 million shares as determined by the average daily volume weighted-averages share price of our common stock during the term of the agreement, less a discount, of $296.19, bringing the total shares received under the July 2019 ASR to 3.4 million. In addition, upon settlement we reclassified the $200 million value of stock initially held back by Citi from capital in excess of par value to treasury stock.
On December 22, 2020, we entered into separate accelerated stock repurchase agreements, ("the December 2020 ASR Agreements"), with Citibank, N.A., or Citi, and JPMorgan Chase Bank, or JPM, to repurchase $1.75 billion of our common stock as part of the $3 billion repurchase program authorized by the Board of Directors on July 30, 2019. On December 23, 2020, in accordance with the December 2020 ASR Agreements, we made a payment of $1.75 billion ($875 million to Citi and $875 million to JPM) and received an initial delivery of 3.8 million shares of our common stock (1.9 million shares each from Citi and JPM). We recorded the payments to Citi and JPM as a reduction to stockholders’ equity, consisting of an $1.5 billion increase in treasury stock, which reflects the value of the initial 3.8 million shares received upon initial settlement, and a $262.5 million decrease in
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
capital in excess of par value, which reflects the value of stock held back by Citi and JPM pending final settlement of the December 2020 ASR Agreements. The final number of shares that we may receive, or be required to remit, under the December 2020 ASR Agreements, will be determined based on the daily volume-weighted average share price of our common stock over the term of the December 2020 ASR Agreements, less a discount and subject to adjustments pursuant to the terms and conditions of the December 2020 ASR Agreements. We expect final settlement under the December 2020 Agreements to occur during the second quarter of 2021. The December 2020 Agreements contain provisions customary for agreements of this type, including provisions for adjustments to the transaction terms upon certain specified events, the circumstances generally under which final settlement of the agreement may be accelerated, extended, or terminated early by Citi, JPM or Humana as well as various acknowledgments and representations made by the parties to each other. At final settlement, under certain circumstances, we may be entitled to receive additional shares of our common stock from Citi and JPM or we may be required to make a payment. If we are obligated to make a payment, we may elect to satisfy such obligation in cash or shares of our common stock.
On February 18, 2021, the Board of Directors replaced the previous share repurchase authorization of up to $3 billion (of which approximately $250 million remained unused) with a new authorization for repurchases of up to $3 billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 18, 2024.
Excluding shares acquired in connection with employee stock plans, share repurchases were as follows during the years ended December 31, 2020, 2019 and 2018.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
2018
|
|
Authorization Date
|
|
Purchase Not to Exceed
|
|
Shares
|
|
Cost
|
|
Shares
|
|
Cost
|
|
Shares
|
|
Cost
|
|
|
|
(in millions)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 2017
|
|
3,000
|
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
$
|
—
|
|
|
3.07
|
|
|
$
|
1,024
|
|
|
July 2019
|
|
3,000
|
|
|
3.80
|
|
|
1,750
|
|
|
3.40
|
|
|
1,000
|
|
|
—
|
|
|
—
|
|
|
Total repurchases
|
|
|
|
3.80
|
|
|
$
|
1,750
|
|
|
3.40
|
|
|
$
|
1,000
|
|
|
3.07
|
|
|
$
|
1,024
|
|
|
In connection with employee stock plans, we acquired 0.2 million common shares for $70 million in 2020, 0.2 million common shares for $70 million in 2019, and 0.4 million common shares for $116 million in 2018.
Regulatory Requirements
Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity’s level of statutory income and statutory capital and surplus. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an extraordinary dividend requiring prior regulatory approval. In most states, prior notification is provided before paying a dividend even if approval is not required.
Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Our state regulated insurance subsidiaries had aggregate statutory capital and surplus of approximately $9.4 billion and $8.0 billion as of December 31, 2020 and 2019, respectively, which exceeded aggregate minimum regulatory requirements of $7.0 billion and $5.9 billion, respectively. The amount of ordinary dividends that may be paid to our parent company in 2021 is approximately $1.4 billion in the aggregate. The amount, timing and mix of ordinary and extraordinary dividend payments will vary due to state regulatory requirements, the level of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix. Actual
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
dividends that were paid to our parent company were approximately $1.3 billion in 2020, $1.8 billion in 2019, and $2.3 billion in 2018.
17. COMMITMENTS, GUARANTEES AND CONTINGENCIES
Purchase Obligations
We have agreements to purchase services, primarily information technology related services, or to make improvements to real estate, in each case that are enforceable and legally binding on us and that specify all significant terms, including: fixed or minimum levels of service to be purchased; fixed, minimum or variable price provisions; and the appropriate timing of the transaction. We have purchase obligation commitments of $291 million in 2021, $250 million in 2022, $138 million in 2023, $77 million in 2024, and $51 million in 2025. Purchase obligations exclude agreements that are cancellable without penalty.
Off-Balance Sheet Arrangements
As part of our ongoing business, we do not participate or knowingly seek to participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, or SPEs, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of December 31, 2020, we were not involved in any SPE transactions.
Guarantees and Indemnifications
Through indemnity agreements approved by the state regulatory authorities, certain of our regulated subsidiaries generally are guaranteed by Humana Inc., our parent company, in the event of insolvency for (1) member coverage for which premium payment has been made prior to insolvency; (2) benefits for members then hospitalized until discharged; and (3) payment to providers for services rendered prior to insolvency. Our parent also has guaranteed the obligations of certain of our non-regulated subsidiaries and funding to maintain required statutory capital levels of certain regulated subsidiaries.
In the ordinary course of business, we enter into contractual arrangements under which we may agree to indemnify a third party to such arrangement from any losses incurred relating to the services they perform on behalf of us, or for losses arising from certain events as defined within the particular contract, which may include, for example, litigation or claims relating to past performance. Such indemnification obligations may not be subject to maximum loss clauses. Historically, payments made related to these indemnifications have been immaterial.
Government Contracts
Our Medicare products, which accounted for approximately 82% of our total premiums and services revenue for the year ended December 31, 2020, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2021, and all of our product offerings filed with CMS for 2021 have been approved.
CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997 (BBA) and the Benefits Improvement and Protection Act of 2000 (BIPA), generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to reflect the health status of our enrolled membership. Under the
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data to calculate the risk-adjusted premium payment to MA plans, which CMS adjusts for coding pattern differences between the health plans and the government fee-for-service program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model. These compliance efforts include the internal contract level audits described in more detail below, as well as ordinary course reviews of our internal business processes.
CMS is phasing-in the process of calculating risk scores using diagnoses data from the Risk Adjustment Processing System, or RAPS, to diagnoses data from the Encounter Data System, or EDS. The RAPS process requires MA plans to apply a filter logic based on CMS guidelines and only submit diagnoses that satisfy those guidelines. For submissions through EDS, CMS requires MA plans to submit all the encounter data and CMS will apply the risk adjustment filtering logic to determine the risk scores. For 2020, 50% of the risk score was calculated from claims data submitted through EDS. CMS increased that percentage to 75% for 2021 and will complete the phased-in transition from RAPS to EDS by using only EDS data to calculate risk scores in 2022. The phase-in from RAPS to EDS could result in different risk scores from each dataset as a result of plan processing issues, CMS processing issues, or filtering logic differences between RAPS and EDS, and could have a material adverse effect on our results of operations, financial position, or cash flows.
CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, are continuing to perform audits of various companies’ selected MA contracts related to this risk adjustment diagnosis data. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices which influence the calculation of premium payments to MA plans.
In 2012, CMS released a “Notice of Final Payment Error Calculation Methodology for Part C Medicare Advantage Risk Adjustment Data Validation (RADV) Contract-Level Audits.” The payment error calculation methodology provided that, in calculating the economic impact of audit results for an MA contract, if any, the results of the RADV audit sample would be extrapolated to the entire MA contract after a comparison of the audit results to a similar audit of the government’s traditional fee-for-service Medicare program, or Medicare FFS. We refer to the process of accounting for errors in FFS claims as the "FFS Adjuster." This comparison of RADV audit results to the FFS error rate is necessary to determine the economic impact, if any, of RADV audit results because the government used the Medicare FFS program data set, including any attendant errors that are present in that data set, to estimate the costs of various health status conditions and to set the resulting adjustments to MA plans’ payment rates in order to establish actuarial equivalence in payment rates as required under the Medicare statute. CMS already makes other adjustments to payment rates based on a comparison of coding pattern differences between MA plans and Medicare FFS data (such as for frequency of coding for certain diagnoses in MA plan data versus the Medicare FFS program dataset).
The final RADV extrapolation methodology, including the first application of extrapolated audit results to determine audit settlements, is expected to be applied to CMS RADV contract level audits conducted for contract year 2011 and subsequent years. CMS is currently conducting RADV contract level audits for certain of our Medicare Advantage plans.
Estimated audit settlements are recorded as a reduction of premiums revenue in our consolidated statements of income, based upon available information. We perform internal contract level audits based on the RADV audit methodology prescribed by CMS. Included in these internal contract level audits is an audit of our Private Fee-For Service business which we used to represent a proxy of the FFS Adjuster which has not yet been finalized. We based our accrual of estimated audit settlements for each contract year on the results of these internal contract level audits and update our estimates as each audit is completed. Estimates derived from these results were not material to our
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
results of operations, financial position, or cash flows. We report the results of these internal contract level audits to CMS, including identified overpayments, if any.
On October 26, 2018, CMS issued a proposed rule and accompanying materials (which we refer to as the “Proposed Rule”) related to, among other things, the RADV audit methodology described above. If implemented, the Proposed Rule would use extrapolation in RADV audits applicable to payment year 2011 contract-level audits and all subsequent audits, without the application of a FFS Adjuster to audit findings. We believe that the Proposed Rule fails to address adequately the statutory requirement of actuarial equivalence, and have provided substantive comments to CMS on the Proposed Rule as part of the notice-and-comment rulemaking process. Whether, and to what extent, CMS finalizes the Proposed Rule, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.
In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS, that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows.
We believe that CMS's statements and policies regarding the requirement to report and return identified overpayments received by MA plans are inconsistent with CMS's 2012 RADV audit methodology, and the Medicare statute's requirements. These statements and policies, such as certain statements contained in the preamble to CMS’s final rule release regarding Medicare Advantage and Part D prescription drug benefit program regulations for Contract Year 2015 (which we refer to as the "Overpayment Rule"), and the Proposed Rule, appear to equate each Medicare Advantage risk adjustment data error with an “overpayment” without addressing the principles underlying the FFS Adjuster referenced above. On September 7, 2018, the Federal District Court for the District of Columbia vacated CMS's Overpayment Rule, concluding that it violated the Medicare statute, including the requirement for actuarial equivalence, and that the Overpayment Rule was also arbitrary and capricious in departing from CMS's RADV methodology without adequate explanation (among other reasons). CMS has appealed the decision to the Circuit Court of Appeals.
We will continue to work with CMS to ensure that MA plans are paid accurately and that payment model principles are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.
At December 31, 2020, our military services business, which accounted for approximately 1% of our total premiums and services revenue for the year ended December 31, 2020, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprises 32 states and approximately six million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract is a 5-year contract set to expire on December 31, 2022 and is subject to renewals on January 1 of each year during its term at the government's option.
Our state-based Medicaid business accounted for approximately 6% of our total premiums and services revenue for the year ended December 31, 2020. In addition to our state-based Temporary Assistance for Needy Families, or TANF, Medicaid contracts in Florida and Kentucky, we have contracts in Florida for Long Term Support Services (LTSS), and in Illinois for stand-alone dual eligible demonstration programs serving individuals dually eligible for both the federal Medicare program and the applicable state-based Medicaid program.
The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Legal Proceedings and Certain Regulatory Matters
As previously disclosed, the Civil Division of the United States Department of Justice provided us with an information request in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We continue to cooperate with the Department of Justice. These matters are expected to result in additional qui tam litigation.
As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned United States of America ex rel. Steven Scott v. Humana, Inc., in United States District Court, Central District of California, Western Division. The complaint alleges certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana’s Basic PDP plan, a prescription drug plan offered by us under Medicare Part D. The action seeks damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator could proceed, following notice from the U.S. Government that it was not intervening at that time. On January 29, 2018, the suit was transferred to the United States District Court, Western District of Kentucky, Louisville Division. We take seriously our obligations to comply with applicable CMS requirements and actuarial standards of practice, and continue to vigorously defend against these allegations since the transfer to the Western District of Kentucky. We have substantially completed discovery with the relator who has pursued the matter on behalf of the United States following its unsealing, and expect the Court to consider our motion for summary judgment.
Other Lawsuits and Regulatory Matters
Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, utilization management practices, pharmacy benefits, access to care, and sales practices, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.
We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.
As a government contractor, we may also be subject to qui tam litigation brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.
A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.
We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.
The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.
18. SEGMENT INFORMATION
We manage our business with three reportable segments: Retail, Group and Specialty, and Healthcare Services. Beginning January 1, 2018, we exited the individual commercial fully-insured medical health insurance business, as well as certain other business in 2018, and therefore no longer report separately the Individual Commercial segment and the Other Businesses category in the current year. Previously, the Other Businesses category included businesses that were not individually reportable because they did not meet the quantitative thresholds required by generally accepted accounting principles, primarily our closed-block of commercial long-term care insurance policies which were sold in 2018. The reportable segments are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources.
The Retail segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts. In addition, the Retail segment also includes our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. The Group and Specialty segment consists of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO products. In addition, our Group and Specialty segment includes our military services business, primarily our TRICARE T2017 East Region contract. The Healthcare Services segment includes services offered to our health plan members as well as to third parties, including pharmacy solutions, provider services, and clinical care service, such as home health and other services and capabilities to promote wellness and advance population health, including our non-consolidating minority investment in Kindred at Home and the strategic partnership with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
Our Healthcare Services intersegment revenues primarily relate to managing prescription drug coverage for members of our other segments through Humana Pharmacy Solutions®, or HPS, and includes the operations of Humana Pharmacy, Inc., our mail order pharmacy business. These revenues consist of the prescription price (ingredient cost plus dispensing fee), including the portion to be settled with the member (co-share) or with the government (subsidies), plus any associated administrative fees. Services revenues related to the distribution of prescriptions by third party retail pharmacies in our networks are recognized when the claim is processed and product revenues from dispensing prescriptions from our mail order pharmacies are recorded when the prescription or product is shipped. Our pharmacy operations, which are responsible for designing pharmacy benefits, including defining member co-share responsibilities, determining formulary listings, contracting with retail pharmacies, confirming member eligibility, reviewing drug utilization, and processing claims, act as a principal in the arrangement on behalf of members in our other segments. As principal, our Healthcare Services segment reports revenues on a gross basis, including co-share amounts from members collected by third party retail pharmacies at the point of service.
In addition, our Healthcare Services intersegment revenues include revenues earned by certain owned providers derived from risk-based and non-risk-based managed care agreements with our health plans. Under risk based agreements, the provider receives a monthly capitated fee that varies depending on the demographics and health status of the member, for each member assigned to these owned providers by our health plans. The owned provider assumes the economic risk of funding the assigned members’ healthcare services. Under non risk-based agreements, our health plans retain the economic risk of funding the assigned members' healthcare services. Our Healthcare Services segment reports provider services revenues associated with risk-based agreements on a gross basis, whereby capitation fee revenue is recognized in the period in which the assigned members are entitled to receive healthcare services. Provider services revenues associated with non-risk-based agreements are presented net of associated healthcare costs.
We present our consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $16.5 billion in 2020, $14.9 billion in 2019, and $13.4 billion in 2018. In addition, depreciation and amortization expense associated with certain businesses in our Healthcare Services segment delivering benefits to our members, primarily associated with our provider services and pharmacy operations, are included with benefits expense. The amount of this expense was $127 million in 2020, $117 million in 2019, and $129 million in 2018.
Other than those described previously, the accounting policies of each segment are the same and are described in Note 2. Transactions between reportable segments primarily consist of sales of services rendered by our Healthcare Services segment, primarily pharmacy, provider, and clinical care services, to our Retail and Group and Specialty segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below.
Premium and services revenues derived from our contracts with the federal government, as a percentage of our total premium and services revenues, were approximately 83% for 2020, 82% for 2019 and 81% for 2018.
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retail
|
|
Group and Specialty
|
|
Healthcare Services
|
|
|
|
|
|
Eliminations/
Corporate
|
|
Consolidated
|
|
(in millions)
|
2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Premiums:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Individual Medicare Advantage
|
$
|
51,697
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
$
|
—
|
|
|
$
|
51,697
|
|
Group Medicare Advantage
|
7,774
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
—
|
|
|
7,774
|
|
Medicare stand-alone PDP
|
2,742
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
—
|
|
|
2,742
|
|
Total Medicare
|
62,213
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
—
|
|
|
62,213
|
|
Fully-insured
|
688
|
|
|
4,761
|
|
|
—
|
|
|
|
|
|
|
602
|
|
|
6,051
|
|
Specialty
|
—
|
|
|
1,699
|
|
|
—
|
|
|
|
|
|
|
—
|
|
|
1,699
|
|
Medicaid and other
|
4,223
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
—
|
|
|
4,223
|
|
Total premiums
|
67,124
|
|
|
6,460
|
|
|
—
|
|
|
|
|
|
|
602
|
|
|
74,186
|
|
Services revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provider
|
—
|
|
|
—
|
|
|
435
|
|
|
|
|
|
|
—
|
|
|
435
|
|
ASO and other
|
19
|
|
|
780
|
|
|
—
|
|
|
|
|
|
|
—
|
|
|
799
|
|
Pharmacy
|
—
|
|
|
—
|
|
|
581
|
|
|
|
|
|
|
—
|
|
|
581
|
|
Total services revenue
|
19
|
|
|
780
|
|
|
1,016
|
|
|
|
|
|
|
—
|
|
|
1,815
|
|
Total external revenues
|
67,143
|
|
|
7,240
|
|
|
1,016
|
|
|
|
|
|
|
602
|
|
|
76,001
|
|
Intersegment revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Services
|
—
|
|
|
29
|
|
|
19,491
|
|
|
|
|
|
|
(19,520)
|
|
|
—
|
|
Products
|
—
|
|
|
—
|
|
|
7,928
|
|
|
|
|
|
|
(7,928)
|
|
|
—
|
|
Total intersegment revenues
|
—
|
|
|
29
|
|
|
27,419
|
|
|
|
|
|
|
(27,448)
|
|
|
—
|
|
Investment income
|
155
|
|
|
16
|
|
|
13
|
|
|
|
|
|
|
970
|
|
|
1,154
|
|
Total revenues
|
67,298
|
|
|
7,285
|
|
|
28,448
|
|
|
|
|
|
|
(25,876)
|
|
|
77,155
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Benefits
|
56,537
|
|
|
5,529
|
|
|
—
|
|
|
|
|
|
|
(438)
|
|
|
61,628
|
|
Operating costs
|
7,402
|
|
|
1,818
|
|
|
27,395
|
|
|
|
|
|
|
(26,563)
|
|
|
10,052
|
|
Depreciation and amortization
|
342
|
|
|
81
|
|
|
183
|
|
|
|
|
|
|
(117)
|
|
|
489
|
|
Total operating expenses
|
64,281
|
|
|
7,428
|
|
|
27,578
|
|
|
|
|
|
|
(27,118)
|
|
|
72,169
|
|
Income (loss) from operations
|
3,017
|
|
|
(143)
|
|
|
870
|
|
|
|
|
|
|
1,242
|
|
|
4,986
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
—
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
283
|
|
|
283
|
|
Other expense, net
|
—
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
103
|
|
|
103
|
|
Income (loss) before income taxes and equity in net earnings
|
3,017
|
|
|
(143)
|
|
|
870
|
|
|
|
|
|
|
856
|
|
|
4,600
|
|
Equity in net earnings
|
—
|
|
|
—
|
|
|
74
|
|
|
|
|
|
|
—
|
|
|
74
|
|
Segment earnings (loss)
|
$
|
3,017
|
|
|
$
|
(143)
|
|
|
$
|
944
|
|
|
|
|
|
|
$
|
856
|
|
|
$
|
4,674
|
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retail
|
|
Group and Specialty
|
|
Healthcare Services
|
|
Eliminations/
Corporate
|
|
Consolidated
|
|
(in millions)
|
2019
|
|
|
|
|
|
|
|
|
|
External revenues
|
|
|
|
|
|
|
|
|
|
Premiums:
|
|
|
|
|
|
|
|
|
|
Individual Medicare Advantage
|
$
|
43,128
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
43,128
|
|
Group Medicare Advantage
|
6,475
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
6,475
|
|
Medicare stand-alone PDP
|
3,165
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3,165
|
|
Total Medicare
|
52,768
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
52,768
|
|
Fully-insured
|
588
|
|
|
5,123
|
|
|
—
|
|
|
—
|
|
|
5,711
|
|
Specialty
|
—
|
|
|
1,571
|
|
|
—
|
|
|
—
|
|
|
1,571
|
|
Medicaid and other
|
2,898
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,898
|
|
Total premiums
|
56,254
|
|
|
6,694
|
|
|
—
|
|
|
—
|
|
|
62,948
|
|
Services revenue:
|
|
|
|
|
|
|
|
|
|
Provider
|
—
|
|
|
—
|
|
|
446
|
|
|
—
|
|
|
446
|
|
ASO and other
|
17
|
|
|
790
|
|
|
—
|
|
|
—
|
|
|
807
|
|
Pharmacy
|
—
|
|
|
—
|
|
|
186
|
|
|
—
|
|
|
186
|
|
Total services revenue
|
17
|
|
|
790
|
|
|
632
|
|
|
—
|
|
|
1,439
|
|
Total external revenues
|
56,271
|
|
|
7,484
|
|
|
632
|
|
|
—
|
|
|
64,387
|
|
Intersegment revenues
|
|
|
|
|
|
|
|
|
|
Services
|
—
|
|
|
18
|
|
|
18,255
|
|
|
(18,273)
|
|
|
—
|
|
Products
|
—
|
|
|
—
|
|
|
6,894
|
|
|
(6,894)
|
|
|
—
|
|
Total intersegment revenues
|
—
|
|
|
18
|
|
|
25,149
|
|
|
(25,167)
|
|
|
—
|
|
Investment income
|
195
|
|
|
23
|
|
|
2
|
|
|
281
|
|
|
501
|
|
Total revenues
|
56,466
|
|
|
7,525
|
|
|
25,783
|
|
|
(24,886)
|
|
|
64,888
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
Benefits
|
48,602
|
|
|
5,758
|
|
|
—
|
|
|
(503)
|
|
|
53,857
|
|
Operating costs
|
5,306
|
|
|
1,651
|
|
|
24,852
|
|
|
(24,428)
|
|
|
7,381
|
|
Depreciation and amortization
|
323
|
|
|
88
|
|
|
156
|
|
|
(109)
|
|
|
458
|
|
Total operating expenses
|
54,231
|
|
|
7,497
|
|
|
25,008
|
|
|
(25,040)
|
|
|
61,696
|
|
Income from operations
|
2,235
|
|
|
28
|
|
|
775
|
|
|
154
|
|
|
3,192
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
—
|
|
|
—
|
|
|
—
|
|
|
242
|
|
|
242
|
|
Other income, net
|
—
|
|
|
—
|
|
|
—
|
|
|
(506)
|
|
|
(506)
|
|
Income before income taxes and equity in net earnings
|
2,235
|
|
|
28
|
|
|
775
|
|
|
418
|
|
|
3,456
|
|
Equity in net earnings
|
—
|
|
|
—
|
|
|
14
|
|
|
—
|
|
|
14
|
|
Segment earnings
|
$
|
2,235
|
|
|
$
|
28
|
|
|
$
|
789
|
|
|
$
|
418
|
|
|
$
|
3,470
|
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Retail
|
|
Group and Specialty
|
|
Healthcare Services
|
|
Individual Commercial
|
|
Other Businesses
|
|
Eliminations/
Corporate
|
|
Consolidated
|
|
(in millions)
|
2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Premiums:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Individual Medicare Advantage
|
$
|
35,656
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
35,656
|
|
Group Medicare Advantage
|
6,103
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
6,103
|
|
Medicare stand-alone PDP
|
3,584
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3,584
|
|
Total Medicare
|
45,343
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
45,343
|
|
Fully-insured
|
510
|
|
|
5,444
|
|
|
—
|
|
|
8
|
|
|
—
|
|
|
—
|
|
|
5,962
|
|
Specialty
|
—
|
|
|
1,359
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,359
|
|
Medicaid and other
|
2,255
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
22
|
|
|
—
|
|
|
2,277
|
|
Total premiums
|
48,108
|
|
|
6,803
|
|
|
—
|
|
|
8
|
|
|
22
|
|
|
—
|
|
|
54,941
|
|
Services revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provider
|
—
|
|
|
—
|
|
|
404
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
404
|
|
ASO and other
|
11
|
|
|
835
|
|
|
—
|
|
|
—
|
|
|
4
|
|
|
—
|
|
|
850
|
|
Pharmacy
|
—
|
|
|
—
|
|
|
203
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
203
|
|
Total services revenue
|
11
|
|
|
835
|
|
|
607
|
|
|
—
|
|
|
4
|
|
|
—
|
|
|
1,457
|
|
Total external revenues
|
48,119
|
|
|
7,638
|
|
|
607
|
|
|
8
|
|
|
26
|
|
|
—
|
|
|
56,398
|
|
Intersegment revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Services
|
—
|
|
|
18
|
|
|
16,840
|
|
|
—
|
|
|
—
|
|
|
(16,858)
|
|
|
—
|
|
Products
|
—
|
|
|
—
|
|
|
6,330
|
|
|
—
|
|
|
—
|
|
|
(6,330)
|
|
|
—
|
|
Total intersegment revenues
|
—
|
|
|
18
|
|
|
23,170
|
|
|
—
|
|
|
—
|
|
|
(23,188)
|
|
|
—
|
|
Investment income
|
136
|
|
|
23
|
|
|
34
|
|
|
—
|
|
|
110
|
|
|
211
|
|
|
514
|
|
Total revenues
|
48,255
|
|
|
7,679
|
|
|
23,811
|
|
|
8
|
|
|
136
|
|
|
(22,977)
|
|
|
56,912
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Benefits
|
40,925
|
|
|
5,420
|
|
|
—
|
|
|
(70)
|
|
|
77
|
|
|
(470)
|
|
|
45,882
|
|
Operating costs
|
5,327
|
|
|
1,810
|
|
|
22,905
|
|
|
4
|
|
|
6
|
|
|
(22,527)
|
|
|
7,525
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
270
|
|
|
88
|
|
|
163
|
|
|
—
|
|
|
—
|
|
|
(116)
|
|
|
405
|
|
Total operating expenses
|
46,522
|
|
|
7,318
|
|
|
23,068
|
|
|
(66)
|
|
|
83
|
|
|
(23,113)
|
|
|
53,812
|
|
Income from operations
|
1,733
|
|
|
361
|
|
|
743
|
|
|
74
|
|
|
53
|
|
|
136
|
|
|
3,100
|
|
Loss on sale of business
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
786
|
|
|
786
|
|
Interest expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
218
|
|
|
218
|
|
Other expense, net
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
33
|
|
|
33
|
|
Income (loss) before income taxes and equity in net earnings
|
1,733
|
|
|
361
|
|
|
743
|
|
|
74
|
|
|
53
|
|
|
(901)
|
|
|
2,063
|
|
Equity in net earnings
|
—
|
|
|
—
|
|
|
11
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
11
|
|
Segment earnings (loss)
|
$
|
1,733
|
|
|
$
|
361
|
|
|
$
|
754
|
|
|
$
|
74
|
|
|
$
|
53
|
|
|
$
|
(901)
|
|
|
$
|
2,074
|
|
Humana Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
19. REINSURANCE
Certain blocks of insurance assumed in acquisitions, primarily life and annuities in run-off status are subject to reinsurance where some or all of the underwriting risk related to these policies has been ceded to a third party. In addition, a large portion of our reinsurance takes the form of 100% coinsurance agreements where, in addition to all of the underwriting risk, all administrative responsibilities, including premium collections and claim payment, have also been ceded to a third party. We acquired these policies and related reinsurance agreements with the purchase of stock of companies in which the policies were originally written. We acquired these companies for business reasons unrelated to these particular policies, including the companies’ other products and licenses necessary to fulfill strategic plans.
A reinsurance agreement between two entities transfers the underwriting risk of policyholder liabilities to a reinsurer while the primary insurer retains the contractual relationship with the ultimate insured. As such, these reinsurance agreements do not completely relieve us of our potential liability to the ultimate insured. However, given the transfer of underwriting risk, our potential liability is limited to the credit exposure which exists should the reinsurer be unable to meet its obligations assumed under these reinsurance agreements.
Reinsurance recoverables represent the portion of future policy benefits payable and benefits payable that are covered by reinsurance. Reinsurance recoverables, included in other current and long-term assets, were $194 million at December 31, 2020 and $267 million at December 31, 2019. The amount of these reinsurance recoverables resulting from 100% coinsurance agreements was approximately $193 million at December 31, 2020 and approximately $267 million at December 31, 2019. Premiums ceded were $29 million in 2020, $1 billion in 2019 and $976 million in 2018. Benefits ceded were $7 million in 2020, $881 million in 2019, and $980 million in 2018. Historical ceded premium and benefits reflect the activity associated with ceding all risk under a Medicaid contract to a third party reinsurer. The reinsurance agreement ceding all risk under the Medicaid contract was terminated effective January 1, 2020.
We evaluate the financial condition of our reinsurers on a regular basis. Protective Life Insurance Company with $171 million in reinsurance recoverables is well-known and well-established with a AM Best rating of A+ at December 31, 2020. The remaining reinsurance recoverables of $22 million are divided between 10 other reinsurers, with $3 million subject to funds withheld accounts or other financial guarantees supporting the repayment of these amounts.
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders of Humana Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Humana Inc. and its subsidiaries (the “Company”) as of December 31, 2020 and 2019, and the related consolidated statements of income, comprehensive income, stockholders’ equity and cash flow for each of the three years in the period ended December 31, 2020, including the related notes and financial statement schedules listed in the index appearing under Item 15(a)(2) (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail,
accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Valuation of Incurred but not yet Reported Benefits Payable
As described in Notes 2 and 11 to the consolidated financial statements, the Company’s incurred but not yet reported benefits payable (IBNR) was $5.3 billion as of December 31, 2020. Management develops its estimate for IBNR using actuarial methodologies and assumptions, primarily based upon historical claim experience. Actuarial standards of practice generally require a level of confidence such that the liabilities established for IBNR have a greater probability of being adequate versus being insufficient, or such that the liabilities established for IBNR are sufficient to cover obligations under an assumption of moderately adverse conditions. As described by management, for the periods prior to the most recent two months, a completion factor method uses historical paid claims patterns to estimate the percentage of claims incurred during a given period that have historically been adjudicated as of the reporting period. Changes in claim inventory levels and known changes in claim payment processes are taken into account in these estimates. For the most recent two months, IBNR is estimated primarily from a trend analysis based upon per member per month claims trends developed from historical experience in the preceding months, adjusted for known changes in estimates of hospital admissions, recent hospital and drug utilization data, provider contracting changes, changes in benefit levels, changes in member cost sharing, changes in medical management processes, product mix and workday seasonality.
The principal considerations for our determination that performing procedures relating to the valuation of IBNR is a critical audit matter are the significant judgment by management when developing the estimate of IBNR, which in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures to evaluate the actuarial methodologies and significant assumptions related to completion factors, per member per month claims trends, and the potential for moderately adverse conditions. Also, the audit effort involved the use of professionals with specialized skill and knowledge to assist in evaluating the audit evidence obtained.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the valuation of IBNR, including controls over the actuarial methodologies and development of significant assumptions related to completion factors, per member per month claims trends, and the potential for moderately adverse conditions. These procedures also included, among others, the involvement of professionals with specialized skill and knowledge to assist in developing an independent estimate of IBNR. This independent estimate includes a range of reasonable outcomes, including outcomes under moderately adverse conditions, which are compared to management’s estimate of IBNR. Developing the independent estimate involved developing independent completion factors and per member per month claims trends assumptions using management’s data,
testing the completeness and accuracy of data provided by management, and evaluating the reasonableness of management’s assumptions.
Goodwill Impairment Assessment - Provider and Clinical Reporting Units
As described in Notes 2 and 9 to the consolidated financial statements, the Company’s consolidated goodwill balance was $4.4 billion as of December 31, 2020, and the goodwill associated with the Provider and Clinical Reporting Units was $761 million and $524 million, respectively. Management conducts an impairment test in the fourth quarter of each year and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. Management relies on a discounted cash flow analysis to determine fair value and uses discount rates that correspond to a market-based weighted-average cost of capital, and terminal growth rates that correspond to long-term growth prospects, consistent with the long-term inflation rate. Key assumptions in management’s cash flow projections, including revenue growth rates, medical and operating cost trends, and projected operating income, are supported with management’s long-range business plan and annual planning process.
The principal considerations for our determination that performing procedures relating to the goodwill impairment assessment of the Provider and Clinical Reporting Units is a critical audit matter are the significant judgment by management when developing the fair value estimate of the reporting units, which in turn led to a high degree of auditor judgment, subjectivity, and audit effort in performing procedures to evaluate management’s cash flow projections, including significant assumptions related to the revenue and terminal growth rates, projected operating income, and the discount rate. Also, the audit effort involved the use of professionals with specialized skill and knowledge to assist in evaluating the audit evidence obtained.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s goodwill impairment assessment, including controls over the significant assumptions used in the valuation of the Provider and Clinical Reporting Units. These procedures also included, among others, testing management's process for developing the fair value estimate of the reporting units; evaluating the appropriateness of the discounted cash flow analysis; testing the completeness and accuracy of underlying data used in the analysis; and evaluating the reasonableness of the significant assumptions used by management related to the revenue and terminal growth rates and projected operating income, by considering the past performance of the reporting units and considering whether these assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in the evaluation of the appropriateness of the Company’s discounted cash flow analysis and the reasonableness of the significant assumptions related to the terminal growth rates and the discount rate impacting the reporting units’ future cash flows.
/s/ PricewaterhouseCoopers LLP
Louisville, Kentucky
February 18, 2021
We have served as the Company’s auditor since 1968.